Author Index

Abbur R, 506A
Abe K, 467A, 490A
Abe T, 129A, 546A
Abrahamowicz M, 541A
Abramczk S, 457A
Abrous DN, 103
Abu-Issa R, 522A
Achari M, 476A
Ackerley C, 469A
Adami A, 448A
Adamson J, 243
Adelman L, 459A
Adelson PD, 343, 445A
Aebischer P, 887
Aerssens P, 532A
Aggarwal R, 506A
Agid Y, 103, 217
Aguglia U, 465A
Åhlberg G, 399
Ahmed W, 494A
Aissaoui A, 559
Akiguchi I, 484A
Aksamit AJ, 471A
Al-Asmi A, 253
Alavi A, 522A
Albers GW, 568
Albert SM, 504A
Alder H, 469A
Alekov AK, 305
Aleong R, 551A
Alexander G, 447A
Alexianu M, 463A
Alford M, 454A
Allam GJ, 494A
Allan WC, 536A
Allaria S, 119
Allder SJ, 479A
Allen J, 496A, 526A
Allred E, 527A
Almer G, 135
Al-Mubarek N, 496A
ALS C.A.R.E. Study Group, 506A
Altieri M, 509A
Alvarez E, 492A
Alvarez RB, 482A
Alvarez-Buylla A, 867
Amano T, 505A
Amato A, 494A
Anand R, 453A
Andermann F, 88
Anderson AE, 529A
Anderson C, 488A
Anderson DP, 452A
Anderson JH, 481A
Anderson WF, 938
Andrews WL, 534A
Anene O, 536A
Angelicheva D, 36
Annesi F, 465A
Annesi G, 465A
ANOCEF Group, 913
Ansari M, 541A
Antel JP, 253, 319
Antonelli G, 473A
Antonini G, 473A
Antunes NL, 550A
Anvret M, 399
Aoyagi Y, 112
Appel SH, 463A
Araki SS, 502A
Arbusow V, 416
Ardouin C, 217
Arias-Mendoza F, 534A, 549A
Arkinson JLD, 504A
Armstrong D, 529A
Armstrong R, 462A
Arnulf I, 217
Aronowski J, 496A
Asada T, 136
Asahara H, 453A, 459A
Asahina M, 62
Asano E, 530A
Asherov A, 115
Ashizawa T, 462A, 480A
Ashley DM, 491A
Ashwal S, 520A, 527A
Askanas V, 482A
Asleson G, 467A
Assadi M, 534A
Assirati JA, 343
Atalla LR, 938
Atkinson EJ, 456A
Atkinson JLD, 475A
Atlas D, 495A
Attia-Sobol J, 530A
Augood SJ, 761
August G, 526A
August JT, 444A
Auld E, 474A
Aurora S, 476A
Avoli M, 816
Awaad Y, 466A
Aykut-Bingol C, 894
Azieh BY, 538A
Aziz K, 534A

Bachetti P, 490A
Back T, 478A
Backstrom JW, 526A
Bagan BT, 523A
Bagnato F, 473A
Bahra A, 791
Baier H, 708
Baird AE, 478A
Bajenaru ML, 446A
Bakay RAE, 22, 477A
Baker CW, 460A
Baker JV, 488A
Baker M, 243
Bakshi R, 469A
Bakst A, 508A
Baldini L, 119
Bale JF Jr, 523A
Ball D, 935
Balsamo L, 528A
Bandy DJ, 550A
Bannan JD, 6
Barber PA, 450A
Barker GJ, 468A, 850
Barker PB, 494A, 528A
Barkhof F, 79, 471A, 747
Barkovich AJ, 539A
Barnes GN, 537A
Barnes PD, 755
Barnes PL, 520A
Barnett JL, 271
Barnitz C, 671
Barohn R, 494A
Barr J, 522A
Barron TF, 542A
Basso G, 528A
Bastian A, 544A
Bastos AC, 88
Bates J, 450A
Bates V, 495A
Bayer N, 508A
Beach RL, 476A
Beal MF, 842
Beall S, 498A
Beaulieu C, 568
Becerra P, 462A
Becker G, 260
Becker JT, 490A
Becker KG, 425
Becker LE, 466A
Beers D, 463A
Beeson D, 639
Begleiter AF, 545A
Behen ME, 533A
Bejjani P, 217
Belasco J, 522A
Bell J, 207, 488A
Bell K, 412
Belman AL, 458A
Benabid AL, 217
Ben-Ari Y, 95
Bennett D, 452A
Bennett J, 541A
Ben-Sira L, 520A
Berg D, 260
Bergeron M, 444A
Bergk J, 693
Berkowitch M, 522A
Berlin CI, 460A
Bernard V, 103
Bernardini GL, 450A
Bernasconi A, 816
Berrih-Aknin S, 559
Bersudsky M, 461A
Bertini E, 530A
Betty M, 639
Beyreuther K, 860
Bhattacharjee MB, 937
Biddison WE, 425
Biervert C, 305
Biesecker L, 456A
Bigner DD, 491A
Bilak MM, 462A
Bilak SR, 462A
Billings D, 534A
Bindoff L, 161
Binkofski F, 51
Bird TD, 271, 453A
Bix GJ, 522A
Blackstone CD, 936
Blaschko E, 504A
Bloch B, 103
Blomström-Lundqvist C, 684
Blumberg B, 488A
Blumen SC, 115, 475A, 492A
Blumenfeld S, 529A
Blumhardt L, 502A
Blunk JC, 534A
Boatman D, 579
Bobustuc G, 541A
Bode H, 305
Boden-Albala B, 452A
Boespflug-Tanguy O, 530A
Boeve B, 243
Bone I, 481A
Bonilla E, 462A
Bonini NM, 935
Bonmartin A, 256
Bono F, 465A
Bonomo R, 496A
Booze R, 488A
Borg K, 399
Born DE, 343
Borthwick GM, 787
Bosch P, 494A
Bottini N, 529A
Bouchard J-P, 115
Bowe CM, 534A
Boyd J, 549A
Boyett J, 526A
Boylan KB, 457A
Bradley WE, 490A
Brady RO, 536A
Brais B, 115
Braiterman LT, 409
Brammer MJ, 468A
Brandt J, 579
Brandt T, 416
Braniecki SH, 528A
Brashear A, 176

July issue, pp 1–40; August issue, pp 141–278; September issue, pp 279–552; October issue, pp 553–680; November issue, pp 681–802; December issue, 803–986.

Copyright © 1999 by the American Neurological Association

Brasher PMA, 183
Bratina PL, 509A
Breakefield XO, 176, 761
Brechtel C, 452A
Breen G, 664
Brenneman DE, 458A
Brenner T, 534A
Bressman SB, 176, 794
Breteler MMB, 827
Bretschneider F, 305
Brex PA, 468A
Briggs D, 509A
Broccolini A, 482A
Brochet B, 471A
Broderick J, 450A
Broitman M, 524A
Bromberg M, 494A
Bronstein JM, 464A
Brooks WM, 494A
Brott T, 450A
Broussolle E, 256
Brouwers P, 521A
Brown AM, 489A
Brown AN, 505A
Brown FR, 529A
Brown LJ, 267
Brown P, 224
Brown RH Jr, 934
Brown TR, 534A, 549A
Brown WD, 543A
Browne RG, 528A
Browner WS, 479A
Brunquell PJ, 531A
Brunstrom J, 544A
Brüstle O, 716
Bryan W, 494A
Buccino G, 51
Buchan AM, 450A
Buchanan CP, 523A
Büchel C, 791
Buckley C, 482A
Budka H, 224
Bullmore ET, 468A
Burghes SC, 456A
Burgio D, 459A
Burkard RF, 460A
Bush AI, 860
Butinar D, 36
Byrne E, 656
Byrne P, 481A

Caballero-Ramos CI, 425
Cahan LD, 343
Cain V, 508A
Cairncross JG, 183
Calder CS, 495A
Campbell J, 482A
Campbell NR, 477A
Canady A, 523A
Cannella B, 144
Cao L, 457A, 470A, 935
Cao Y, 476A
Capellari S, 224
Caplan L, 478A
Cappellari A, 119
Carasso RL, 475A, 492A
Carlsson B, 684
Carney PR, 546A
Carson B, 579
Caruso JM, 543A, 545A
Castelijns JA, 79, 747
Caviness VS, 545A
Cendes F, 88
Chabrier S, 934
Chai Y, 935
Chambers CB, 325
Chan S, 481A
Chang C, 531A
Chang R, 536A
Chapman J, 115
Charapata S, 505A
Charlier C, 671
Chase BA, 374
Chateau D, 559
Chaturvedi S, 506A
Chaudhry V, 679
Chaves C, 478A
Chaves-Carballo E, 466A
Chedrawi AK, 529A
Chemelli RM, 935
Chen C, 794
Chen C-J, 651
Chen E-Y, 419
Chen J, 445A
Chen J-F, 445A
Chen K-L, 271
Chen LS, 531A
Chen M, 445A
Chen TJ, 548A
Cheng H-L, 485A, 486A
Cheng Y, 472A
Cherin E, 498A
Cherny RA, 860
Chez M, 536A
Chez MG, 523A
Chieffe C, 473A
Chikaoka H, 660
Chimelli L, 343
Chin SS, 481A
Chinarian J, 466A
Chinn C, 508A
Chmura TA, 477A
Cho A, 536A
Chockkan V, 22
Choksi R, 536A
Chong DJ, 477A
Chou D, 464A
Christiaens GCML, 739
Christou I, 509A
Chu N-S, 651
Chua T-S, 428
Chugani DC, 530A
Chugani HT, 530A, 532A, 533A
Chun JT, 487A
Chutorian A, 532A
Cipolla MJ, 449A
Ciusani E, 435
Civitello L, 521A
Clancy RR, 525A
Clark GD, 522A, 547A
Clark L, 455A
Clark P, 533A
Clark RSB, 445A
Clark W, 448A
Clark WM, 449A
Clatterbuck R, 464A
Clausen T, 274
Clawson LL, 506A
Clayton DF, 460A
Clemenzi A, 473A
Clover L, 482A, 483A
Cochran EJ, 419, 452A
Cockrell J, 534A
Codère F, 115
Coffman KA, 542A
Cohen B, 526A
Cohen BA, 490A
Cohen BH, 535A
Cohen ZS, 523A
Cohen-Kaminsky S, 559
Cokgor I, 491A
Coles AJ, 296
Colier WNJM, 667
Collatz MB, 708
Collins T, 455A
Combes M, 535A
Comeau RM, 88
Comella CD, 419
Comi AM, 528A
Comi G-P, 161
Commichau C, 450A
Compston A, 296
Conant K, 391
Connolly AM, 536A
Connolly ES, 450A
Conry JA, 523A
Conway JE, 464A
Cookfair D, 132
Copeland D, 450A
Corey-Bloom J, 454A
Cornu P, 913
Corral J, 449A
Corrigan F, 664
Corse AM, 462A
Corsini E, 435
Cortez S, 543A
Cosman M, 936
Cotleur A, 490A
Cotman CW, 538A
Couderc J, 559
Covey DF, 539A
Coward L, 457A, 935
Coyle PK, 458A, 475A, 488A, 489A
Craufurd D, 243
Crawford TO, 287
Crawley AP, 551A
Cristofalo V, 462A
Crook R, 382
Croxen R, 639
Crum BA, 449A
Cruz T, 470A
Cruz TF, 469A
Cuccaro P, 525A
Cudkowicz ME, 934
Culver D, 937
Cumming A, 664
Cummings J, 453A
Curatolo P, 529A
Currenti M, 473A
Curtis M, 549A
Cusmai R, 530A
Cwik VA, 462A

Dabbagh O, 466A
Dadgari JM, 938
Dahiyat M, 664
Dahl N, 684
Dai AI, 526A, 541A
Dalmau J, 465A, 774
Damier P, 217
Dammann O, 527A
Darras BT, 535A, 547A
Data JL, 524A
Davie A, 541A
Davie CM, 296
Davis A, 530A
Davis KD, 249
Davis L, 543A
Davis MR, 477A
D'Costa A, 538A
D'Cruz O, 476A
Dean DA, 479A
DeCarli C, 521A
de Chadarevian J-P, 522A
de Crespigny A, 568
Defeo R, 522A
De Groot CJA, 747
de Groot JC, 827
de Koning I, 617
DeKosky ST, 452A
de la Cruz MAM, 539A
Delaney C, 485A
Delattre J-Y, 913
Delay RS, 479A
de Leeuw F-E, 827
de Leon D, 176
Delfiner J, 549A
Delgado MR, 535A, 545A
de Lissovoy G, 509A
Delivoria-Papadopoulos M, 520A, 522A, 538A
Dellatre O, 550A
DeLong MR, 22, 477A, 492A, 800
De Luca D, 529A
Demchuk AM, 448A, 509A
Denckla MB, 139, 528A
Deputy SR, 550A
de Saint Martin A, 929
Desfreres L, 95
Desimone R, 732
Desmond DW, 453A, 481A
Desmurget M, 447A
DeToledo JC, 472A
Dettorre MD, 542A
Deuschl G, 126
Developmental Epidemiology Network Investigators, 527A
De Vivo DC, 142
Deyo RA, 507A
Diaz JH, 508A
di Capua M, 530A

Dickson AC, 938
Dickson D, 243
Diem G, 498A
Diener HC, 901
Dieterich M, 416
DiMario FJ Jr, 531A
DiMauro S, 462A
Ding L, 6
Di Piero V, 509A
Di Troia A, 119
Dobyns WB, 176
Dodd CA, 510A
Dodick DW, 878
Dohle C, 51
Dolan E, 491A
Dolei A, 799
Domingues R, 548A
Donahue B, 526A
Dooley NP, 319
Dostrovsky JO, 249
Drachman DA, 458A
Drachman DB, 444A, 553
Drory VE, 461A
Du J, 938
Duan W, 587
Duane DD, 477A
Dubeau F, 88
Dubey N, 541A
Duffner PK, 526A
Dufour A, 435
Dulac O, 524A
Duncan ID, 716
Dunn JK, 525A
duPlessis AJ, 520A, 546A
Dupret JM, 433
Duquette P, 253, 319
Durrani S, 456A
Dyck PJ, 482A
Dzhala V, 95

Ebens A, 537A
Ebers G, 493A
Edelman R, 478A
Edström L, 399
Edwards KR, 453A
Edwards M, 449A
Eeg-Olofsson KE, 684
Efron L, 524A
Eguchi S, 263
Eisenfeld LI, 531A
Ekesbo A, 359
Elkin TD, 834
Elkins L, 475A
Ellgring H, 498A
Elliott I, 627
Ellis D, 505A
El Masry WS, 15
Elmquist JK, 935
Emsley CL, 454A
Engel AG, 681
Engel WK, 482A
Engelke UFH, 925
Engelstad J, 482A
Enger C, 490A
Epstein CJ, 135
Epstein CM, 477A
Essa M, 466A
Estevez A, 489A
Estevez M, 489A
Etzl MM Jr, 550A
Eunson L, 916
European/Canadian Propentofylline Study Group, 493A
Evans RM, 454A
Evatt M, 22
Exconde R, 480A
Eymard B, 559
Eymard E, 530A

Faden AI, 496A
Fagan AM, 444A
Fahn S, 498A
Falsaperla R, 459A
Fan L, 496A
Fardeau M, 115
Farlow MR, 176, 454A
Faught E, 508A
Feasby TE, 501A
Feikema W, 925
Fejerman N, 701
Felberg RA, 448A, 509A
Feldman EL, 460A, 485A, 486A
Feldman H, 45
Fernandez H, 491A
Ferrante RJ, 842
Filippi M, 471A
Fincke G, 507A
Finelli D, 680
Fink DJ, 935
Fink JS, 445A
Finklestein SP, 934
Fiorani M, 732
Fischbeck KH, 271
Fischer SJ, 445A
Fisher M, 333
Fishman DJ, 544A
Fitting J-W, 887
Fletcher DD, 467A
Flitman SS, 447A
Foa R, 467A
Fock K-M, 428
Follett PL, 521A
Foltz E, 447A
Fontaine S, 88
Foradada JR III, 529A
Force M, 447A
Forno LS, 598
Forsyth P, 183
Fowler C, 496A, 497A
Francis GS, 319
Francis MK, 462A
Frants RR, 634
Fraser FW, 860
Fredrikson S, 612
Freed C, 498A
Freedman MS, 470A
Freeman J, 579
Freeman JA, 468A, 507A
Freisinger P, 161
Freund H-J, 51
Fridkin M, 458A
Fried I, 343
Friedman AH, 491A
Friedman HS, 491A
Friedman JH, 491A
Frost M, 523A
Frutiger S, 481A
Fu Y-H, 475A
Fueyo M, 545A
Fugger L, 612
Fugio Y, 459A
Fujita N, 467A, 490A
Fukushi K, 62
Fukuuchi Y, 505A
Fuller SJ, 860
Fulton D, 183
Funanage VL, 530A 547A
Furukawa S-e, 538A
Furukawa Y, 936
Futatsubashi M, 723

Gaa J, 478A
Gadag V, 534A
Gaillard WD, 528A, 800
Gajjar A, 834
Galaburda AM, 189
Galanaud P, 559
Galanopoulou AS, 461A
Galicchio S, 701
Galimberti C, 161
Galvin JE, 452A
Gambardella A, 465A
Gambetti P, 224
Garbern J, 471A, 938
Garcia JH, 333
Garcia N, 453A
Garcia-Verdugo JM, 867
Gardner K, 489A
Garside S, 478A
Gascon GG, 543A, 545A
Gash DM, 587
Gass A, 478A
Gates J, 523A
Gee L, 490A
Geffroy MA, 494A
Gelati M, 435
Geldmacher DS, 937
Gelinas D, 494A
Gellido CI, 451A
Genain CP, 144, 936
George JM, 460A
Gerbitz KD, 161
Gerhard H, 901
Gervil M, 606
Gestrich B, 485A
Geyer R, 526A
Ghetti B, 224, 453A
Gibbs CJ Jr, 452A
Giese A, 224, 693
Gilden DH, 4
Gill JS, 483A
Gilliam F, 508A
Giraldo EA, 448A
Giuliano F, 15
Gladman JR, 479A
Glass JO, 834
Glass JD, 937
Glauser TA, 533A
Glennon CM, 531A
Glorioso JC, 935
Goadsby PJ, 791
Goetz CG, 419, 477A
Goins WF, 935
Gold DR, 535A
Gold R, 167
Goldberg LR, 138
Goldman S, 526A
Goldstein E, 536A
Goldstein J, 540A
Goldstein LB, 449A
Goldwein J, 526A
Gomez CM, 481A
Gomez CR, 450A, 510A
Gonzales RG, 556
González LA, 492A
González-Conejero R, 449A
Gooch C, 462A
Goodkin D, 490A
Goodkin DE, 132
Goodman AD, 488A
Goodwin J, 935
Goßrau G, 485A
Gordon EM, 938
Gordon NF, 504A
Gorman M, 450A
Goss JR, 935
Gotoh F, 505A
Goyal M, 540A
Gozes I, 458A
Graber KD, 234
Grafton ST, 447A
Graham GD, 494A
Grandin CB, 528A
Grant E, 548A
Graus F, 774
Graves M, 494A
Gray B, 543A
Green D, 526A
Greenberg M, 526A
Greene PE, 794
Greenlee JE, 465A
Greenwood RJ, 468A
Gregson NA, 267, 484A
Grenell S, 461A
Gress DR, 479A
Griffin DE, 391
Grimley-Evans J, 483A
Groozman GB, 461A
Gropman A, 548A
Grossberg GT, 497A
Gross-Tsur V, 524A, 539A
Grotta JC, 448A, 450A, 496A, 509A
Grover A, 243
Grover WD, 534A
The Growth Hormone Working Group, 526A
Gruenthal K, 671
Guarnieri F, 444A
Guha A, 446A
Guilleminault C, 648
Guiochon-Mantel A, 770
Gunion-Rinker L, 448A

Guo FL, 462A
Guridi J, 492A
Gutekunst C-A, 842
Gutmann DH, 446A, 777
Guttman M, 936, 937

Habermann TM, 463A
Hadden RDM, 484A
Hadjimichael O, 458A, 474A
Hagberg G, 359
Haglund MM, 491A
Hale G, 296
Halevy C, 461A
Haller RG, 274
Hallett M, 123
Haltia M, 382
Ham S, 466A
Hamada T, 480A
Hamant E, 533A
Hamburger E, 524A
Hamelin R, 913
Hamilton M, 183
Hammer MS, 523A
Han SS, 333
Hancock SL, 463A
Hanna MG, 916
Hansen LA, 454A
Harder D, 504A
Hardison H, 542A
Hardy J, 382
Haroun R, 464A
Harrell LE, 451A
Harrington C, 664
Harsanyi K, 550A
Harsh GR, 463A
Hart DE, 495A
Hartman R, 453A
Hartung H-P, 484A
Hashimoto M, 660
Hashimoto T, 22
Hata A, 480A
Hattori N, 920
Hattori T, 62
Hauser SL, 144
Hayasaka K, 660
Hays AP, 135
Hazel K, 448A
He J, 913
Head E, 538A
Hearshen DO, 494A
Hebrink DD, 456A
Hedreen JC, 207
Heideman R, 526A
Heiman GA, 794
Heiss W-D, 126
Helekar SA, 447A
Helmers S, 523A
Hennerici MG, 478A
Henriksson KG, 684
Henry TR, 477A
Henshall DC, 445A
Herndon JE, 491A
Herrera DG, 867
Herrup K, 937
Hersch SM, 842
Herskovitz S, 451A, 461A
Heutink P, 617, 708
Hew JM, 70
Heyer R, 137
Heyes MP, 528A
Hickenbottom SL, 448A
Hickey JV, 509A
Hill MW, 539A
Hillert J, 612
Hinshaw DB Jr, 520A, 527A
Hinton D, 938
Hirabuki N, 490A
Hirano M, 135, 481A
Hirato J, 783
Hirbe A, 777
Hirose G, 485A
Hirotsune S, 522A
Hirsch EC, 103, 929
Hirsch J, 478A
Hirshkowitz M, 494A
Hirt L, 887
Hirtz DG, 525A
Ho B-K, 463A
Ho DY, 479A
Hoang-Xuan K, 913
Hobart JC, 468A, 507A
Hobson GM, 530A
Hockertz M, 498A
Hoertnagel K, 161
Hoffacker V, 167
Hoffman E, 138
Hoffman JM, 477A
Hofman A, 739, 827
Hofmann S, 161
Hohmann SF, 504A
Hokezu Y, 480A
Holder DL, 547A
Holloway RG, 505A
Holshouser BA, 494A, 520A, 527A
Holtzman DM, 444A, 538A
Holzer C, 508A
Honkaniemi J, 444A
Honma T, 660
Hood LJ, 460A
Hooper DC, 473A
Hoppel CL, 535A
Hoque R, 479A
Horiuchi I, 469A, 472A
Hornig GW, 525A
Horwitz C, 536A
Horwitz S, 543A
Hosain S, 532A
Houlden H, 243
Houle S, 937
Hrachovy RA, 525A
Hsiao KK, 444A
Huang Z, 445A
Hughes RAC, 267, 484A
Hui S, 454A
Hulette C, 453A
Hultling C, 15
Hunter JV, 521A
Hunter K, 528A
Hunter W, 470A, 502A
Huppi PS, 755
Husaini BA, 508A
Hutchinson M, 481A
Hutton M, 243
Hwa GGC, 816
Hyder D, 526A
Hyder F, 455A
Hyland K, 936
Hyman BT, 444A

Ikeda K, 136, 492A
Ikeda S-I, 933
Ikonomovic MD, 452A
Illa I, 434
Inaba A, 263
Inanaga Y, 538A
Ince PG, 787
Inder TE, 755
Iniesta JA, 449A
Inoue I, 480A
Inoue K, 313
Inoue M, 460A
Inzelberg R, 475A, 492A
Irani DN, 391
Irie T, 62
Irizarry MC, 444A
Ishida K, 263
Ishizaki E, 129A
Isobe C, 129A
Italian Study Group for Multiple Sclerosis in Twins, 474A
Ito A, 447A, 660
Itoh M, 466A
Ivnik RJ, 454A
Iwaki T, 469A
Iwasaki Y, 492A
Iwata A, 485A
Iyo M, 62

Jack CR Jr, 454A
Jackson C, 494A
Jackson P, 935
Jacobs DM, 412
Jacobson DM, 489A
Jafri Z, 460A
Jakacki R, 526A
Jakobs C, 925
Jaksch M, 161
Jalava H, 533A
Jambou F, 559
Janardhan V, 469A
Janss A, 526A
Jellinger KA, 476A
Jenner AR, 189
Jennings D, 794
Jensen E, 464A
Jensen FE, 521A
Johnson MA, 787
Johnson MI, 537A
Johnson RT, 1, 802
Johnston J, 547A
Johnston SC, 479A, 501A, 505A
Johnston W, 494A
Jolesz F, 755
Jonas RA, 546A
Jones CR, 484A
Jones HR Jr, 535A
Jones M, 488A
Joo IS, 474A
Joosse M, 617, 708
Joseph A, 539A
Joshi C, 532A
Jueptner M, 901
Juhász C, 532A, 533A
Julien J, 224
Juncos J, 492A
Jurkat-Rott K, 305

Kadakia S, 549A
Kaddurah AK, 532A
Kadimi S, 450A, 510A
Kalaydjieva L, 36
Kalb RG, 366
Kalifa C, 550A
Kalman B, 456A, 469A
Kamholz J, 471A, 938
Kaminski HJ, 485A
Kamphorst W, 617, 747
Kamran S, 495A
Kanazawa I, 806
Kane K, 453A
Kaneoke Y, 22
Kang D, 920
Kang J, 467A
Kang PB, 544A
Kanno T, 723
Kantarci OH, 456A
Kaplan AM, 550A
Kaplan JA, 598
Kaplan RF, 494A
Karch H, 484A
Karia RM, 531A
Karluk D, 598
Kaslow R, 490A
Kastrukoff LF, 457A, 487A
Kato M, 660
Katsetos CD, 520A, 522A, 538A, 542A
Katz ML, 521A
Kaufmann WE, 528A
Kawano Y, 472A
Kaye E, 534A
Kazis L, 507A
Keating GF, 550A
Keats B, 36
Kelkar P, 480A
Kemp S, 409
Kemper TL, 207
Kennedy DN, 545A
Kennedy WR, 461A
Kenney KL, 452A
Keran CM, 505A
Kerby T, 491A
Khajavi M, 462A
Khan E, 548A
Khan O, 471A, 938
Khazipov R, 95
Khella SL, 492A
Khoury P, 533A
Khurana V, 910

Kida H, 480A
Kiernan M, 526A
Kikinis R, 755
Kikuchi H, 469A
Kikui S, 474A
Kilpinen-Loisa P, 533A
Kim S, 501A
Kim SU, 457A, 473A, 474A
Kim T, 508A
Kimura J, 484A
Kinman J, 45
Kinoshita M, 492A
Kira J-i, 453A, 459A, 469A, 472A
Kirk M, 457A, 935
Kirsch J, 509A
Kish S, 937
Kish SJ, 936
Kitzler H, 485A
Klausner Y, 495A
Kleeberger C, 490A
Klein AM, 842
Klein C, 176, 794
Klingel-Schmitt I, 559
Klingler W, 305
Kneissl M, 207
Knoblach S, 496A
Kobayashi H, 112
Kobayashi T, 263
Koch-Henriksen N, 612
Kochounian HH, 938
Koenigsberger MR, 531A
Koeppen AH, 938
Koivikko M, 533A
Kokkinakis DM, 491A
Kokmen E, 454A, 486A
Kolasa K, 451A
Kolbasnik A, 478A
Kolodny EH, 530A
Konchanin L, 549A
Kondapaneni P, 528A
Kontula K, 382
Koo B, 523A
Kopp N, 224
Koppenhafer SL, 935
Koprowski H, 473A
Korczyn AD, 115, 461A
Kordower JH, 419
Kornblum HI, 343
Koroshetz WJ, 556
Korson MS, 547A
Kossak B, 536A
Koth CW, 528A
Kothari R, 450A
Koumaras B, 453A
Kovach I, 461A
Kovacs J, 544A
Kowall NW, 460A
Kozovska M, 463A
Krack P, 126
Kramer P, 794
Kramer PL, 176
Kreimer A, 936
Kreiter K, 450A
Kretzschmar H, 224
Kretzschmar HA, 693
Krishnamoorthy KS, 548A
Krishnan VV, 936
Krupp L, 475A
Kuban K, 527A
Kubota K, 467A
Kuemmerle S, 842
Kugler SL, 531A
Kuhn R, 671
Kukull WA, 501A
Kulkarni AB, 536A
Kumar SM, 547A
Kun L, 526A
Kun LE, 834
Kuncl RW, 462A
Kuntz KM, 486A
Kurohara K, 452A
Kurup A, 428
Kuzniecky R, 508A
Kwak S, 806
Kyvik KO, 606

Laaksonen M, 612
Labaye N, 648
Lacroix C, 770
Ladenheim B, 539A
Lafranchise EF, 504A
Lagae L, 532A
Lahat E, 522A, 524A
Lahiri D, 454A
La Mantia L, 435
Lampe JB, 485A
Lane J, 525A
Lang AE, 936
Langdon DW, 507A
Lange HKW, 260
Langston J, 834
Langston JW, 598
Långström B, 359
Lannon MC, 491A
Lapresle J, 770
Laribi O, 103
Larsen F, 612
Larsson E, 684
Latov N, 461A
Lau AS, 487A
Lau N, 446A
Lawn ND, 464A, 467A
Lawrence E, 496A
Lawson MA, 550A
Lax D, 462A
Learish RD, 716
Lederman HM, 287
Lee A, 507A
Lee DA, 937
Lee JM, 325
Lee K-E, 428
Lee KS, 474A
Lee L, 470A, 502A
Lee RT, 547A
Lee WB, 543A
Lee W-L, 428
Lee YB, 473A, 474A
Legarda S, 543A
Leger D, 648
Legido A, 520A, 522A, 538A, 542A
Lehmann-Horn F, 305
Leite JP, 343
Lennon VA, 457A, 464A, 465A
Lennox GG, 479A
Lenzi GL, 509A
Leon C, 453A
Leonard DGB, 271
Leonardis L, 36
Leonhardt G, 901
Le Piane E, 465A
Leppert M, 671
Lerche H, 305
Lesaux J, 493A
Lesca G, 530A
Lessard D, 506A
Lessov N, 448A, 449A
Leung GY, 487A
Leurgans S, 477A
Levasseur P, 559
Leverenz JB, 271
Levey AI, 103
Levine R, 508A
Levinrad LI, 504A
Levinson A, 478A
Levisohn P, 523A
Leviton a, 527A
Levy R, 249
Lewis R, 938
Lewis RF, 287
Li DKB, 197, 472A
Li F, 333
Li H, 504A
Li LYJ, 480A
Li Q, 491A
Li S-H, 842
Li X-J, 842
Liau L, 464A
Lidell C, 684
Lieberman AP, 271
Lima GM, 548A
Limousin P, 217
Lin I-F, 452A
Lin M-I, 531A
Lin WL, 542A
Lindall AW, 461A
Lindhout D, 739
Lindner M, 305
Linzer M, 507A
Liow K, 456A
Liow M, 456A
Lipani JD, 937
Liporace JD, 45
Lippa CF, 452A, 453A
Lipton R, 509A
Lisak R, 471A, 938
Lisak RP, 457A
Liu C, 502A
Liu J, 444A
Liu K-F, 333
Liu X-S, 520A
Lleó A, 434
Lochmüller H, 485A
Locke GE, 507A
Lockwood AH, 460A
Loehr A, 446A
Logan WJ, 551A
Long D, 464A
Longstreth WT Jr, 501A
Longuemaux S, 433
López G, 492A
Lopez-Terradas MJM, 536A
Lott IT, 538A
Lozano AM, 249
Lu C-S, 651
Lu F, 456A
Lu M, 450A
Lublin F, 132
Lucarelli P, 529A
Lucchinetti CF, 878
Lucotte G, 433
Ludolph AC, 708
Ludwin S, 470A
Lulli L, 161
Lunn MPT, 267
Luo Y, 537A
Lupski JR, 313
Lycklama á Nijeholt GJ, 747
Lyden P, 450A
Lynch T, 243

Ma J, 445A
Ma SY, 419
Macaskill P, 910
Macias R, 492A
Mackey B, 444A
MacKinnon JA, 183
MacMahon EME, 267
MacManus DG, 850
MacMillan L, 549A
Mactutus C, 488A
Madsen HO, 612
Mahendru P, 460A
Maillot MC, 559
Majnemer A, 541A
Mak M, 469A
Makris N, 545A
Malandrini A, 271
Malkoff M, 448A, 509A
Malkoff MD, 509A
Mallory GB Jr, 540A
Mandelbaum DE, 531A
Manly J, 412
Mann D, 243
Manor O, 539A
Manwaring KH, 550A
Maragoto C, 492A
Marescaux C, 929
Marín C, 774
Markopoulou K, 374
Marks HG, 530A, 547A, 549A
Marks MP, 448A, 568
Marler J, 450A
Marrosu MG, 799
Martel AR, 479A
Martin DM, 761
Martin R, 508A
Marubuchi S, 492A
Marx A, 167
Maselli RA, 534A
Masliah E, 454A

Mason WP, 464A
Massa G, 435
Massa R, 929
Massa S, 444A
Massa SM, 436
Mast J, 539A
Masters CL, 656, 860
Mathern GW, 343
Mathew RK, 934
Maton BM, 508A
Matoth I, 534A
Matsumura K, 459A
Matsuno S, 933
Matsuura T, 462A, 480A
Mattia D, 816
Mattson MP, 587
Mattson RH, 455A
Matusevicius D, 470A
Matveeva EA, 487A
May A, 791
Mayer SA, 450A
Mayeux R, 412, 452A
Mayo M, 505A
Maytom M, 15
Mazurek MF, 478A
McAbee G, 549A
McArthur JC, 391, 490A
McCarthy KS, 523A
McCormick E, 536A
McDonald ES, 445A
McDonald WI, 468A, 471A
McFarland H, 132
McFarland HF, 141, 425
McGaum SA, 525A
McGee K, 533A
McGuire D, 505A
McKee AC, 460A
McKelvie P, 656
McKhann G, 579
McLean CA, 656, 860
McLellan DL, 468A
McLendon RE, 491A
McLeod JG, 910
McMillan M, 938
McMonagle P, 481A
McMurray CT, 456A
McNamara JO, 537A
McNeil RS, 522A
McRae C, 454A, 498A
Medinsky S, 115
Meekins GD, 484A
Megdad Z, 476A
Mehta M, 526A
Mehta PD, 412, 489A
Mehta S, 536A
Meier TJ, 479A
Meitinger T, 161
Melamed E, 459A, 495A
Melamed M, 458A
Melanson D, 88
Melberg A, 684
Melville PM, 488A
Melvin J, 534A, 542A
Melyan Z, 95
Menache CC, 546A
Mendoza D, 343
Mendoza M, 494A
Merchant C, 412, 504A
Mesleh MF, 936
Messina J, 453A, 497A
Messina LM, 479A
Metz-Lutz MN, 929
Meucci N, 119
Mewes K, 22
Michon AM, 536A
Miglioretti D, 579
Mikami A, 467A
Mikulis DJ, 551A
Milanese C, 435
Milazzo M, 458A
Miller D, 296
Miller DH, 468A, 471A, 850
Miller EN, 490A
Miller F, 549A
Miller J, 464A, 496A, 497A
Miller RG, 494A, 506A
Miller SP, 545A, 548A
Miller TM, 462A
Miller VS, 540A
Milrod L, 536A, 546A
Milstien S, 528A
Minagar A, 472A, 497A
Minahan R, 579
Minami M, 479A
Minassian BA, 627
Minderhoud JM, 70
Mineta M, 176
Ming X, 531A
Mink J, 544A
Minohara M, 472A
Mintz M, 529A
Mishra BB, 486A, 487A
Mishra L, 486A, 487A
Mishra OP, 520A, 522A, 538A
Mister DT, 524A
Mitchell BS, 504A
Mitchell W, 536A
Mitchell WG, 531A
Mitchell WM, 6
Mitoma H, 263
Mitrovic N, 305
Mitsuroto H, 506A
Mittman B, 501A
Miyai I, 467A
Miyako K-i, 920
Mizrahi EM, 525A
Mizuno Y, 920
Mizusawa H, 263
Mock DJ, 488A
Mohamed A, 910
Mohamed AH, 463A
Mohamed IS, 545A
Mohamed TS, 530A
Mohr JP, 481A, 680
Mokhtari K, 913
Mokri B, 475A
Moll A, 482A
Möller T, 472A
Molloy PT, 522A
Molyneux PD, 296, 850
Monaghan EP, 524A
Monga SPS, 486A, 487A
Monpiou S, 929
Montalban X, 471A
Monti L, 207
Moody AR, 479A
Moore D, 494A
Moragos W, 488A
Moratalla R, 445A
Morel-Betances KT, 453A
Morello A, 541A
Morgan PS, 479A
Morgan-Hughes JA, 916
Morgenstern LB, 448A
Morikawa A, 783
Moroney JT, 452A, 453A, 481A
Morris DC, 494A
Moscarello MA, 469A, 470A
Moschel RM, 491A
Mosek A, 486A
Moseley IF, 850
Moseley ME, 448A, 568
Moses JW, 496A
Moshang T, 526A
Mosier D, 463A
Moskowitz M, 445A
Moss SD, 550A
MRI Analysis Center, 470A, 502A
Mufson EJ, 419, 452A
Muir AB, 546A
Muir KW, 481A
Muir P, 267
Mulhern RK, 834
Mulkern RV, 520A
Müller S, 901
Müller-Hermelink H-K, 167
Mulroy A, 451A
Muma NA, 325
Munoz S, 466A
Munsat TL, 140
Munson PJ, 425
Murasko K, 526A
Murata T, 129A
Muriel M-P, 103
Murphy JV, 525A
Murphy K, 436
Muruguppan A, 506A
Musante DB, 472A
Muzik O, 530A
Myllykangas L, 382
Myong NH, 474A

Nadareishvili Z, 508A
Nagamatsu K, 480A
Nagamitsu S, 462A, 480A
Nagatsuka S-i, 62
Nägele A, 693
Naiman D, 936
Naini A, 481A
Nakabeppu Y, 453A, 920
Nakagawa E, 457A
Nakamura H, 490A
Nakamuro T, 474A
Nakano S, 484A
Nakazato Y, 783
Nako Y, 783
Namba H, 62
Namba Y, 136
Narayana PA, 470A, 471A, 502A
Nath A, 488A
National Multiple Sclerosis Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, 132
Natowicz MR, 547A
Navia BA, 207
Neary D, 243
Nee LE, 453A
Nelles G, 901
Nelson IP, 916
Neumann PJ, 502A
Neve R, 459A
Neville H, 494A
New G, 496A
Newbrough JR, 508A
Newland C, 639
Newsom-Davis J, 639
Newton HB, 493A
Ngo H, 522A
Ni OK, 546A
Nicholson HS, 526A
Niermeijer MF, 617
Niesen CE, 542A
Nigro MA, 536A
Niinistö L, 382
NINDS t-PA Stroke Study Investigators, 450A
Nishino I, 794
Nishizawa M, 480A
Nisipeanu P, 115, 475A, 492A
Nitta H, 112
Nix W, 167
Nizam MF, 536A
Nobezawa S, 723
Nobile-Orazio E, 119
Nochlin D, 453A
Noetzel M, 536A
Norona F, 471A
Norris J, 508A
Noseworthy JH, 878
Novero J, 473A
Nowinski CV, 523A
Nygaard TG, 794

Obeso JA, 492A
O'Brien PC, 382, 454A, 878
Ochoa L, 492A
O'Connor MJ, 45
O'Connor PW, 470A, 502A
Oda T, 480A
Oda Y, 546A
Oetgen M, 496A
Oexle K, 137
O'Fallon WM, 486A

Offen D, 458A, 459A, 495A
Oger J, 482A
O'Gorman AM, 545A, 548A
Oh HM-L, 428
Oh PI, 508A
Ohnishi A, 480A
Ohshima T, 536A
Ohta T, 660
Ohyagi Y, 453A, 459A
Ojaimi J, 656
Ojemann GA, 343
Okada H, 723
Oldfield EH, 732
Oldfors A, 684
Olesen J, 606
Oleszak E, 542A
Oliveri RL, 465A
Olivier A, 88, 816
Olvera R, 528A
O'Neill BP, 463A
Ono S, 492A
Opeskin K, 656
Ornon F, 524A
Orr M, 15
Oshiro Y, 490A
Osterloh IH, 15
Otsubo H, 627
Otterud B, 671
Oturai A, 612
Ouchi Y, 136, 723
Oudkerk M, 827
Ovrutskaya I, 523A
Owen F, 243
Ozand PT, 466A
Ozawa T, 112
Ozelius LJ, 176, 761, 794

Packer RJ, 526A
Paclitaxel Study Group, 470A, 502A
Paganini-Hill A, 455A
Pagano M, 527A
Pahapill PA, 249
Paik MC, 452A
Paillard M, 648
Paillex R, 887
Palfi S, 419
Palmbach M, 708
Palmer SC, 546A
Palmer SL, 834
Palminiello S, 529A
Pan JW, 475A
Panet H, 459A
Pant HC, 536A
Paolillo A, 296
Papa SM, 732
Pappas C, 671
Paradiso G, 701
Parchi P, 224
Pardo JV, 281
Parfrey N, 481A
Parry GJ, 480A, 494A, 506A
Parsons DS, 451A
Parsons SK, 502A
Parvez S, 458A
Pasquinelli G, 465A
Pasternak JF, 520A
Patel R, 531A
Patenaude Y, 545A, 548A
Patterson V, 916
Paty D, 498A
Paty DW, 197, 472A
Paulin M, 452A
Paulson HL, 935
Pavón N, 492A
Pearl P, 548A
Pearl PL, 524A
Pedersen T, 453A
Pediatric Oncology Group, 526A
Pegg AE, 491A
Peiffer E, 217
Pendlebury WW, 448A
Penn R, 419
Pennell PB, 477A
Penney JB Jr, 761
Pérez-Tur J, 382
Pestronk A, 536A
Petajan J, 494A
Peters ACB, 634
Petersen RC, 243, 454A
Peterson K, 463A
Peterson P, 532A
Petroff OAC, 455A
Petterson TM, 878
Petty R, 481A
Peyron R, 256
Pfeiffer A, 671
Pfeiffer RF, 374
Phan TG, 463A
Philip P, 648
Philippart M, 544A
Phillips P, 526A
Piccardo P, 224
Pickering-Brown S, 243
Pierre-Khan A, 550A
Pifarré A, 774
Pillon B, 217
Pineda AA, 878
Pinter JD, 539A
Pinto F, 534A
Plant GT, 468A
Planté-Bordeneuve V, 770
Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group, 484A
Platsoucas CD, 542A
Platt B, 504A
Plauchu H, 530A
Pliszka S, 528A
Pluda J, 491A
Podratz JL, 483A
Pohlmann-Eden B, 468A
Poirier J, 454A
Polk MJ, 451A
Pollak P, 217
Pollard JD, 910
Pollen DA, 453A
Polman CH, 79, 471A, 747
Polvikoski T, 382
Pongratz DE, 485A
Popovic M, 36
Porfirio C, 529A
Poser S, 224, 693
Potter DL, 495A
Pouwels PJW, 79, 925
Powers JM, 488A
Pozzilli C, 473A
Prabhu VV, 425
Prados M, 526A
Prasad A, 534A
Prat A, 253
Presley R, 505A
Pressley J, 504A
Pretorius JK, 343
Prevot E, 648
Prince DA, 234
PRISMS Study Group, 197, 472A
Pryor J, 481A
Przedborski S, 135
Ptáček LJ, 455A, 475A
Pugliatti M, 799
Pugliese M, 528A
Pulkes T, 916
Pulsifer M, 579
Puri V, 536A
Pusa A-K, 382

Quarles RH, 486A
Quattrone A, 465A
Querfurth H, 459A, 494A
Quintero-Del-Rio AI, 540A

Rabinstein A, 497A
Ragheb S, 457A
Raine CS, 144
Rajdev S, 444A
Rammohan KW, 456A
Ramsey NF, 405
Rando TA, 135
Ransohoff RM, 679
Ransom BR, 472A, 489A
Rauch E, 416
Rausch W-D, 260
Ravid R, 617, 747
Ravits J, 494A
Raymond D, 794
Reddick WE, 834
Reeves AG, 598
Reggin JD, 536A
Reich S, 325
Reichmann H, 485A
Reilly S, 475A
Reiners K, 260
Reingold S, 132
Ren JM, 934
Ren XS, 507A
Reske S, 708
Rewcastle NB, 183
Rezai AR, 249
Riback PS, 540A
Rice GPA, 493A
Rice J, 541A
Rich JN, 491A
Richmonds C, 485A
Riederer P, 260
Rigamonti D, 464A
Ringel S, 494A, 506A
Rioux SD, 536A
Ris MD, 526A
Ristanovic R, 494A
Ristori G, 474A
Rita D, 547A
Rivkin MJ, 520A
Rizvi S, 488A
Rizzu P, 617
Roach S, 541A
Robbins J, 279
Roberson M, 451A
Roberts RG, 936
Robertson P, 526A
Robertson RL, 520A
Robin E, 913
Robinson BH, 549A
Robinson W, 536A
Robitaille Y, 271
Rodrigues FS, 548A
Rodriguez M, 878
Rogg J, 543A
Rojas R, 434
Rojiani A, 224
Romagne F, 559
Ropper AH, 463A
Rorke L, 526A
Rosati G, 799
Rosebush P, 478A
Rosen GD, 189
Rosenbaum DM, 479A
Rosenbaum P, 541A
Rosenbaum PS, 479A
Rosenberg PA, 521A
Rosenblum MK, 550A
Rosenfield DB, 447A
Rosoklija G, 135
Ross BD, 544A
Ross M, 494A
Rosso SM, 617
Rostasy K, 207
Rother M, 493A
Rothermel R, 523A
Rothman DL, 455A
Rothman SM, 539A
Rothstein TL, 468A
Roubin GS, 496A
Rouleau GA, 115, 936
Royal W, 462A
Royall DR, 451A
Rudick R, 490A
Rurangirwa L, 531A
Russell D, 498A
Russell JW, 460A, 483A
Russell MB, 606
Russo C, 526A
Rutecki P, 446A
Rutka JT, 627
Rutten GJM, 405
Ryder LP, 612
Rydin E, 359
Rye DB, 800

Sabbagh MN, 454A
Sabroso RL, 548A
Sacco RL, 452A
Sadrzadeh SMH, 462A
Said G, 770
Saito E, 660
Saito F, 459A
Saiz A, 774
Sakamoto M, 723
Sakuragawa N, 538A
Salganicoff L, 534A, 549A
Salmaggi A, 435
Salmon RD, 504A
Salvetti M, 473A
Salvi RJ, 460A
Samrén EB, 739
Samson R, 462A
Sanahuja J, 434
Sandberg-Wollheim M, 612
Sands N, 548A
Sano M, 453A
Sanson M, 913
Santa H, 459A
Santoro M, 461A
Saper CB, 935
Sapolsky RM, 479A
Sappey-Marinier D, 256
Saragovi HU, 537A
Sasaki H, 480A
Sato S, 456A
Saunders-Pullman RJ, 794
Savitz SI, 479A
Sawcer S, 612
Sayin U, 446A
Scammell TE, 935
Scarlato G, 119
Scavina M, 547A
Schalke B, 167
Schechtman E, 492A
Scheffer S, 475A
Schiff HB, 494A
Schilling K, 176
Schleithoff L, 305
Schluep M, 887
Schmalbruch H, 274
Schmier J, 509A
Schmoll CM, 525A
Schold SC Jr, 491A
Schor NF, 537A
Schrader JW, 473A
Schreiber SS, 487A
Schreiner A, 468A
Schultz A, 167
Schultz G, 449A
Schulz P, 416
Schulz-Schaeffer WJ, 224, 693
Schwarz J, 708
Schwarzschild MA, 445A
Schweiger C, 493A
Scioscia F, 473A
Scott GS, 473A
Scott JN, 183
Scott TF, 473A
Scribanu N, 467A
Sébire G, 934
Sei S, 521A
Seitz RJ, 51
Sekijima Y, 933
Selak MA, 534A, 549A
Selcen D, 536A
Selim AJ, 507A
Selim MH, 458A
Sendera T, 419
Serra C, 799
Serrano C, 434
Seybold ME, 140
Seymour K, 544A
Shah NS, 542A
Shahar E, 524A
Shaikh ZA, 469A
Shalev R, 539A
Shalev RS, 524A
Shanske S, 462A
Shapira SK, 529A
Sharief M, 496A, 497A
Sharki J, 458A, 495A
Sharp FR, 436, 444A
Shaw D, 664
Shaw PJ, 787, 803
Sheng M, 936
Shevell MI, 541A, 545A, 548A
Shibuya S, 460A
Shimadzu M, 936
Shimizu T, 459A
Shimura-Miura H, 920
Shinnoh N, 466A
Shinotoh H, 62
Shionoya A, 522A
Shiraishi K, 480A
Shoji S, 933
Shu S, 520A, 527A
Shuaib A, 491A
Shulman LM, 497A, 802
Sibley W, 132
Sicsic C, 534A
Siddiqui A, 916
Siderowf A, 508A
Siklos L, 463A
Sildenafil Study Group, 15, 497A
Silver B, 478A
Silver K, 543A
Simmons B, 534A
Simmons Z, 462A
Simon EM, 539A
Simon RP, 445A
Simovic D, 463A
Singh M, 479A
Singleton JR, 484A
Sininger Y, 36
Siren A, 533A
Sjulson L, 391
Skotzko MJ, 938
Skworc KH, 693
Slevin JT, 487A
Slivka MA, 493A
Sloan R, 490A
Sluiter WJ, 70
Slyer S, 496A
Small S, 504A
Small SA, 412
Smiroldo J, 475A
Smith AG, 484A
Smith B, 494A
Smith MD, 15
Smith MJ, 860
Smith R, 509A
Smith RG, 463A
Smith RH, 465A
Smurawska L, 508A
Snead OC III, 627
Snodgrass SR, 542A
Snowden J, 243
Solomon G, 532A
Song S-Y, 263
Sorensen PS, 612
Sorenson EJ, 483A
Sotak CH, 333
Sotgiu S, 799
Souayah N, 492A
Soufflet C, 524A
Soung M, 464A
Spadafora P, 465A
Spanaki M, 456A
Spandou E, 520A, 522A, 538A
Sparagana SP, 936
SPASE-I Study, 509A
Spataro J, 550A
Spencer SS, 894
Sperfeld AD, 708
Sperling MR, 45
Spiekermann G, 901
Spillantini MG, 617
Spiro A, 461A
Spitsin S, 473A
Sposto R, 526A
Spring P, 910
Sriram S, 6
Staats P, 505A
Stadelmann C, 476A
Stålberg E, 684
Standaert D, 445A
Standaert DG, 761
Starr A, 36
Stavrou T, 526A
St Clair D, 664
Stein MA, 524A
Steinberg GK, 479A
Steinberg SJ, 409
Steinlein OK, 305
Steinway M, 486A
Stenzel-Poore M, 448A
Stephenson J, 481A
Stern MB, 508A
Stern Y, 412, 504A
Stevens C, 493A
Stevens LN, 878
Stevens M, 617
Stevenson VL, 471A
Stewart D, 937
St Louis EK, 504A
Stopa E, 543A
Storch A, 708
Storen EA, 449A
Storey JR, 495A
Stowe TG, 543A
Stowell N, 530A
Strasser S, 472A
Stratton CW, 6
Streichemberger N, 224
Strittmatter SM, 366
Stroke Scale Committee of the Japan Stroke Society, 505A
Strong R, 496A
Strupp M, 416
Struys EA, 925
Stuart SB, 477A
Studney D, 498A
Stuve O, 319
Styren SD, 452A
Suchowersky O, 477A
Sue CM, 462A
Sufit RL, 506A
Sulkava R, 382
Sullivan K, 460A
Sun D, 470A
Sun GH, 479A
Sun Y, 444A
Sunada Y, 459A
Sung C-Y, 651
Suwan N, 543A, 547A
Suzuki T, 467A
Suzuki Y, 480A
Suzumura A, 447A, 474A
Svejgaard A, 612
Swan AV, 484A
Swanson JW, 486A
Swarztrauber K, 501A, 505A
Swearer JM, 453A
Swoboda KJ, 547A
Szumlanski C, 477A

Tabaa MA, 504A
Taher M, 484A
Taillandier L, 913
Taji K, 462A
Takada A, 480A
Takahashi H, 452A
Takanashi M, 467A, 490A
Takayanagi T, 474A
Takiyama Y, 480A
Takizawa N, 660
Takuma H, 806
Talalay P, 139
Tamaoka A, 933
Tamaru T, 447A
Tampieri D, 88
Tan AK-Y, 428
Tan C-B, 428
Tan Z, 487A
Tanabe Y, 313
Tanada S, 62
Tanaka H, 490A
Tanaka K, 112, 457A
Tanaka T, 536A
Tang M-X, 412
Tani LY, 523A
Taniwaki T, 453A, 459A
Tao ML, 502A
Tardo C, 523A
Tashiro K, 480A
Tasker RR, 249

Tatlisumak T, 333
Tatsch K, 708
Tayem H, 466A
Taylor J, 834
Taylor ML, 520A, 522A
Tedroff J, 359
Teijeiro J, 492A
Tein I, 549A
Tenner AJ, 538A
Tennison M, 476A
Terayama Y, 505A
Terry JB, 450A, 510A
Tetrud J, 598
Thal LJ, 454A
Tharp A, 6
Tharp B, 529A
Theodore WH, 800
Thiessen B, 482A
Thio LL, 537A
Thomas EE, 487A
Thomas G, 913
Thompson AJ, 468A, 471A, 507A, 747
Thompson JA, 523A, 532A, 671
Thompson M, 537A
Thorarensen O, 521A
Thornton KM, 936
Tienari PJ, 382
Tifft C, 548A
Tijssen MAJ, 634
Tiraboschi P, 454A
Tiranti V, 161
Tirschwell DL, 501A
Tjia HT-L, 428
Tohgi H, 129A
Tokuda T, 933
Tolmie J, 481A
Tolosa E, 774
Tomé FMS, 115
Tong DC, 448A, 568
Torizuka T, 723
Torres A, 492A
Torres AR, 535A
Toyka KV, 484A
Tran TX, 546A
Trent JM, 425
Tresser NJ, 425
Trevathan E, 531A
Triche S, 22
Tripoli J, 701
Trivedi J, 541A
Trojanowski JQ, 271
Trommer BL, 520A
Troncoso JC, 325
Trugman JM, 936
Tselis A, 471A, 938
Tsuji S, 112
Tubiana AL, 550A
Tulyapronchote R, 450A, 510A
Tung G, 543A
Turkel CC, 494A
Turnbull DM, 787
Turner R, 791
Twamley B, 447A
Tzartos S, 167

UBC MS/MRI Analysis Research Group, 197
UBC MS/MRI Research Group, 472A
Uchida S, 538A
Uchihara T, 263
Uchio EM, 490A
Ueki A, 136
Uhl GR, 936
Uhm JH, 319
Ulrich V, 606
Umapathi T, 428
Upton-Rice MN, 934
Uziel G, 161

Vadiei K, 494A
Vaisleib I, 523A
Valk J, 925
Vanacore N, 509A
Vanaman TC, 487A
van Beekvelt MCP, 667
van der Knaap MS, 925
van der Naalt J, 70
van der Valk P, 747
van der Veen R, 938
van Duijn CM, 739
van Engelen BGM, 667
van Gelderen P, 123
van Gijn J, 827
Van Orman CB, 532A
van Rijen PC, 405
van Schijndel RA, 79
van Swieten JC, 617
van Veelen CWM, 405
van Waesberghe JHTM, 747
van Walderveen MAA, 79, 747
van Zomeren A, 70
Varsou A, 528A
Varvil T, 671
Vasconcelos MM, 548A
Veeranna, 536A
Venkataraman V, 523A
Verghese J, 451A
Vergouwe MN, 634
Verhelle B, 532A
Verhoeven NM, 925
Verkkoniemi A, 382
Vernino S, 464A, 465A
Verro P, 506A
Vervisch J, 532A
Vezina G, 526A
Vicente V, 449A
Vickrey B, 501A
Vieregge P, 693
Vighetto A, 256
Viikinsalo M, 508A
Vincent A, 482A, 483A, 559, 639
Vining E, 579
Vissing J, 274
Viswanath NS, 447A
Vital C, 224
Vitek JJ, 496A
Vitek JL, 22
Vo A, 454A, 498A
Vollmer TL, 458A, 474A
Volpe BT, 467A
Volpe JJ, 521A, 546A, 755
von Reinhardstoettner A, 416
von Tell D, 399
Votaw JR, 477A

Wagner K, 850
Wahl LM, 391
Wakayama Y, 460A
Waldmann H, 296
Waldvogel D, 123
Walsh CA, 444A, 547A
Walsh K, 459A
Walter MC, 485A
Walther D, 936
Wang M, 937
Wang PY, 528A
Wang XY, 472A
Wara W, 526A
Warach S, 478A
Warfield S, 755
Waring S, 243
Warren L, 934
Wasay M, 541A
Wasiewski W, 541A
Watamura S, 494A
Watanabe Y, 467A, 490A
Watase K, 480A
Watkins PA, 409
Watkins SC, 445A
Waubant E, 490A
Webb S, 481A
Wei WW, 938
Weidenheim K, 461A
Wein TH, 448A
Weinberg DH, 463A
Weiner LP, 938
Weiner WJ, 497A
Weinshenker BG, 456A, 878
Weinshilboum RW, 477A
Weisberg S, 447A
Weiss MD, 486A
Weiss S, 627
Weissbrich B, 484A
Welch KMA, 476A
Wendelschafer-Crabb G, 461A
Wender R, 489A
Werring DJ, 468A
Wessel DL, 546A
Westmoreland B, 464A
Wevers RA, 667, 925
Wheless JW, 523A
Whitaker JN, 457A, 470A, 935
White S, 455A
Whiteheart SW, 487A
Whitney LW, 425
Widener WG, 504A
Wielaard R, 634
Wijdicks EFM, 449A, 467A, 504A
Wikström G, 684
Wilisch A, 167
Willcox N, 483A
Willis J, 541A
Wilms H, 126
Wilver K, 547A
Windebank AJ, 445A, 483A
Windl O, 224, 693
Wing MG, 296
Winner PK, 541A
Winning S, 536A
Wirguin I, 461A
Wischik C, 664
Wise MS, 525A
Wisniewski HM, 412
Wissoff J, 526A
Witteman JCM, 827
Wolinsky JS, 132, 470A, 471A, 502A
Wolters P, 521A
Wong LJ, 548A
Wong M, 537A, 540A, 544A
Woo D, 450A
Wood DD, 469A
Wood NW, 916
Woods D, 449A
Woods WS, 460A
Wright B, 495A
Wright P, 495A
Wszolek ZK, 374, 454A
Wu B, 444A
Wu J-M, 444A
Wu Q, 937
Wu S, 444A, 522A
Wu Y, 937
Würker M, 126
Wynne SK, 528A
Wynshaw-Boris A, 522A

Xin X, 486A
Xu B, 528A
Xu G, 508A
Xuereb J, 664
Xun N, 487A

Yabe I, 480A
Yalamanchi K, 546A
Yamada KA, 537A, 538A, 540A
Yamada S, 660
Yamada T, 453A, 459A, 466A
Yamaguchi M, 62
Yamanouchi H, 783
Yamasaki K, 469A, 472A
Yamashita I, 480A
Yamaya Y, 485A
Yamazaki K, 129A
Yamazaki S, 546A
Yanagihara T, 490A
Yanagisawa M, 935
Yang CC, 490A
Yang Y, 491A
Yanko M, 495A

Yao S-y, 6
Yasuda T, 467A
Ye G-l, 520A
Yen L, 366
Yenari MA, 479A
Yence C, 648
Yiannoutsos C, 207
Yokoo H, 783
Yong VW, 319
Yoshii A, 548A
Yoshikawa E, 723
Yoshikawa H, 546A
Yoshioka A, 485A
Yoshizawa T, 806
Young R, 507A
Younkin DP, 521A, 544A
Younkin S, 453A
Yuen AR, 463A
Zald DH, 281
Zanelli SA, 520A, 538A
Zappulla RA, 536A
Zerr I, 224, 693
Zeviani M, 161
Zhang J, 450A
Zhang J-Y, 22
Zhang S-C, 716
Zhang Y, 777
Zhang Z, 587
Zhao GJ, 472A
Zhou X-P, 913
Zhu JM, 445A
Zidar J, 36
Zielasek J, 484A
Zientara GP, 755
Zimmerman AW, 528A
Zoghbi HY, 480A

Subject Index

Absence epilepsy; *see* Epilepsy, absence

Acetylcholine
- antibodies to acetylcholine receptors, potassium channels, and titin in a patient with thymoma, myasthenia gravis, and limbic encephalitis (Buckley et al) 1999;46:482A
- antibodies to acetylcholine receptors and voltage-gated potassium channels in apparently healthy elderly subjects (Vincent et al) 1999;46:483A
- cranial-manual-cervical dystonia in three unrelated women associated with acetylcholine receptor antibodies: a new syndrome? (Duane and Stuart) 1999;46:477A
- decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease (Tiraboschi et al) 1999;46:454A
- novel functional ϵ-subunit polypeptide generated by a single nucleotide deletion in acetylcholine receptor deficiency congenital myasthenic syndrome (Croxen et al) 1999;46:639

Acetylcholinesterase
- anti-acetylcholinesterase therapy in dementia with Lewy bodies (Querfurth et al) 1999;46:494A
- positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy (Shinotoh et al) 1999;46:62

Acetylcysteine
- *N*-acetylcysteine failure in Friedreich's ataxia (Selcen et al) 1999;46:536A

Acetyltransferases
- acetylator genotype for *N*-acetyltransferase 2 and Parkinson's disease (Dupret et al) 1999;46:433 (Letter)

Acoustic nerve diseases
- hereditary auditory, vestibular, motor, and sensory neuropathy in a Slovenian Roma (Gypsy) kindred (Butinar et al) 1999;46:36
- positron emission tomography studies of auditory pathways in patients with auditory neuropathy (Lockwood et al) 1999;46:460A

Acyl coenzyme A
- role of very-long-chain acyl–coenzyme A synthetase in X-linked adrenoleukodystrophy (Steinberg et al) 1999;46:409

Adams-Oliver syndrome
- progressive central and peripheral nervous system involvement in Adams-Oliver syndrome (Asleson et al) 1999;46:467A

Adderall
- comparing adderall and methylphenidate in attention deficit hyperactivity disorder (Pliszka et al) 1999;46:528A

Adenosine
- focal ischemic brain injury is reduced in mice lacking A2a adenosine receptors (Chen et al) 1999;46:445A

Adenosine cyclic monophosphate
- cyclic adenosine monophosphate– or cyclic guanosine monophosphate–elevating agents prevent oxygen-glucose deprivation–induced oligodendroglial injury (Yoshioka et al) 1999;46:485A

Adenosine deaminase
- adenosine deaminase polymorphism in autistic children (De Luca et al) 1999;46:529A

Adrenoleukodystrophy
- adrenoleukodystrophy protein deficiency does not enhance the activation of microglia (Yamada and Shinnoh) 1999;46:466A
- role of very-long-chain acyl–coenzyme A synthetase in X-linked adrenoleukodystrophy (Steinberg et al) 1999;46:409

African Americans
- clinical profile of relapsing multiple sclerosis in African Americans: impact of immunomodulating therapy on disease course (Khan et al) 1999;46:471A

Age factors
- age-dependent nitric oxide damage of skeletal muscle (Kaminski and Richmonds) 1999;46:485A
- effect of age on presentation of peripheral neuropathy (Gellido et al) 1999;46:451A

Aged
- antibodies to acetylcholine receptors and voltage-gated potassium channels in apparently healthy elderly subjects (Vincent et al) 1999;46:483A
- correlates of dementia and health care cost among Medicare elderly (Husaini et al) 1999;46:508A
- genetic association of α_2-macroglobulin with Alzheimer's disease in a Finnish elderly population (Myllykangas et al) 1999;46:382
- outcomes of prolonged mechanical ventilation in the elderly (Diaz) 1999;46:508A
- SPASE-I (Italian Study on Pharmacological Treatment of Acute Stroke in the Elderly): preliminary results (Lenzi et al) 1999;46:509A
- use of dopamine agonists in very elderly patients with Parkinson's disease (Shulman et al) 1999;46:497A

Aggression
- children with epilepsy and aggression: a distinct pattern of positron emission tomography glucose metabolism (Chugani et al) 1999;46:533A

Aging
- biochemical alterations in the central nervous system of aging mice lacking the gene for myelin-associated glycoprotein (Weiss and Quarles) 1999;46:486A
- dating mechanism for senile plaque formation in Down's syndrome: link between development and aging (Azieh et al) 1999;46:538A
- hippocampal volumes in normal aging predict subsequent cognitive decline (Petersen et al) 1999;46:454A
- irregular distribution of cytochrome *c* oxidase protein subunits in aging and Alzheimer's disease (Ojaimi et al) 1999;46:656
- role of cyclin-dependent kinase 5 in developing and aging nervous system: spatial and temporal expression and phenotype studies by generating new transgenic mice (Tanaka et al) 1999;46:536A

Agnosia
- mirror agnosia and mirror ataxia constitute different parietal lobe disorders (Binkofski et al) 1999;46:51

July issue, pp 1–40; August issue, pp 141–278; September issue, pp 279–552; October issue, pp 553–680; November issue, pp 681–802; December issue, 803–986.

Copyright © 1999 by the American Neurological Association

AIDS-dementia complex
cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia (Conant et al) 1999;46:391
human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex (Rostasy et al) 1999;46:207
influence of human major histocompatibility complex genes on the development of human immunodeficiency virus–associated dementia (McArthur et al) 1999; 46:490A

Alleles
reduced expressoin of the G209A α-synuclein allele in familial parkinsonism (Markopoulou et al) 1999;46:374
tumor necrosis factor 2 allele does not contribute to increased tumor necrosis factor-α production in Sardinian multiple sclerosis (Sotgiu et al) 1999;46:799 (Letter)

Alpha macroglobulins
genetic association of α_2-macroglobulin with Alzheimer's disease in a Finnish elderly population (Myllykangas et al) 1999;46:382

Alpha-synuclein; *see* Synuclein

Alteplase
effect of ischemia and tissue plasminogen activator on middle cerebral artery myogenic reactivity (Cipolla et al) 1999;46:449A
oropharyngeal angioedema: a clinically important complication of intravenous recombinant tissue plasminogen activator (Felberg et al) 1999;46:448A
preliminary observations on the ability of diffusion weighted imaging and perfusion weighted imaging to predict intracranial hemorrhage in patients treated with recombinant tissue plasminogen activator (Tong et al) 1999;46:448A

Alzheimer's disease, analysis
choline acetyltransferase activity in cortex and hippocampus of mild cognitively impaired and Alzheimer's disease patients (DeKosky et al) 1999;46:452A
irregular distribution of cytochrome *c* oxidase protein subunits in aging and Alzheimer's disease (Ojaimi et al) 1999;46:656
overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease (Chambers et al) 1999;46:325
plasma amyloid β-peptide 1–42 and incipient Alzheimer's disease (Mayeux et al) 1999;46:412
soluble pool of amyloid β protein as a determinant of severity of neurodegeneration in Alzheimer's disease (McLean et al) 1999;46:860

Alzheimer's disease, drug therapy
behavioral effects of rivastigmine: interim results from the Neuropsychiatric Inventory-Nursing Home version in nursing home patients with Alzheimer's disease (Edwards et al) 1999;46:453A
effect of rivastigmine on activities of daily living in Alzheimer's disease patients (Grossberg and Messina) 1999;46:497A
72-week study assessing propentofylline's safety, efficacy, and impact on disease progression in patients with Alzheimer's disease (Rother and European/Canadian Propentofylline Study Group) 1999;46:493A

Alzheimer's disease, genetics
apolipoprotein E genotype interaction with serum cholesterol level may influence rate of progression in Alzheimer's disease (Evans et al) 1999;46:454A
association between Alzheimer's disease and the *NOS3* gene (Dahiyat et al) 1999;46:664
familial Alzheimer's disease: site of mutation influences clinical phenotype (Lippa et al) 1999;46:453A
genetic association of α_2-macroglobulin with Alzheimer's disease in a Finnish elderly population (Myllykangas et al) 1999;46:382
lack of apolipoprotein E decreases amyloid deposition and prevents fibrillar plaque formation in the APPsw transgenic model of Alzheimer's disease (Holtzman et al) 1999;46:444A
lack of association between bleomycin hydrolase gene polymorphism and Alzheimer's disease in Japanese people (Namba et al) 1999;46:136 (Letter)

Alzheimer's disease, pathology
Alzheimer's disease and sympathetic ingrowth (Harrell et al) 1999;46:451A
apoptosis in familial Alzheimer's disease (Galvin and Lippa) 1999;46:452A
decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease (Tiraboschi et al) 1999;46: 454A
models of neuronal death in Alzheimer's disease: synergistic effects of β-amyloid and microglia on cell cycle–mediated death of cultured neurons (Geldmacher et al) 1999;46:937A (Works in progress)
pathological determinants of dementia in Alzheimer's disease (Royall et al) 1999;46:451A

Alzheimer's disease, physiopathology
brain plasticity during acquisition of a script verification task (Flitman et al) 1999;46:447A
health utilities in Alzheimer's disease: exploring health states 'worse than dead' (Araki and Neumann) 1999; 46:502A

American Academy of Neurology
trends in university-based neurologists' practice in the 1990s: a report of the American Academy of Neurology Practice Characteristics Subcommittee (Swarztrauber et al) 1999;46:505A

Amino acids
amino acid loading studies and L-serine supplementation in 3-phosphoglycerate dehydrogenase deficiency (Swoboda et al) 1999;46:547A
de novo splice donor site mutation causes in-frame deletion of 14 amino acids in the proteolipid protein in Pelizaeus-Merzbacher disease (Aoyagi et al) 1999; 46:112

Amniotic fluid
synthesis and release of brain-derived neurotrophic factor and neurotrophin-3 by human amniotic epithelial cells (Sakuragawa et al) 1999;46:538A

Amyloid
lack of apolipoprotein E decreases amyloid deposition and prevents fibrillar plaque formation in the APPsw transgenic model of Alzheimer's disease (Holtzman et al) 1999;46:444A

Amyloid beta-protein
amyloid β protein species in cerebrospinal fluid and in brain from patients with Down's syndrome (Tamaoka et al) 1999;46:933 (Letter)
β-amyloid expression is associated with apoptosis in myotubes and triad protein abnormalities in inclusion body myositis (Querfurth et al) 1999;46:459A

amyloid-β peptide levels in serum and cerebrospinal fluid of multiple sclerosis patients (Coyle and Mehta) 1999;46:489A
amyloid-β protein 42 forms a 24-kd complex in normal cells and is deposited in apoptotic neurons (Ohyagi et al) 1999;46:453A
models of neuronal death in Alzheimer's disease: synergistic effects of β-amyloid and microglia on cell cycle–mediated death of cultured neurons (Geldmacher et al) 1999;46:937A (Works in progress)
plasma amyloid β-peptide 1–42 and incipient Alzheimer's disease (Mayeux et al) 1999;46:412
regulation of redox factor expression by β-amyloid (Xun et al) 1999;46:487A
soluble pool of amyloid β protein as a determinant of severity of neurodegeneration in Alzheimer's disease (McLean et al) 1999;46:860

Amyotrophic lateral sclerosis
ALS Patient Care Database: insights into end-of-life palliative care in amyotrophic lateral sclerosis (Clawson et al) 1999;46:506A
basic fibroblast growth factor does not prolong survival in a transgenic model of familial ALS (Upton-Rice et al) (Letter); (Sébire and Chabrier) (Reply) 1999;46:934
calcium, glutamate, and amyotrophic lateral sclerosis: more evidence, but no certainties (Shaw) 1999;46:803 (Editorial)
electrophysiological evaluation of upper motor neuron involvement in amyotrophic lateral sclerosis (Kovach et al) 1999;46:461A
elevated pigment epithelium-derived factor levels in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (Bilak et al) 1999;46:462A
mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death (Borthwick et al) 1999;46:787
paralbumin overexpression alters calcium homeostasis and prolongs survival in a transgenic model of familial amyotrophic lateral sclerosis (Appel et al) 1999;46:463A
phase III placebo-controlled trial of gabapentin in amyotrophic lateral sclerosis (Miller et al) 1999;46:494A
prevalence and treatment outcome of sialorrhea in amyotrophic lateral sclerosis patients as assessed by the ALS Patient Care Database (Sufit et al) 1999;46:506A
proton magnetic resonance spectroscopy in patients with amyotrophic lateral sclerosis (Abe et al) 1999;46:467A
reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis (Takuma et al) 1999;46:806
remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis (Tohgi et al) 1999;46:129A
sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis (Fitting et al) 1999;46:887

Angelman's syndrome
cerebral glucose metabolism in patients with Angelman's syndrome (Mohamed et al) 1999;46:530A

Angiography
cocaine-induced cerebrovascular occlusive disease: new angiographic findings (Storen et al) 1999;46:449A

Angioneurotic edema
oropharyngeal angioedema: a clinically important complication of intravenous recombinant tissue plasminogen activator (Felberg et al) 1999;46:448A

Annals of Neurology
message from the editor (Johnson) 1999;46:1

Anoxia
alterations of calbindin-D_{28k} localization in cerebellar Purkinje cells in the hypoxic guinea pig fetus at term (Spandou et al) 1999;46:522A
apoptosis in perinatal hypoxic–ischemic brain damage: a histopathological study in pontosubicular neuron necrosis (Itoh and Becker) 1999;46:466A
early prediction of poor outcome in anoxic-ischemic coma (Schreiner and Pohlmann-Eden) 1999;46:468A
effect of hypoxia on the expression of inducible nitric oxide synthase in the hippocampus of term fetal guinea pigs (Spandou et al) 1999;46:520A
epileptogenic action of caffeine during anoxia in the neonatal rat hippocampus (Dzhala et al) 1999;46:95
hippocampal long-term potentiation is preserved following neonatal hypoxia-ischemia (Yamada et al) 1999;46:538A
hypoxia-induced nitration of protein in the hippocampus of the guinea pig fetus (Zanelli et al) 1999;46:538A

Antibodies
antibodies to acetylcholine receptors, potassium channels, and titin in a patient with thymoma, myasthenia gravis, and limbic encephalitis (Buckley et al) 1999;46:482A
antibodies to acetylcholine receptors and voltage-gated potassium channels in apparently healthy elderly subjects (Vincent et al) 1999;46:483A
anti–myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy (Meucci et al) 1999;46:119
cerebellar ataxia with glutamic acid decarboxylase antibody (Boylan and Lennon) 1999;46:457A
cranial-manual-cervical dystonia in three unrelated women associated with acetylcholine receptor antibodies: a new syndrome? (Duane and Stuart) 1999;46:477A
cytomegalovirus is not associated with IgM anti–myelin-associated glycoprotein/sulphate-3-glucuronyl paraglycoboside antibody–associated neuropathy (Lunn et al) 1999;46:267
demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation (Raine et al) 1999;46:144
detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders (Saiz et al) 1999;46:774
neurtralizing antibodies to endogenous interferons in multiple sclerosis and myasthenia gravis (Bagnato et al) 1999;46:473A
path to damage in multiple sclerosis (McFarland) 1999;46:141 (Editorial)
Purkinje cell antibody type 2: a new marker of neurological autoimmunity related to small cell lung cancer (Vernino and Lennon) 1999;46:465A
subacute cerebellar degeneration and atypical antineuronal antibody response with anti-Hu reactivity in a patient without identifiable malignancy (Greenlee et al) 1999;46:465A

Antibodies, monoclonal
monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis (Coles et al) 1999;46:296

Anticonvulsants
antiepileptic drug regimens and major congenital abnormalities in the offspring (Samrén et al) 1999;46:739

effects of anticonvulsant lactams on in vitro seizures in the hippocampal slice preparation (Hill et al) 1999; 46:539A

Antigens
demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation (Raine et al) 1999;46:144
heightened IgE response to mite antigens in inflammatory neuropathies (Horiuchi et al) 1999;46:472A
neurofilament is an autoantigenic determinant in myasthenia gravis (Schultz et al) 1999;46:167
novel strategy for specific immunotherapy of autoimmune disease by genetically engineered antigen-presenting cells (Wu et al) 1999;46:444A
structural plasticity of a protein antigen implicated in the immunopathogenesis of multiple sclerosis (Genain et al) 1999;46:936A (Works in progress)

Antiphospholipid syndrome
cardioembolic stroke and the antiphospholipid antibody syndrome: a case report (Kang and Younkin) 1999;46: 544A

Apolipoprotein E
apolipoprotein E genotype interaction with serum cholesterol level may influence rate of progression in Alzheimer's disease (Evans et al) 1999;46:454A
lack of apolipoprotein E decreases amyloid deposition and prevents fibrillar plaque formation in the APPsw transgenic model of Alzheimer's disease (Holtzman et al) 1999;46:444A
prion gene and apolipoprotein E in sporadic inclusion body myositis (Lampe et al) 1999;46:485A

Apoptosis; *see* Cell death

Aquaporin
identification of aquaporin 4 molecule in the replica of normal rat sarcolemma: fracture-label immunoelectron microscopic study (Shibuya et al) 1999;46:460A

Arabitol
leukoencephalopathy associated with a disturbance in the metabolism of polyols (van der Knaap et al) 1999;46: 925

Arachnoid
primary peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the leptomeninges (Antunes et al) 1999;46:550A

Arm
forced use improves upper limb function in childhood hemiparesis (Willis et al) 1999;46:541A

Arrhythmia
autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q (Melberg et al) 1999;46:684
myofibrillar myopathy (Engel) 1999;46:681 (Editorial)

Arterial occlusive diseases
long-term features and prognosis of basilar artery occlusion survivors (Kadimi et al) 1999;46:450A

Arthrogryposis
electromyography and biopsy correlation study of infants with arthrogryposis multiplex congenita (Torres et al) 1999;46:535A

Asperger's syndrome
fluoxetine treatment in children and adolescents with Asperger's syndrome (Mintz and Blumenfeld) 1999; 46:529A

Astrocytes
involvement of p38 MAP kinase pathway in TNF-α production in human astrocytes and microglia (Lee et al) 1999;46:473A

Astrocytoma
molecular pathogenesis of astrocytoma development in neurofibromatosis 1 (Gutmann et al) 1999;46:446A

Ataxia
C13 spectroscopy in vanishing white matter syndrome (Kovacs et al) 1999;46:544A
mirror agnosia and mirror ataxia constitute different parietal lobe disorders (Binkofski et al) 1999;46:51
phosphorus and proton magnetic resonance spectroscopy in episodic ataxia type 2 (Sappey-Marinier et al) 1999; 46:256

Ataxia telangiectasia
ocular motor abnormalities in ataxia telangiectasia (Lewis et al) 1999;46:287

Ataxin
ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease (Lieberman et al) 1999;46:271

Atherosclerosis
Chlamydia pneumoniae and carotid atherosclerosis (Johnston et al) 1999;46:479A

Athetosis
choreoathetosis caused by combined lamotrigine and phenytoin: a pharmacodynamic interaction? (Megdad et al) 1999;46:476A

Atopic myelitis; *see* Myelitis

Atrophy
misleading diagnoses of cerebral atrophy in infants (Snodgrass) 1999;46:542A

Attention deficit disorder with hyperactivity
cerebral palsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? (Shalev et al) 1999;46:539A
comparing adderall and methylphenidate in attention deficit hyperactivity disorder (Pliszka et al) 1999;46:528A
retrospective study of efficacy of tizanidine in children and young adults presenting with Tourette's syndrome, motor tic disorders, attention deficit disorder, or attention deficit hyperactivity disorder (Foradada) 1999;46:529A
sleep disturbances in children with attention deficit hyperactivity disorder (Pearl et al) 1999;46:524A

Auditory neuropathy; *see* Acoustic nerve diseases

Australia
prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia (McLeod et al) 1999;46:910

Autism
adenosine deaminase polymorphism in autistic children (De Luca et al) 1999;46:529A
etiological yield in childhood global developmental delay without autistic traits: a prospective study (Shevell et al) 1999;46:541A
quinolinic acid and neopterin in children with autism: an analysis of cerebrospinal fluid (Comi et al) 1999; 46:528A
secretin used in the treatment of autism: a double-blind clinical trial in children (Chez et al) 1999;46:523A

Autoantibodies
selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase (Ishida et al) 1999;46:263
serum IgM autoantibodies in patients with paraneoplastic and idiopathic opsoclonus myoclonus syndrome recognize neurofilament and histone in neural preparations (Connolly et al) 1999;46:536A

Autoimmune diseases
acquired cerebellar degeneration with Hashimoto's thyroiditis: possible autoimmune mechanisms (Selim and

Drachman) 1999;46:458A
demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation (Raine et al) 1999;46:144
novel strategy for specific immunotherapy of autoimmune disease by genetically engineered antigen-presenting cells (Wu et al) 1999;46:444A
prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis (Aissaoui et al) 1999;46:559

Autoimmunity
Purkinje cell antibody type 2: a new marker of neurological autoimmunity related to small cell lung cancer (Vernino and Lennon) 1999;46:465A

Avonex
prospective, controlled, open-label trial comparing the effect of Avonex, Betaseron, and glatiramer acetate on the relapse rate in patients with relapsing-remitting multiple sclerosis (Khan et al) 1999;46:938A (Works in progress)

Axons
axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability (van Waesberghe et al) 1999;46:747
electrophysiological and morphological characteristics of suramin-induced neuropathy in rats (Russell et al) 1999;46:483A
epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: a reappraisal (Paradiso et al) 1999;46:701
experimental axonal ion channel encephalitis (Burghes and Rammohan) 1999;46:456A
nicotine reduces axonal length and Schwann cell numbers in cultures of sympathetic ganglia (Johnson and Thompson) 1999;46:537A

Backache
assessment of functional status, low back disability, and use of diagnostic imaging in patients with low back pain and radiating leg pain (Ren et al) 1999;46:507A

Baclofen
intrathecal baclofen therapy for the treatment of cerebral palsy in children (Awaad et al) 1999;46:466A

Balo's concentric sclerosis; *see* Encephalitis periaxialis

Basal ganglia
neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus (Vitek et al) 1999;46:22

Basic fibroblast growth factor; *see* Fibroblast growth factor, basic

Basilar artery
long-term features and prognosis of basilar artery occlusion survivors (Kadimi et al) 1999;46:450A

Becker muscular dystrophy; *see* Muscular dystrophy

Beta-amyloid protein; *see* Amyloid beta-protein

Betaseron
prospective, controlled, open-label trial comparing the effect of Avonex, Betaseron, and glatiramer acetate on the relapse rate in patients with relapsing-remitting multiple sclerosis (Khan et al) 1999;46:938A (Works in progress)

Bilateral periventricular nodular heterotopia
familial bilateral periventricular nodular heterotopia in a boy (Wilver et al) 1999;46:547A

Bis(2-chloroethyl)nitrosourea
phase I trial of O^6-benzylguanine plus bis(2-chloroethyl)-nitrosourea for patients undergoing surgery for malignant glioma (Cokgor et al) 1999;46:491A

Bleomycin
lack of association between bleomycin hydrolase gene polymorphism and Alzheimer's disease in Japanese people (Namba et al) 1999;46:136 (Letter)

Blindness
cortically blind or can't tell? (Mast and Ladenheim) 1999;46:539A
sleep disorders in children with blindness (Leger et al) 1999;46:648

Blister
quantitative epidermal nerve analysis in skin blister and skin biopsies (Kennedy et al) 1999;46:461A

Blood pressure
follow-up study of blood pressure and cerebral white matter lesions (de Leeuw et al) 1999;46:827

Blood-brain barrier
newly synthesized thiol-containing substances crossing the blood-brain barrier protect oxidative stress–induced neurodegeneration (Melamed et al) 1999;46:495A

Blood-nerve barrier
opening of the blood-nerve barrier in experimental autoimmune neuritis (Hadden et al) 1999;46:484A

Body mass index
relationship of cerebrospinal fluid opening pressure and body mass index (Mosek et al) 1999;46:486A

Books
Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice, by Eisen and Krieger (Munsat) 1999;46:140
Cerebrovascular Disorders, 5th ed, by Toole (Mohr) 1999;46:680
Clinical Neuroimmunology, edited by Antel et al (Ransohoff) 1999;46:679
Dystonia 3, Advances in Neurology, Volume 78, edited by Fahn et al (Shulman) 1999;46:802
Fifty Neurological Cases from the National Hospital, edited by Wills and Marsden (Johnson) 1999;46:802
Genetics of Cerebrovascular Disease, edited by Alberts (Massa and Sharp) 1999;46:436
The Human Frontal Lobes: Functions and Disorders, edited by Miller and Cummings (Denckla) 1999;46:139
Interventional Neuroradiology: Strategies and Practical Techniques, by Connors and Wojak (Murphy) 1999;46:436
Magnetic Resonance Techniques in Clinical Trials in Multiple Sclerosis: Topics in Neuroscience, edited by Filippi et al (Finelli) 1999;46:680
Mononeuropathies—Examination, Diagnosis, and Treatment, by Staal et al (Chaudhry) 1999;46:679
Neurologic Disease in Women, edited by Kaplan (Seybold) 1999;46:140
Publishing Your Medical Research Paper: What They Don't Teach in Medical School, by Bryne (Talalay) 1999;46:139

Borrelia burgdorferi
disseminated Lyme disease in children (Belman et al) 1999;46:458A
symptomatic early Lyme disease in adults (Coyle et al) 1999;46:488A

***Botulinum* toxins**
retrospective review of dose and safety of *Botulinum* toxin injections in children with cerebral palsy (Delgado and Combes) 1999;46:535A

Brain, growth and development
elf3, a novel β-spectrin gene in brain development (Mishra et al) 1999;46:486A
Brain, metabolism
evaluation of brain metabolism in neurofibromatosis type 1 by magnetic resonance spectroscopy (Kaufmann et al) 1999;46:528A
Brain, surgery
language recovery after left hemispherectomy in children with late-onset seizures (Boatman et al) 1999;46:579
Brain abnormalities
vigabatrin in the treatment of refractory seizures in children with brain malformations (Holder et al) 1999;46:547A
Brain diseases
misleading diagnoses of cerebral atrophy in infants (Snodgrass) 1999;46:542A
Brain edema
cerebral edema after subarachnoid hemorrhage: frequency, causes, and impact on outcome (Mayer et al) 1999;46:450A
Brain injuries
apoptosis in perinatal hypoxic–ischemic brain damage: a histopathological study in pontosubicular neuron necrosis (Itoh and Becker) 1999;46:466A
caspase inhibition reduces posttraumatic neuronal cell loss in vitro and improves motor and cognitive outcome after traumatic brain injury (Faden et al) 1999;46:496A
outcome prediction after acute traumatic brain injury in children using magnetic resonance imaging and proton magnetic resonance spectroscopy (Ashwal et al) 1999;46:520A
proton magnetic resonance spectroscopy in neonates with acute brain injury: comparison of short and long echo time acquisitions (Shu et al) 1999;46:527A
relative afferent pupillary defect with normal vision: a localizing sign of midbrain or brachium injury (Jacobson) 1999;46:489A
Brain neoplasms; *see also specific neoplasms*
clinical and neuroradiological findings in infants with intracranial supratentorial nonpineoblastic primitive neuroectodermal tumors (Dai et al) 1999;46:526A
growth hormone in children with medulloblastoma: use and effect on tumor control (Packer et al) 1999;46:526A
neurocognitive status in children with medulloblastoma following reduced-dose craniospinal radiotherapy and chemotherapy (Packer et al) 1999;46:526A
parenchymal brain lymphoma as the presenting feature of subclinical systemic lymphoma (Peterson et al) 1999;46:463A
preradiotherapy chemotherapy and hyperfractionated craniospinal radiotherapy for high-risk primitive neuroectodermal tumors: a preliminary report of CCG protocol 9931 (Allen et al) 1999;46:526A
quality of life assessment in children with cancer at risk for brain impairment: development of a new pediatric brain-specific instrument, PBS version 1.0 (Tao and Parsons) 1999;46:502A
role of FDG positron emission tomography imaging in the clinical management of pediatric brain tumor patients (Molloy et al) 1999;46:522A
temozolomide: an oral cytotoxic agent with promising activity against recurrent malignant glioma (Mason) 1999;46:464A
treatment of gliomas with a recombinant *Listeria* vaccine in rats (Bronstein et al) 1999;46:464A
Brain-derived neurotrophic factor
synthesis and release of brain-derived neurotrophic factor and neurotrophin-3 by human amniotic epithelial cells (Sakuragawa et al) 1999;46:538A
Breast neoplasms
cognitive function in breast cancer patients treated with tamoxifen (Paganini-Hill and Clark) 1999;46:455A
Broca's area; *see* Frontal lobe

Cabergoline
comparison of the efficacy and tolerability of cabergoline, pergolide, pramipexole, ropinirole, and tolcapone in Parkinson's disease (Inzelberg et al) 1999;46:492A
Caenorhabditis
four revertants of *Unc2*, an uncoordinated mutant calcium channel phenotype in *C. elegans*, implicate genes potentially important in migraine and neurodegeneration (Estevez et al) 1999;46:489A
Caffeine
epileptogenic action of caffeine during anoxia in the neonatal rat hippocampus (Dzhala et al) 1999;46:95
will a glass of wine or Irish coffee lessen the severity of ischemic stroke? a lesson from rats (Grotta et al) 1999;46:496A
Calbindin
alterations of calbindin-D_{28k} localization in cerebellar Purkinje cells in the hypoxic guinea pig fetus at term (Spandou et al) 1999;46:522A
calbindin 827K overexpression using gene transfer therapy improves striatal neuron survival following transient focal cerebral ischemia (Yenari et al) 1999;46:479A
Calcium
calcium, glutamate, and amyotrophic lateral sclerosis: more evidence, but no certainties (Shaw) 1999;46:803 (Editorial)
lysophosphatidic acid–induced calcium signal and cation current in cultured rat microglial cells (Musante et al) 1999;46:472A
paralbumin overexpression alters calcium homeostasis and prolongs survival in a transgenic model of familial amyotrophic lateral sclerosis (Appel et al) 1999;46:463A
reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis (Takuma et al) 1999;46:806
role of extracellular calcium in hypoglycemic injury to the rat optic nerve, a central white matter tract (Brown et al) 1999;46:489A
Calcium channels
four revertants of *Unc2*, an uncoordinated mutant calcium channel phenotype in *C. elegans*, implicate genes potentially important in migraine and neurodegeneration (Estevez et al) 1999;46:489A
Calpain
calpain inhibition is protective in experimental vincristine neuropathy (Glass et al) 1999;46:937A (Works in progress)
Campylobacter jejuni
synergistic action of *Campylobacter jejuni* lipopolysaccharide and cholera toxin induces conduction block and demyelination in rat nerves (Wirguin et al) 1999;46:461A
Carbamazepine
effects of carbamazepine on inflammatory mediators produced by stimulated glial cells (Matoth et al) 1999;46:534A

Carcinoma, oat cell
Purkinje cell antibody type 2: a new marker of neurological autoimmunity related to small cell lung cancer (Vernino and Lennon) 1999;46:465A
Cardiac arrest; *see* Heart arrest
Cardiac conduction; *see* Heart conduction system
Cardiomyopathy
autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q (Melberg et al) 1999;46:684
myofibrillar myopathy (Engel) 1999;46:681 (Editorial)
Cardiovascular diseases
cardiovascular disease risk factor status of patients referred to a private practice stroke secondary prevention program (Lafranchise et al) 1999;46:504A
Carotid artery diseases
Chlamydia pneumoniae and carotid atherosclerosis (Johnston et al) 1999;46:479A
is appropriateness an appropriate process measure for carotid endarterectomy? (Feasby) 1999;46:501A
neurological protocols and outcomes following carotid stenting (Bonomo et al) 1999;46:496A
results of carotid endarterectomy with prospective neurologist follow-up (Chaturvedi et al) 1999;46:506A
Caspase
caspase expression following ischemia-reperfusion injury in rat retina (Singh et al) 1999;46:479A
caspase inhibition reduces posttraumatic neuronal cell loss in vitro and improves motor and cognitive outcome after traumatic brain injury (Faden et al) 1999;46:496A
insulin-like growth factor-I prevents caspase-mediated apoptosis in Schwann cells following serum withdrawal (Delaney et al) 1999;46:485A
Cataplexy
efficacy or safety profile of Provigil (modafinil) tablets in patients with and without cataplexy: results from two US multicenter, double-blind, randomized, placebo-controlled trials (Hirshkowitz et al) 1999;46:494A
Catechol methyltransferase
catechol-O-methyltransferase reduced levodopa toxicity in PC12 cells: implications for treatment of Parkinson's disease (Offen et al) 1999;46:459A
prediction of the effectiveness of tolcapone, a catechol-*O*-methyltransferase inhibitor, in patients with Parkinson's disease by COMT genotype (Chong et al) 1999;46:477A
cDNA; *see* DNA, circular
Cell death
β-amyloid expression is associated with apoptosis in myotubes and triad protein abnormalities in inclusion body myositis (Querfurth et al) 1999;46:459A
amyloid-β protein 42 forms a 24-kd complex in normal cells and is deposited in apoptotic neurons (Ohyagi et al) 1999;46:453A
apoptosis in familial Alzheimer's disease (Galvin and Lippa) 1999;46:452A
apoptosis in perinatal hypoxic–ischemic brain damage: a histopathological study in pontosubicular neuron necrosis (Itoh and Becker) 1999;46:466A
Bcl-2 and caspase gene family proteins regulating programmed cell death are expressed in human temporal lobe epilepsy (Simon et al) 1999;46:445A
caspase expression following ischemia-reperfusion injury in rat retina (Singh et al) 1999;46:479A
caspase inhibition reduces posttraumatic neuronal cell loss in vitro and improves motor and cognitive outcome after traumatic brain injury (Faden et al) 1999;46:496A
cisplatin induces apoptosis in dorsal root ganglion neurons in vivo (Windebank et al) 1999;46:445A
correlation of human herpesvirus 6 p41 and p101 expression and oligodendroglial cell death in progressive multifocal leukoencephalopathy (Goodman et al) 1999;46:488A
dependence of the mechanism of nerve growth factor–mediated protection of neural crest cells from apoptosis on the p75/TrkA ratio (Schor and Saragovi) 1999;46:537A
huntingtin aggregates may not predict neuronal death in Huntington's disease (Kuemmerle et al) 1999;46:842
insulin-like growth factor-I prevents caspase-mediated apoptosis in Schwann cells following serum withdrawal (Delaney et al) 1999;46:485A
mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death (Borthwick et al) 1999;46:787
models of neuronal death in Alzheimer's disease: synergistic effects of β-amyloid and microglia on cell cycle–mediated death of cultured neurons (Geldmacher et al) 1999;46:937A (Works in progress)
multiple molecular penumbras following cerebral infarction (Sharp et al) 1999;46:444A
participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease (Duan et al) 1999;46:587
PRAJA1, a novel RING finger protein involved in apoptosis, and a marker of hepatic stem cells, is expressed in specific embryonic neuroblasts (Mishra et al) 1999;46:487A
problems of cell death in Parkinson's disease and related disorders (Jellinger and Stadelmann) 1999;46:476A
reversal of acute apparent diffusion coefficient abnormalities and delayed neuronal death following transient focal cerebral ischemia in rats (Li et al) 1999;46:333
α-synuclein upregulation following MPP^+ administration in cerebellar granule cells in culture (Taniwaki et al) 1999;46:459A
Cell division
sequence-specific cleavage of huntingtin mRNA by catalytic DNA (Yen et al) 1999;46:366
Cell movement
lymphocyte migration and multiple sclerosis: relation with disease course and therapy (Prat et al) 1999;46:253
migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon β-1b therapy (Uhm et al) 1999;46:319
olfactory bulb dysplasia: a novel subtype of neuronal migration disorder (Yamanouchi et al) 1999;46:783
reduction of transendothelial migration of mononuclear cells in interferon-β1b–treated multiple sclerosis patients (Corsini et al) 1999;46:435 (Letter)
Cellular inclusions
paired helical filaments in sporadic inclusion body myositis muscle contain RNA and survival motor neuron protein (Broccolini et al) 1999;46:482A
Central nervous system
interleukin-6 'knockout' mice are not protected against focal central nervous system ischemia (Clark et al) 1999;46:448A
myelin deficiencies in both the central and the peripheral nervous systems associated with a *SOX10* mutation (Inoue et al) 1999;46:313
Central nervous system neoplasms
central nervous system hemangioblastomas: a review (Conway et al) 1999;46:464A

posttransplant primary central nervous system lymphoma (Phan et al) 1999;46:463A

Cerebellar ataxia; *see also* Spinocerebellar degeneration

autosomal dominant cerebellar ataxia with generalized convulsive seizures: a distinct syndrome (Achari) 1999; 46:476A

cerebellar ataxia with glutamic acid decarboxylase antibody (Boylan and Lennon) 1999;46:457A

distinct form of dominantly inherited late onset pure cerebellar ataxia associated with maternal anticipation and intermittent axial tremor (Yamashita et al) 1999;46:480A

Cerebellar diseases

acquired cerebellar degeneration with Hashimoto's thyroiditis: possible autoimmune mechanisms (Selim and Drachman) 1999;46:458A

diffuse pachygyria with cerebellar hypoplasia: a milder form of microlissencephaly or a new genetic syndrome? (Kato et al) 1999;46:660

ondansetron versus placebo for disabling cerebellar tremor: final report of a randomized clinical trial (Rice et al) 1999;46:493A

paraneoplastic cerebellar degeneration in a child with leukemia (Deputy) 1999;46:550A

platelet-activating factor rescues migration defects in Pafah1b1 (LIS1)-deficient cerebellar granule cells (Bix et al) 1999;46:522A

subacute cerebellar degeneration and atypical antineuronal antibody response with anti-Hu reactivity in a patient without identifiable malignancy (Greenlee et al) 1999;46:465A

what makes the neurosurgeon think surgery is beneficial in spontaneous cerebellar hematomas? (St Louis et al) 1999;46:504A

Cerebellar nuclei

increased iron in the dentate nucleus of patients with Friedreich's ataxia (Waldvogel et al) 1999;46:123

Cerebellum

function of the cerebellum in parkinsonian rest tremor and Holmes' tremor (Deuschl et al) 1999;46:126

selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase (Ishida et al) 1999;46:263

α-synuclein upregulation following MPP^+ administration in cerebellar granule cells in culture (Taniwaki et al) 1999;46:459A

Cerebral aneurysm

do highly specialized services improve outcomes at academic medical centers? cerebral aneurysm treatment (Johnston) 1999;46:501A

Cerebral arteries

effect of ischemia and tissue plasminogen activator on middle cerebral artery myogenic reactivity (Cipolla et al) 1999;46:449A

spontaneous middle cerebral artery dissection: an unusual case of stroke (Giraldo and Pendlebury) 1999;46:448A

Cerebral artery diseases

developmental disorders in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (Desmond et al) 1999;46:481A

Cerebral cortex

cortically blind or can't tell? (Mast and Ladenheim) 1999; 46:539A

epileptiform discharges in the human dysplastic neocortex: in vitro physiology and pharmacology (Avoli et al) 1999;46:816

genes required for normal development of the human cerebral cortex (Walsh) 1999;46:444A

periventricular white matter injury in the premature infant is followed by reduced cerebral cortical gray matter volume at term (Inder et al) 1999;46:755

predilection of frontotemporal cortex involvement in early Rasmussen's syndrome: a positron emission tomographic study (Kaddurah et al) 1999;46:532A

presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study (Ouchi et al) 1999;46:723

septo-optic dysplasia plus: a spectrum of malformations of cortical development (Miller et al) 1999;46:548A

serine/threonine phosphorylation of *N*-ethylmaleimide–sensitive factor is associated with Ca^{2+}-dependent K^+-stimulated release of L-glutamate in neocortical synaptosomes (Slevin et al) 1999;46:487A

Cerebral edema; *see* Brain edema

Cerebral embolism and thrombosis

fatal cerebral embolic infarctions due to thrombosis of HeartMate left ventricular assist device (Li et al) 1999; 46:480A

Cerebral hemorrhage

neuroprotection in intracerebral hemorrhage with tinprotoporphyrin (Koeppen and Dickson) 1999;46:938A (Works in progress)

preliminary observations on the ability of diffusion weighted imaging and perfusion weighted imaging to predict intracranial hemorrhage in patients treated with recombinant tissue plasminogen activator (Tong et al) 1999;46:448A

Cerebral infarction

developmental disorders in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (Desmond et al) 1999;46:481A

fatal cerebral embolic infarctions due to thrombosis of HeartMate left ventricular assist device (Li et al) 1999; 46:480A

multiple molecular penumbras following cerebral infarction (Sharp et al) 1999;46:444A

Cerebral ischemia

calbindin 827K overexpression using gene transfer therapy improves striatal neuron survival following transient focal cerebral ischemia (Yenari et al) 1999;46:479A

effect of ischemia and tissue plasminogen activator on middle cerebral artery myogenic reactivity (Cipolla et al) 1999;46:449A

focal ischemic brain injury is reduced in mice lacking A2a adenosine receptors (Chen et al) 1999;46:445A

hippocampal long-term potentiation is preserved following neonatal hypoxia-ischemia (Yamada et al) 1999; 46:538A

initial experience with murine 7E3 $F(ab')_2$ (GP IIb/IIIa antagonist) in focal cerebral ischemia model (Yang et al) 1999;46:491A

magnetic resonance line scan diffusion imaging of term neonates with perinatal brain ischemia (Rivkin et al) 1999;46:520A

use and validity of a quantitative computed tomographic score in early cerebral ischemia (Barber et al) 1999;46: 450A

Cerebral ischemia, transient

reversal of acute apparent diffusion coefficient abnormalities and delayed neuronal death following transient focal cerebral ischemia in rats (Li et al) 1999;46:333

Cerebral palsy
cerebral palsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? (Shalev et al) 1999;46:539A
intrathecal baclofen therapy for the treatment of cerebral palsy in children (Awaad et al) 1999;46:466A
motor benefit from L-dopa in spastic cerebral palsy (Brunstrom et al) 1999;46:544A
retrospective review of dose and safety of *Botulinum* toxin injections in children with cerebral palsy (Delgado and Combes) 1999;46:535A
Cerebral sclerosis, diffuse
de novo splice donor site mutation causes in-frame deletion of 14 amino acids in the proteolipid protein in Pelizaeus-Merzbacher disease (Aoyagi et al) 1999; 46:112
mutations in noncoding regions of the proteolipid protein gene in patients with Pelizaeus Merzbacher disease (PMD) and PMD-like disorders (Hobson et al) 1999; 46:530A
Cerebral veins
cerebral venous thrombosis in pediatric patients: a review of 22 cases (Wasay et al) 1999;46:541A
Cerebrospinal fluid
amyloid β protein species in cerebrospinal fluid and in brain from patients with Down's syndrome (Tamaoka et al) 1999;46:933 (Letter)
amyloid-β peptide levels in serum and cerebrospinal fluid of multiple sclerosis patients (Coyle and Mehta) 1999; 46:489A
cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia (Conant et al) 1999;46:391
Chlamydia: a role for multiple sclerosis or more confusion? (Gilden) 1999;46:4 (Editorial)
Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis (Sriram et al) 1999;46:6
detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders (Saiz et al) 1999;46:774
elevated pigment epithelium-derived factor levels in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (Bilak et al) 1999;46:462A
elevated production of tumor necrosis factor-α by γ/δ T-cell lines generated from cerebrospinal fluid of multiple sclerosis patients (Matusevicius and Freedman) 1999;46:470A
false pituitary tumor in spontaneous cerebrospinal fluid leak (Mokri and Atkinson) 1999;46:475A
relation between neuroimaging abnormalities and cerebrospinal fluid viral load in children with human immunodeficiency virus disease (Civitello et al) 1999; 46:521A
relationship of cerebrospinal fluid opening pressure and body mass index (Mosek et al) 1999;46:486A
remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis (Tohgi et al) 1999;46:129A
Cerebrovascular disorders, classification
application of conjoint analysis to the development of a novel, weighted stroke scale: Japan stroke scale (Gotoh et al) 1999;46:505A
Cerebrovascular disorders, complications
cardioembolic stroke and the antiphospholipid antibody syndrome: a case report (Kang and Younkin) 1999;46: 544A
Cerebrovascular disorders, diagnosis
limitations of clinical diagnosis in acute stroke: implications for clinical trials (Allder et al) 1999;46:479A
Cerebrovascular disorders, drug therapy
dichloroacetate treatment after ischemic stroke produces declines in cerebral lactate (Graham et al) 1999; 46:494A
SPASE-I (Italian Study on Pharmacological Treatment of Acute Stroke in the Elderly): preliminary results (Lenzi et al) 1999;46:509A
Cerebrovascular disorders, epidemiology
prediction of prestroke cognitive impairment in the Northern Manhattan Stroke Study: a statistical approach (Moroney et al) 1999;46:452A
Cerebrovascular disorders, etiology
cocaine-induced cerebrovascular occlusive disease: new angiographic findings (Storen et al) 1999;46:449A
spontaneous middle cerebral artery dissection: an unusual case of stroke (Giraldo and Pendlebury) 1999;46:448A
Cerebrovascular disorders, genetics
role of factor XIII Val 34 Leu mutation in ischemic cerebrovascular disease (Iniesta et al) 1999;46:449A
Cerebrovascular disorders, mortality
administrative data, comorbidity, and survival after ischemic stroke (Tirschwell et al) 1999;46:501A
improving outcomes comparison and benchmark selection with clinical risk adjustment models: a case study of stroke mortality among New Jersey hospitals (Hohmann) 1999;46:504A
Cerebrovascular disorders, pathology
failure to demonstrate spreading depression by serial assessment of the apparent diffusion coefficient in acute human stroke (Back et al) 1999;46:478A
imaging stroke in progress: magnetic resonance advances but computed tomography is poised for counterattack (Koroshetz and Gonzales) 1999;46:556 (Editorial)
longitudinal functional magnetic resonance imaging study in hemiparetic stroke (Miyai et al) 1999;46:467A
longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: evolution of lesion volume and correlation with clinical outcome (Beaulieu et al) 1999;46:568
predictive value of diffusion-weighted imaging in acute ischemic stroke (Baird et al) 1999;46:478A
transcranial Doppler ultrasonography in childhood ischemic stroke (Thorarensen et al) 1999;46:521A
Cerebrovascular disorders, physiopathology
adjustment of case mix for stroke quality of care and outcome studies (Goldstein et al) 1999;46:449A
does the National Institutes of Health Stroke Scale favor left hemisphere strokes? (Woo et al) 1999;46:450A
evolution of functional reorganization in hemiplegic stroke: a serial positron emission tomographic activation study (Nelles et al) 1999;46:901
impact of protocols and clinical pathways on stroke outcome (Tabaa et al) 1999;46:504A
prospective, controlled study of stroke outcome as predicted by the Functional Independence Measurement Scale acquired during acute rehabilitation (Verro and Abbur) 1999;46:506A
prospective evaluation of health-related quality of life and cost in acute stroke (Kim et al) 1999;46:508A
reliability of the Clinical Dementia Rating in a stroke sample: implications for clinical trials (Desmond et al) 1999;46:453A

Cerebrovascular disorders, prevention and control
cardiovascular disease risk factor status of patients referred to a private practice stroke secondary prevention program (Lafranchise et al) 1999;46:504A
Cerebrovascular disorders, therapy
admission to the stroke unit: outcomes and cost (Christou et al) 1999;46:509A
early readmission rates in patients with ischemic stroke: the UAB experience (Tulyapronchote et al) 1999;46:510A
should mild or moderate strokes be admitted to an intensive care unit? (Briggs et al) 1999;46:509A
treatment of acute stroke more than 3 hours after onset of symptoms: success with the use of structural and functional imaging (Kamran et al) 1999;46:495A
will a glass of wine or Irish coffee lessen the severity of ischemic stroke? a lesson from rats (Grotta et al) 1999;46:496A
Charcot-Marie-Tooth disease
Charcot-Marie-Tooth disease presenting as bilateral vocal cord paralysis and ascending weakness in a teen with lymphoma (Harsanyi and Keating) 1999;46:550A
Roussy-Lévy family: from the original description to the gene (Planté-Bordeneuve et al) 1999;46:770
Chemokines
expression and down-regulation of CXCR4 and CCR5 chemokine receptors in cultured murine microglia (Tamaru et al) 1999;46:447A
Chickenpox
Child development disorders
etiological yield in childhood global developmental delay without autistic traits: a prospective study (Shevell et al) 1999;46:541A
Chlamydia pneumoniae
Chlamydia: a role for multiple sclerosis or more confusion? (Gilden) 1999;46:4 (Editorial)
Chlamydia pneumoniae and carotid atherosclerosis (Johnston et al) 1999;46:479A
Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis (Sriram et al) 1999;46:6
Cholera toxin
synergistic action of *Campylobacter jejuni* lipopolysaccharide and cholera toxin induces conduction block and demyelination in rat nerves (Wirguin et al) 1999;46:461A
Cholesterol
apolipoprotein E genotype interaction with serum cholesterol level may influence rate of progression in Alzheimer's disease (Evans et al) 1999;46:454A
Choline acetyltransferase
choline acetyltransferase activity in cortex and hippocampus of mild cognitively impaired and Alzheimer's disease patients (DeKosky et al) 1999;46:452A
Cholinergic activity; *see* Acetylcholine
Chorea
choreoathetosis caused by combined lamotrigine and phenytoin: a pharmacodynamic interaction? (Megdad et al) 1999;46:476A
Sydenham chorea: the Utah experience (Thompson et al) 1999;46:523A
Chromosome deletion
clinical characterization of the neurogenetic disorder and 1p36 deletion syndrome (Chedrawi et al) 1999;46:529A
Chromosomes, human, pair 2
cognitive impairment: a feature common to families with autosomal dominant hereditary spastic paraparesis linked to chromosome 2 (McMonagle et al) 1999;46:481A
genetic linkage of Welander distal myopathy to chromosome 2p13 (Åhlberg et al) 1999;46:399
locus for febrile seizures (FEB3) maps to chromosome 2q23-24 (Pfeiffer et al) 1999;46:671 (Expedited publication)
Chromosomes, human, pair 5
linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis (Oturai et al) 1999;46:612
Chromosomes, human, pair 6
linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis (Oturai et al) 1999;46:612
Chromosomes, human, pair 7
localization of a gene for myoclonus-dystonia to chromosome 7q21-q31 (Nygaard et al) 1999;46:794
Chromosomes, human, pair 9
loss-of-function mutations of SURF-1 are specifically associated with Leigh syndrome with cytochrome *c* oxidase deficiency (Tiranti et al) 1999;46:161
Chromosomes, human, pair 10
autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q (Melberg et al) 1999;46:684
myofibrillar myopathy (Engel) 1999;46:681 (Editorial)
Chromosomes, human, pair 19
rapid-onset dystonia–parkinsonism: linkage to chromosome 19q13 (Kramer et al) 1999;46:176
Chronic inflammatory demyelinating polyneuropathy
prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia (McLeod et al) 1999;46:910
Chylomicrons
vitamin E deficiency as a result of chylomicron retention disease in autosomal recessive Marinesco-Sjögren syndrome (Aguglia et al) 1999;46:465A
Cisplatin
cisplatin induces apoptosis in dorsal root ganglion neurons in vivo (Windebank et al) 1999;46:445A
Clinical Dementia Rating
reliability of the Clinical Dementia Rating in a stroke sample: implications for clinical trials (Desmond et al) 1999;46:453A
Clinical trials
guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from Phase III clinical trials (Goodkin et al) 1999;46:132 (Special report)
limitations of clinical diagnosis in acute stroke: implications for clinical trials (Allder et al) 1999;46:479A
Clozapine
clozapine replacement by quetiapine for dopamimetic psychosis in Parkinson's disease (Fernandez et al) 1999;46:491A
Cocaine
cocaine-induced cerebrovascular occlusive disease: new angiographic findings (Storen et al) 1999;46:449A
enhancement of human immunodeficiency virus protein–induced neurotoxicity with methamphetamine and cocaine (Nath et al) 1999;46:488A

Coffee
will a glass of wine or Irish coffee lessen the severity of ischemic stroke? a lesson from rats (Grotta et al) 1999; 46:496A
Cognition
cognitive performance and magnetic resonance spectroscopy: correlates in multiple sclerosis (Pan et al) 1999; 46:475A
Cognition disorders
choline acetyltransferase activity in cortex and hippocampus of mild cognitively impaired and Alzheimer's disease patients (DeKosky et al) 1999;46:452A
cognitive function in breast cancer patients treated with tamoxifen (Paganini-Hill and Clark) 1999;46:455A
cognitive impairment: a feature common to families with autosomal dominant hereditary spastic paraparesis linked to chromosome 2 (McMonagle et al) 1999;46: 481A
hippocampal volumes in normal aging predict subsequent cognitive decline (Petersen et al) 1999;46:454A
neurocognitive deficits in medulloblastoma survivors and white matter loss (Mulhern et al) 1999;46:834
prediction of prestroke cognitive impairment in the Northern Manhattan Stroke Study: a statistical approach (Moroney et al) 1999;46:452A
Coma
early prediction of poor outcome in anoxic-ischemic coma (Schreiner and Pohlmann-Eden) 1999;46:468A
Comorbidity
administrative data, comorbidity, and survival after ischemic stroke (Tirschwell et al) 1999;46:501A
Complex I
succinic acid–responsive complex I deficiency (Tein et al) 1999;46:549A
Complex III
characterization of biochemical and clinical features of children with electron transport chain complex III deficiency (Gold et al) 1999;46:535A
Computed tomography; *see* Tomography, x-ray computed
Conjunctiva
functional magnetic resonance imaging in spontaneous attacks of SUNCT: short-lasting neuralgiform headache with conjunctival injection and tearing (May et al) 1999;46:791
Convulsions
reduced K^+ current due to a novel mutation in KCNQ2 causes neonatal convulsions (Lerche et al) 1999;46:305
Convulsions, febrile
locus for febrile seizures (FEB3) maps to chromosome 2q23-24 (Pfeiffer et al) 1999;46:671 (Expedited publication)
prospective randomized study comparing intranasal midazolam with intravenous diazepam for the treatment of febrile seizures in children (Lahat et al) 1999;46:522A
Copaxone; *see* Glatiramer acetate
Copper
copper/zinc superoxide dismutase: more is not necessarily better! (Rando and Epstein) 1999;46:135 (Letter)
increased tissue copper and manganese content in the lentiform nucleus in primary adult-onset dystonia (Becker et al) 1999;46:260
Coronary thrombosis
cardioembolic stroke and the antiphospholipid antibody syndrome: a case report (Kang and Younkin) 1999;46: 544A
Corpus striatum
levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (Muriel et al) 1999;46:103
presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study (Ouchi et al) 1999;46:723
Costs and cost analysis
admission to the stroke unit: outcomes and cost (Christou et al) 1999;46:509A
correlates of dementia and health care cost among Medicare elderly (Husaini et al) 1999;46:508A
prospective evaluation of health-related quality of life and cost in acute stroke (Kim et al) 1999;46:508A
Cranial nerve
neuroradiological findings in Möbius syndrome (Vasconcelos et al) 1999;46:548A
Cranial-manual-cervical dystonia; *see* Dystonia
Creatine
possible creatine synthesis deficit demonstrated by in vivo ^{31}P magnetic resonance spectroscopy (Arias-Mendoza et al) 1999;46:549A
Cresols
p-cresol sulfate is a prominent component of urinary myelin basic protein-like material in multiple sclerosis (Whitaker et al) 1999;46:457A
urinary p-cresol sulfate in multiple sclerosis (Whitaker et al) 1999;46:935A (Works in progress)
Creutzfeldt-Jakob disease
classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects (Parchi et al) 1999;46:224
detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders (Saiz et al) 1999;46:774
enzyme-linked immunosorbent assay for the detection of 14-3-3 protein in the cerebrospinal fluid of clinically suspected Creutzfeldt-Jakob disease patients (Kenney et al) 1999;46:452A
familial Creutzfeldt-Jakob disease with a novel 120-bp insertion in the prion protein gene (Skworc et al) 1999; 46:693
Cryoglobulinemia
peripheral neuropathy associated with hepatitis C and cryoglobulinemia: treatment with cyclophosphamide (Souayah and Khella) 1999;46:492A
Cyclic adenosine monophosphate; *see* Adenosine cyclic monophosphate
Cyclin
role of cyclin-dependent kinase 5 in developing and aging nervous system: spatial and temporal expression and phenotype studies by generating new transgenic mice (Tanaka et al) 1999;46:536A
Cyclophosphamide
peripheral neuropathy associated with hepatitis C and cryoglobulinemia: treatment with cyclophosphamide (Souayah and Khella) 1999;46:492A
Cytochrome *c* oxidase
irregular distribution of cytochrome *c* oxidase protein subunits in aging and Alzheimer's disease (Ojaimi et al) 1999;46:656
loss-of-function mutations of SURF-1 are specifically associated with Leigh syndrome with cytochrome *c* oxidase deficiency (Tiranti et al) 1999;46:161
solving the COX puzzle (De Vivo) 1999;46:142 (Editorial)

Cytomegaloviruses
cytomegalovirus is not associated with IgM anti–myelin-associated glycoprotein/sulphate-3-glucuronyl paraglboside antibody–associated neuropathy (Lunn et al) 1999;46:267

Dantrolene
muscle phosphoglycerate mutase deficiency with tubular aggregates: effect of dantrolene (Vissing et al) 1999;46:274

Deafness
early dissociation of verbal and non-verbal gestural ability in an epileptic deaf child (Metz-Lutz et al) 1999;46:929
interaction of the deafness-dystonia protein DDP with the dynamin-like GTPase DVLP (Blackstone et al) 1999;46:936A (Works in progress)

Death
basic fibroblast growth factor does not prolong survival in a transgenic model of familial ALS (Upton-Rice et al) (Letter); (Sébire and Chabrier) (Reply) 1999;46:934
echogenicity on cranial sonograms in preterm infants: risk profiles and death (Kuban et al) 1999;46:527A
mortality and morbidity rates in pediatric patients with acute respiratory failure: comparison between patients with and without preexisting neurological conditions (Coffman et al) 1999;46:542A
seizure control and mortality in epilepsy (Sperling et al) 1999;46:45
which glioblastoma multiforme patient will become a long-term survivor? a population-based study (Scott et al) 1999;46:183

Deglutition
evolution of swallowing neuroanatomy and physiology in humans: a practical perspective (Robbins) 1999;46:279 (Editorial)
functional neuroanatomy of voluntary swallowing (Zald and Pardo) 1999;46:281

Dementia
anti-acetylcholinesterase therapy in dementia with Lewy bodies (Querfurth et al) 1999;46:494A
correlates of dementia and health care cost among Medicare elderly (Husaini et al) 1999;46:508A
follow-up study of blood pressure and cerebral white matter lesions (de Leeuw et al) 1999;46:827
frequency of *tau* mutations in three series of non-Alzheimer's degenerative dementia (Houlden et al) 1999;46:243
FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation (Sperfeld et al) 1999;46:708
longitudinal clinical observations and neuropsychological features of the pallido-ponto-nigral degeneration family (McRae et al) 1999;46:454A
pathological determinants of dementia in Alzheimer's disease (Royall et al) 1999;46:451A
phenotypic variation in hereditary frontotemporal dementia with tau mutations (van Swieten et al) 1999;46:617
reliability of the Clinical Dementia Rating in a stroke sample: implications for clinical trials (Desmond et al) 1999;46:453A
risk of inpatient, outpatient, and ambulatory care associated with dementia (Albert et al) 1999;46:504A

Dementia, vascular
propentofylline for the treatment of vascular dementia: a 48-week study assessing safety, efficacy, and impact on disease progression (Schweiger and European/Canadian Propentofylline Study Group) 1999;46:493A

Demyelinating diseases; *see also specific diseases*
demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation (Raine et al) 1999;46:144
epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: a reappraisal (Paradiso et al) 1999;46:701
herpes simplex virus 1–induced multifocal central nervous system demyelination in mice: mechanisms mediating the development of demyelination during the acute stage of infection (Kastrukoff et al) 1999;46:487A
paclitaxel attenuates demyelination in a transgenic spontaneously demyelinating model (Moscarello et al) 1999;46:469A
prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia (McLeod et al) 1999;46:910
randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease (Weinshenker et al) 1999;46:878
Roussy-Lévy family: from the original description to the gene (Planté-Bordeneuve et al) 1999;46:770
synergistic action of *Campylobacter jejuni* lipopolysaccharide and cholera toxin induces conduction block and demyelination in rat nerves (Wirguin et al) 1999;46:461A
V-chain T-cell receptor transcripts are clonally expanded in the cerebrospinal fluid of a patient with demyelinating diseases following hepatitis A infection (Oleszak et al) 1999;46:542A

Dentate nucleus; *see* Cerebellar nuclei

Dexamethasone palmitate
liposteroid (dexamethasone palmitate) therapy for refractory seizures in children (Yoshikawa et al) 1999;46:546A

Diabetic ketoacidosis
epilepsia partialis continua as a presenting manifestation of diabetic ketoacidosis (Tran et al) 1999;46:546A

Diabetic neuropathies
insulin-like growth factor-I inhibits high glucose-induced neuronal oxidative stress and loss of mitochondrial membrane integrity in models of diabetes (Russell et al) 1999;46:460A

Diaminopyridine
3,4-diaminopyridine: therapeutic considerations for chronic use in children with congenital myasthenia (Bowe et al) 1999;46:534A

Diazepam
prospective randomized study comparing intranasal midazolam with intravenous diazepam for the treatment of febrile seizures in children (Lahat et al) 1999;46:522A

Dichloroacetate
dichloroacetate treatment after ischemic stroke produces declines in cerebral lactate (Graham et al) 1999;46:494A

Diet therapy
ketogenic diet: long-term efficacy and patient tolerance in children with intractable pediatric epilepsy (Thompson et al) 1999;46:532A

Diffusion weighted imaging; *see* Magnetic resonance imaging

Dissection
spontaneous middle cerebral artery dissection: an unusual case of stroke (Giraldo and Pendlebury) 1999;46:448A

DNA
sequence-specific cleavage of huntingtin mRNA by catalytic DNA (Yen et al) 1999;46:366
DNA, circular
analysis of gene expression in multiple sclerosis lesions using cDNA microarrays (Whitney et al) 1999;46:425
DNA, mitochondrial
mitochondrial DNA G13513A transition in ND5 is associated with a LHON/MELAS overlap syndrome and may be a frequent cause of MELAS (Pulkes et al) 1999; 46:916
mitochondrial DNA variants in multiple sclerosis (Kalman and Alder) 1999;46:469A
Moyamoya in three generations of a Scottish family: association with a mitochondrial DNA polymorphism typical of Asian populations (Muir et al) 1999;46:481A
oxidative damage to mitochondrial DNA in active lesions of multiple sclerosis (Kalman and Lu) 1999;46:456A
pediatric dystonia due to mtDNA mutation at np 14459: report of the fourth family (Gropman et al) 1999;46: 548A
Dopamine
dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene (Furukawa et al) 1999;46: 936A (Works in progress)
levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (Muriel et al) 1999;46:103
participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease (Duan et al) 1999;46:587
positron emission tomography measurements of striatal dopamine transporter in untreated Parkinson's disease patients: differential regulation with levodopa versus pramipexole (Guttman et al) 1999;46:937A (Works in progress)
presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study (Ouchi et al) 1999;46:723
regulation of dopaminergic activity in early Parkinson's disease (Tedroff et al) 1999;46:359
use of dopamine agonists in very elderly patients with Parkinson's disease (Shulman et al) 1999;46:497A
vagus nerve stimulation does not induce significant changes in striatal fluoro-dopa uptake (Henry et al) 1999;46:477A
vasoactive intestinal peptide protects from dopamine toxicity: relevance for Parkinson's disease (Melamed et al) 1999;46:458A
Doppler ultrasonography; *see* Ultrasonography
Dorsal root ganglia; *see* Ganglia, spinal
Down's syndrome
amyloid β protein species in cerebrospinal fluid and in brain from patients with Down's syndrome (Tamaoka et al) 1999;46:933 (Letter)
dating mechanism for senile plaque formation in Down's syndrome: link between development and aging (Azieh et al) 1999;46:538A
Duchenne muscular dystrophy; *see* Muscular dystrophy
Dynamin
interaction of the deafness-dystonia protein DDP with the dynamin-like GTPase DVLP (Blackstone et al) 1999; 46:936A (Works in progress)
Dysarthria
hypokinetic dysarthria as seen in congenital bilateral perisylvian syndrome (Fishman) 1999;46:544A
Dyskinesia
internal global pallidus discharge is nearly suppressed during levodopa-induced dyskinesias (Papa et al) 1999;46: 732
Dyslexia
neuronal asymmetries in primary visual cortex of dyslexic and nondyslexic brains (Jenner et al) 1999;46:189
Dysphagia
evolution of swallowing neuroanatomy and physiology in humans: a practical perspective (Robbins) 1999;46:279 (Editorial)
functional neuroanatomy of voluntary swallowing (Zald and Pardo) 1999;46:281
Dystonia
cranial-manual-cervical dystonia in three unrelated women associated with acetylcholine receptor antibodies: a new syndrome? (Duane and Stuart) 1999;46:477A
distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain (Augood et al) 1999; 46:761
dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene (Furukawa et al) 1999;46: 936A (Works in progress)
increased tissue copper and manganese content in the lentiform nucleus in primary adult-onset dystonia (Becker et al) 1999;46:260
interaction of the deafness-dystonia protein DDP with the dynamin-like GTPase DVLP (Blackstone et al) 1999; 46:936A (Works in progress)
localization of a gene for myoclonus-dystonia to chromosome 7q21-q31 (Nygaard et al) 1999;46:794
neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus (Vitek et al) 1999; 46:22
pediatric dystonia due to mtDNA mutation at np 14459: report of the fourth family (Gropman et al) 1999;46: 548A
rapid-onset dystonia–parkinsonism: linkage to chromosome 19q13 (Kramer et al) 1999;46:176
Dystrophin
on dystrophin abundance and C-terminal missense mutations in dystrophinopathies (Oexle and Heyer) (Letter); (Goldberg and Hoffman) (Reply) 1999;46:137

Elderly; *see* Aged
Electric stimulation
bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients (Ardouin et al) 1999;46:217
language area localization with three-dimensional functional magnetic resonance imaging matches intrasulcal electrostimulation in Broca's area (Rutten et al) 1999; 46:405
observations on intermittent stimulation of the left vagal nerve in children with pharmacoresistant epilepsy (Murphy et al) 1999;46:525A
vagus nerve stimulation in children: quality of life and side effects (Wheless et al) 1999;46:523A
Electroencephalography
absences with onset before the age of 9 years (Siren et al) 1999;46:533A
clinical, radiological, and electroencephalographic correlates of paraneoplastic limbic encephalitis (Lawn et al) 1999;46:464A
frontal absences in children (Lagae et al) 1999;46:532A

magnetoencephalographic localization in pediatric epilepsy surgery: comparison with invasive intracranial electroencephalography (Minassian et al) 1999;46:627

Electromyography
electromyography and biopsy correlation study of infants with arthrogryposis multiplex congenita (Torres et al) 1999;46:535A

Electron transport
characterization of biochemical and clinical features of children with electron transport chain complex III deficiency (Gold et al) 1999;46:535A

Electrophysiology
correlation of clinical spasticity scale with intraoperative electrophysiological monitoring (Nizam et al) 1999;46:536A

Encephalitis
antibodies to acetylcholine receptors, potassium channels, and titin in a patient with thymoma, myasthenia gravis, and limbic encephalitis (Buckley et al) 1999;46:482A
clinical, radiological, and electroencephalographic correlates of paraneoplastic limbic encephalitis (Lawn et al) 1999;46:464A
experimental axonal ion channel encephalitis (Burghes and Rammohan) 1999;46:456A
neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus (Lee et al) 1999;46:428
persistent focal neurological deficits in 3 children with chronic and insidious Epstein-Barr encephalitis (Caruso et al) 1999;46:543A

Encephalitis, autoimmune
continuous secretion of proteolipid protein epitope suppresses relapsing experimental autoimmune encephalitis in SJL/J mice (Weiner et al) 1999;46:938A (Works in progress)

Encephalitis periaxialis
serial magnetic resonance imaging in patients with Balò's concentric sclerosis: natural history of lesion development (Chen et al) 1999;46:651

Encephalitogenic basic proteins
p-cresol sulfate is a prominent component of urinary myelin basic protein-like material in multiple sclerosis (Whitaker et al) 1999;46:457A

Encephalomyelitis
demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation (Raine et al) 1999;46:144

Encephalomyelitis, allergic
inhibition of experimental allergic encephalomyelitis in Lewis rats by paclitaxel (Cao et al) 1999;46:470A

Endarterectomy, carotid
is appropriateness an appropriate process measure for carotid endarterectomy? (Feasby) 1999;46:501A
results of carotid endarterectomy with prospective neurologist follow-up (Chaturvedi et al) 1999;46:506A

Endothelial growth factors
improvement in ischemic limb neuropathy after vascular endothelial growth factor gene therapy (Simovic et al) 1999;46:463A

Endothelium
reduction of transendothelial migration of mononuclear cells in interferon-β1b–treated multiple sclerosis patients (Corsini et al) 1999;46:435 (Letter)

Enzyme-linked immunosorbent assay
enzyme-linked immunosorbent assay for the detection of 14-3-3 protein in the cerebrospinal fluid of clinically suspected Creutzfeldt-Jakob disease patients (Kenney et al) 1999;46:452A

Enzymes
mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death (Borthwick et al) 1999;46:787

Epidermal nerves
quantitative epidermal nerve analysis in skin blister and skin biopsies (Kennedy et al) 1999;46:461A

Epilepsy, absence
absences with onset before the age of 9 years (Siren et al) 1999;46:533A
frontal absences in children (Lagae et al) 1999;46:532A

Epilepsy, analysis
brain GABA levels are below normal in epilepsy patients treated with valproate and lamotrigine (Petroff et al) 1999;46:455A
epileptiform discharges in the human dysplastic neocortex: in vitro physiology and pharmacology (Avoli et al) 1999;46:816
toward molecular characterization of a reflex epilepsy in the Frings audiogenic seizure-susceptible mouse (Ptáček and White) 1999;46:455A

Epilepsy, drug therapy
antiepileptic drug regimens and major congenital abnormalities in the offspring (Samrén et al) 1999;46:739
efficacy of topiramate in infants and children with symptomatic generalized epilepsies (Hosain et al) 1999;46:532A
ganaxolone in the treatment of refractory epileptic syndromes in pediatric patients (Soufflet et al) 1999;46:524A
ophthalmological abnormalities in children with epilepsy treated with vigabatrin (Gross-Tsur et al) 1999;46:524A

Epilepsy, genetics
FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation (Sperfeld et al) 1999;46:708

Epilepsy, mortality
seizure control and mortality in epilepsy (Sperling et al) 1999;46:45

Epilepsy, partial
diagnosis of subtle focal dysplastic lesions: curvilinear reformatting from three-dimensional magnetic resonance imaging (Bastos et al) 1999;46:88
epilepsia partialis continua as a presenting manifestation of diabetic ketoacidosis (Tran et al) 1999;46:546A

Epilepsy, pathology
association between hippocampal volume and epilepsy duration (Theodore and Gaillard) 1999;46:800 (Letter)
children with epilepsy and aggression: a distinct pattern of positron emission tomography glucose metabolism (Chugani et al) 1999;46:533A

Epilepsy, physiopathology
early dissociation of verbal and non-verbal gestural ability in an epileptic deaf child (Metz-Lutz et al) 1999;46:929

Epilepsy, prevention and control
tetrodotoxin prevents posttraumatic epileptogenesis in rats (Graber and Prince) 1999;46:234

Epilepsy, surgery
magnetoencephalographic localization in pediatric epilepsy surgery: comparison with invasive intracranial electroencephalography (Minassian et al) 1999;46:627
transcranial cortical magnetic stimulation in children: a noninvasive method for localization of functional motor cortex in epilepsy surgery candidates (Koo et al) 1999;46:523A

Epilepsy, temporal lobe
association of magnetic resonance spectroscopic abnormalities with quality of life and mood in patients with temporal lobe epilepsy (Maton et al) 1999;46:508A
Bcl-2 and caspase gene family proteins regulating programmed cell death are expressed in human temporal lobe epilepsy (Simon et al) 1999;46:445A
forced normalization in an adolescent (Caruso et al) 1999; 46:545A
hippocampal *N*-methyl-D-aspartate receptor subunit mRNA levels in temporal lobe epilepsy patients (Mathern et al) 1999;46:343
nontumoural occipitotemporal epilepsy: localizing findings and surgical outcome (Aykut-Bingol and Spencer) 1999;46:894
Epilepsy, therapy
ketogenic diet: long-term efficacy and patient tolerance in children with intractable pediatric epilepsy (Thompson et al) 1999;46:532A
observations on intermittent stimulation of the left vagal nerve in children with pharmacoresistant epilepsy (Murphy et al) 1999;46:525A
Epitope
continuous secretion of proteolipid protein epitope suppresses relapsing experimental autoimmune encephalitis in SJL/J mice (Weiner et al) 1999;46:938A (Works in progress)
Epstein-Barr virus
persistent focal neurological deficits in 3 children with chronic and insidious Epstein-Barr encephalitis (Caruso et al) 1999;46:543A
Erection; *see* Penile erection
Ethnic factors
assessment of quality of life in Parkinson's disease patients of different ethnic groups (Young and Locke) 1999;46: 507A
Ethylmaleimide
serine/threonine phosphorylation of *N*-ethylmaleimide–sensitive factor is associated with Ca^{2+}-dependent K^+-stimulated release of L-glutamate in neocortical synaptosomes (Slevin et al) 1999;46:487A
Evoked potentials
cortical evoked responses from the perineal nerve (Uchio et al) 1999;46:490A
Evoked potentials, somatosensory
evoked responses accurately predict unfavorable outcome after cardiac arrest (Rothstein) 1999;46:468A
Ewing's sarcoma; *see* Sarcoma, Ewing's
Experimental allergic encephalomyelitis; *see* Encephalomyelitis, allergic
Experimental autoimmune neuritis; *see* Neuritis
Extracellular matrix
extracellular matrix provides mechanical stability for myelination in the peripheral nervous system (Windebank and Podratz) 1999;46:483A
Eye movement
ocular motor abnormalities in ataxia telangiectasia (Lewis et al) 1999;46:287

Factor XIII
role of factor XIII Val 34 Leu mutation in ischemic cerebrovascular disease (Iniesta et al) 1999;46:449A
Febrile seizures; *see* Convulsions, febrile
Fetus
antiepileptic drug regimens and major congenital abnormalities in the offspring (Samrén et al) 1999;46:739
hypoxia-induced nitration of protein in the hippocampus of the guinea pig fetus (Zanelli et al) 1999;46:538A
intraventricular transplantation of oligodendrocyte progenitors into a fetal myelin mutant results in widespread formation of myelin (Learish et al) 1999;46:716
Fibroblast growth factor, basic
basic fibroblast growth factor does not prolong survival in a transgenic model of familial ALS (Upton-Rice et al) (Letter); (Sébire and Chabrier) (Reply) 1999;46:934
Finland
genetic association of α_2-macroglobulin with Alzheimer's disease in a Finnish elderly population (Myllykangas et al) 1999;46:382
Fluorodopa
vagus nerve stimulation does not induce significant changes in striatal fluoro-dopa uptake (Henry et al) 1999;46:477A
Fluoxetine
fluoxetine treatment in children and adolescents with Asperger's syndrome (Mintz and Blumenfeld) 1999; 46:529A
Focal cortical dysplasia
diagnosis of subtle focal dysplastic lesions: curvilinear reformatting from three-dimensional magnetic resonance imaging (Bastos et al) 1999;46:88
Forced normalization
forced normalization in an adolescent (Caruso et al) 1999; 46:545A
14-3-3 brain protein; *see* Proteins
Friedreich's ataxia
increased iron in the dentate nucleus of patients with Friedreich's ataxia (Waldvogel et al) 1999;46:123
N-acetylcysteine failure in Friedreich's ataxia (Selcen et al) 1999;46:536A
Frontal lobe
FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation (Sperfeld et al) 1999;46:708
language area localization with three-dimensional functional magnetic resonance imaging matches intrasulcal electrostimulation in Broca's area (Rutten et al) 1999; 46:405
phenotypic variation in hereditary frontotemporal dementia with tau mutations (van Swieten et al) 1999;46:617
Functional Independence Measurement Scale
prospective, controlled study of stroke outcome as predicted by the Functional Independence Measurement Scale acquired during acute rehabilitation (Verro and Abbur) 1999;46:506A
role of item analysis in scale development and evaluation: reducing the Functional Independence Measure (Hobart et al) 1999;46:468A

GABA
brain GABA levels are below normal in epilepsy patients treated with valproate and lamotrigine (Petroff et al) 1999;46:455A
selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase (Ishida et al) 1999;46:263
Gabapentin
phase III placebo-controlled trial of gabapentin in amyotrophic lateral sclerosis (Miller et al) 1999;46:494A
Ganaxolone
ganaxolone in the treatment of refractory epileptic syndromes in pediatric patients (Soufflet et al) 1999;46: 524A

Ganglia, spinal
cisplatin induces apoptosis in dorsal root ganglion neurons in vivo (Windebank et al) 1999;46:445A
Gelastic seizures; *see* Seizures
Gene expression
analysis of gene expression in multiple sclerosis lesions using cDNA microarrays (Whitney et al) 1999;46:425
Gene transfer; *see* Transfection
Genes
genes required for normal development of the human cerebral cortex (Walsh) 1999;46:444A
Genes, suppressor, tumor
germline mutations of *p53* but not *p16/CDKN2* or *PTEN/MMAC1* tumor suppressor genes predispose to gliomas (Zhou et al) 1999;46:913
Geniculate ganglion
distribution of herpes simplex virus type 1 in human geniculate and vestibular ganglia: implications for vestibular neuritis (Arbusow et al) 1999;46:416
Genome
pooled association/linkage disequilibrium genome scanning for complex disorders: modeling, power calculation, variability, and examples (Uhl et al) 1999;46:936A (Works in progress)
Genotype
acetylator genotype for *N*-acetyltransferase 2 and Parkinson's disease (Dupret et al) 1999;46:433 (Letter)
use of genotype–phenotype correlation to dissect liability to develop multiple sclerosis and predict response to interferon-β depending on HLA type: preliminary report (Beall et al) 1999;46:498A
Gestures
early dissociation of verbal and non-verbal gestural ability in an epileptic deaf child (Metz-Lutz et al) 1999;46:929
Gilles de la Tourette syndrome; *see* Tourette syndrome
Glatiramer acetate
effect of treatment of patients with glatiramer acetate (copolymer-1) on the proliferative response of peripheral blood mononuclear cells to glatiramer acetate in vitro (Ragheb et al) 1999;46:457A
magnetic resonance imaging and clinical correlations in a cross-sectional analysis of patients in the open-label extension of the US pivotal trial of glatiramer acetate (copaxone) in relapsing multiple sclerosis (Wolinsky and Narayana) 1999;46:471A
prospective, controlled, open-label trial comparing the effect of Avonex, Betaseron, and glatiramer acetate on the relapse rate in patients with relapsing-remitting multiple sclerosis (Khan et al) 1999;46:938A (Works in progress)
why are eligible patients with multiple sclerosis not using interferon-β or glatiramer acetate? (Vollmer and Hadjimichael) 1999;46:458A
Glioblastoma multiforme
which glioblastoma multiforme patient will become a long-term survivor? a population-based study (Scott et al) 1999;46:183
Glioma
germline mutations of *p53* but not *p16/CDKN2* or *PTEN/MMAC1* tumor suppressor genes predispose to gliomas (Zhou et al) 1999;46:913
phase I trial of O^6-benzylguanine plus bis(2-chloroethyl)-nitrosourea for patients undergoing surgery for malignant glioma (Cokgor et al) 1999;46:491A
temozolomide: an oral cytotoxic agent with promising activity against recurrent malignant glioma (Mason) 1999;46:464A
treatment of gliomas with a recombinant *Listeria* vaccine in rats (Bronstein et al) 1999;46:464A
Globus pallidus
amelioration of sensory limb discomfort of restless legs syndrome by pallidotomy (Rye and DeLong) 1999;46:800 (Letter)
bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients (Ardouin et al) 1999;46:217
internal global pallidus discharge is nearly suppressed during levodopa-induced dyskinesias (Papa et al) 1999;46:732
Glucose
cerebral glucose metabolism in patients with Angelman's syndrome (Mohamed et al) 1999;46:530A
children with epilepsy and aggression: a distinct pattern of positron emission tomography glucose metabolism (Chugani et al) 1999;46:533A
insulin-like growth factor-I inhibits high glucose-induced neuronal oxidative stress and loss of mitochondrial membrane integrity in models of diabetes (Russell et al) 1999;46:460A
Glutamates
calcium, glutamate, and amyotrophic lateral sclerosis: more evidence, but no certainties (Shaw) 1999;46:803 (Editorial)
cerebellar ataxia with glutamic acid decarboxylase antibody (Boylan and Lennon) 1999;46:457A
glutamatergic synapses in developing hippocampal dentate gyrus granule cells (Ye et al) 1999;46:520A
metabotropic glutamate receptor activation decreases paired-pulse inhibition in the CA3 region of the hippocampus (Rutecki and Sayin) 1999;46:446A
protective effects of a glutamate receptor antagonist in a rodent model of periventricular leukomalacia (Follett et al) 1999;46:521A
reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis (Takuma et al) 1999;46:806
selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase (Ishida et al) 1999;46:263
serine/threonine phosphorylation of *N*-ethylmaleimide–sensitive factor is associated with Ca^{2+}-dependent K^+-stimulated release of L-glutamate in neocortical synaptosomes (Slevin et al) 1999;46:487A
Glycoproteins
anti–myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy (Meucci et al) 1999;46:119
biochemical alterations in the central nervous system of aging mice lacking the gene for myelin-associated glycoprotein (Weiss and Quarles) 1999;46:486A
cytomegalovirus is not associated with IgM anti–myelin-associated glycoprotein/sulphate-3-glucuronyl paraglycoside antibody–associated neuropathy (Lunn et al) 1999;46:267
Gray matter
periventricular white matter injury in the premature infant is followed by reduced cerebral cortical gray matter volume at term (Inder et al) 1999;46:755
Growth hormone
growth hormone in children with medulloblastoma: use and effect on tumor control (Packer et al) 1999;46:526A

GTP cyclohydrolase
dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene (Furukawa et al) 1999;46:936A (Works in progress)
GTP phosphohydrolase
increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease (Shimura-Miura et al) 1999;46:920
insulin-like growth factor-I induces Schwann cell motility via phosphatidylinositol-3 kinase and small GTPases (Cheng et al) 1999;46:486A
interaction of the deafness-dystonia protein DDP with the dynamin-like GTPase DVLP (Blackstone et al) 1999;46:936A (Works in progress)
Guanosine cyclic monophosphate
cyclic adenosine monophosphate– or cyclic guanosine monophosphate–elevating agents prevent oxygen-glucose deprivation–induced oligodendroglial injury (Yoshioka et al) 1999;46:485A
Guidelines
guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from Phase III clinical trials (Goodkin et al) 1999;46:132 (Special report)
Guillain-Barré syndrome; *see* Polyradiculoneuritis
Gypsies
hereditary auditory, vestibular, motor, and sensory neuropathy in a Slovenian Roma (Gypsy) kindred (Butinar et al) 1999;46:36

Hamartoma
gelastic seizure as a manifestation of Pallister-Hall syndrome (Liow et al) 1999;46:456A
Hand
functional anatomy of error correction during pointing without vision of the hand (Grafton et al) 1999;46:447A
Hashimoto's thyroiditis; *see* Thyroiditis, autoimmune
Head injuries
computed tomography and magnetic resonance imaging in mild to moderate head injury: early and late imaging related to outcome (van der Naalt et al) 1999;46:70
Headache
factors precipitating migraine headaches in children (Riback) 1999;46:540A
functional magnetic resonance imaging in spontaneous attacks of SUNCT: short-lasting neuralgiform headache with conjunctival injection and tearing (May et al) 1999;46:791
migraine without aura: a population-based twin study (Gervil et al) 1999;46:606
simulation of a randomized trial of treatment for migraine headache (de Lissovoy et al) 1999;46:509A
Health status
improving measurement scales: is adding items the answer? (Freeman et al) 1999;46:507A
Heart
investigation of markers of cardiac muscle damage in Duchenne/Becker muscular dystrophy (Miller et al) 1999;46:462A
Heart arrest
evoked responses accurately predict unfavorable outcome after cardiac arrest (Rothstein) 1999;46:468A
Heart conduction system
autosomal dominant form of limb girdle muscular dystrophy with cardiac conduction defects (Galanopoulou et al) 1999;46:461A
Heart surgery
declining incidence and changing profile of seizures after cardiac surgery (Menache et al) 1999;46:546A
Heart-assist devices
fatal cerebral embolic infarctions due to thrombosis of HeartMate left ventricular assist device (Li et al) 1999;46:480A
Heat-shock proteins
multiple molecular penumbras following cerebral infarction (Sharp et al) 1999;46:444A
role for heat shock protein chaperones in polyglutamine disease: the misfolded protein stress response and suppression of polyglutamine aggregation and neural toxicity by an Hsp40 molecular chaperone (Paulson et al) 1999;46:935A (Works in progress)
Helper cells
drop in relapse rate and a shift of helper T cells in multiple sclerosis by a combination therapy of three different phosphodiesterase inhibitors (Suzumura et al) 1999;46:474A
Hemangioblastoma
central nervous system hemangioblastomas: a review (Conway et al) 1999;46:464A
Hematoma
what makes the neurosurgeon think surgery is beneficial in spontaneous cerebellar hematomas? (St Louis et al) 1999;46:504A
Hemiballismus
neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus (Vitek et al) 1999;46:22
Hemiplegia
evolution of functional reorganization in hemiplegic stroke: a serial positron emission tomographic activation study (Nelles et al) 1999;46:901
forced use improves upper limb function in childhood hemiparesis (Willis et al) 1999;46:541A
longitudinal functional magnetic resonance imaging study in hemiparetic stroke (Miyai et al) 1999;46:467A
Hemispherectomy; *see* Brain, surgery
Hepatitis A
V-chain T-cell receptor transcripts are clonally expanded in the cerebrospinal fluid of a patient with demyelinating diseases following hepatitis A infection (Oleszak et al) 1999;46:542A
Hepatitis C
peripheral neuropathy associated with hepatitis C and cryoglobulinemia: treatment with cyclophosphamide (Souayah and Khella) 1999;46:492A
Hereditary neuropathy with liability to pressure palsy
hereditary neuropathy with liability to pressure palsy presenting as developmental delay and hypotonia (Kadakia et al) 1999;46:549A
Hereditary spastic paraplegia; *see* Spastic paraplegia, hereditary
Herpesvirus hominis
antinociceptive effect of gene transfer with a herpes simplex virus vector coding for human preproenkephalin (Goss et al) 1999;46:935A (Works in progress)
distribution of herpes simplex virus type 1 in human geniculate and vestibular ganglia: implications for vestibular neuritis (Arbusow et al) 1999;46:416
herpes simplex virus 1–induced multifocal central nervous system demyelination in mice: mechanisms mediating the development of demyelination during the acute stage of infection (Kastrukoff et al) 1999;46:487A

Herpesvirus-6, human
correlation of human herpesvirus 6 p41 and p101 expression and oligodendroglial cell death in progressive multifocal leukoencephalopathy (Goodman et al) 1999;46:488A
Heterotopia
familial bilateral periventricular nodular heterotopia in a boy (Wilver et al) 1999;46:547A
Hippocampus
association between hippocampal volume and epilepsy duration (Theodore and Gaillard) 1999;46:800 (Letter)
effect of hypoxia on the expression of inducible nitric oxide synthase in the hippocampus of term fetal guinea pigs (Spandou et al) 1999;46:520A
effects of anticonvulsant lactams on in vitro seizures in the hippocampal slice preparation (Hill et al) 1999;46:539A
epileptogenic action of caffeine during anoxia in the neonatal rat hippocampus (Dzhala et al) 1999;46:95
glutamatergic synapses in developing hippocampal dentate gyrus granule cells (Ye et al) 1999;46:520A
hippocampal long-term potentiation is preserved following neonatal hypoxia-ischemia (Yamada et al) 1999;46:538A
hippocampal *N*-methyl-D-aspartate receptor subunit mRNA levels in temporal lobe epilepsy patients (Mathern et al) 1999;46:343
hippocampal volumes in normal aging predict subsequent cognitive decline (Petersen et al) 1999;46:454A
hypoxia-induced nitration of protein in the hippocampus of the guinea pig fetus (Zanelli et al) 1999;46:538A
ketone bodies do not directly alter excitatory or inhibitory hippocampal synaptic transmission (Thio et al) 1999;46:537A
metabotropic glutamate receptor activation decreases paired-pulse inhibition in the CA3 region of the hippocampus (Rutecki and Sayin) 1999;46:446A
Histones
serum IgM autoantibodies in patients with paraneoplastic and idiopathic opsoclonus myoclonus syndrome recognize neurofilament and histone in neural preparations (Connolly et al) 1999;46:536A
HIV
cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia (Conant et al) 1999;46:391
enhancement of human immunodeficiency virus protein–induced neurotoxicity with methamphetamine and cocaine (Nath et al) 1999;46:488A
human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex (Rostasy et al) 1999;46:207
relation between neuroimaging abnormalities and cerebrospinal fluid viral load in children with human immunodeficiency virus disease (Civitello et al) 1999;46:521A
HIV-associated dementia; *see* AIDS-dementia complex
Holmes' tremor; *see* Tremor
Holoprosencephaly
common topological abnormalities in brains with holoprosencephaly: a magnetic resonance imaging–based analysis (Begleiter et al) 1999;46:545A
neuroradiological spectrum of holoprosencephaly (Pinter et al) 1999;46:539A
Homozygotes
homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease (Blumen et al) 1999;46:115
Hospitalization
status epilepticus among hospitalized children in the United States, 1988–1995 (Trevathan and Rurangirwa) 1999;46:531A
Hospitals, university
trends in university-based neurologists' practice in the 1990s: a report of the American Academy of Neurology Practice Characteristics Subcommittee (Swarztrauber et al) 1999;46:505A
Human immunodeficiency virus; *see* HIV
Human immunodeficiency virus-associated dementia; *see* AIDS-dementia complex
Huntington chorea
huntingtin aggregates may not predict neuronal death in Huntington's disease (Kuemmerle et al) 1999;46:842
sequence-specific cleavage of huntingtin mRNA by catalytic DNA (Yen et al) 1999;46:366
Hydroxyurea
hydroxyurea chemotherapy for unresectable or residual meningioma (Newton et al) 1999;46:493A
Hyperekplexia
hyperekplexia phenotype due to compound heterozygosity for GLRA1 gene mutations (Vergouwe et al) 1999;46:634
neurological complications of hyperekplexia in infancy (Chaves-Carballo et al) 1999;46:466A
Hypersomnolence
pediatric posttraumatic hypersomnolence: an underidentified condition? (Milrod and Yalamanchi) 1999;46:546A
Hypertrophy
pattern of onion-bulb distribution predicts acquired versus inherited hypertrophic neuropathy (Dyck and Engelstad) 1999;46:482A
Hypoglycemia
role of extracellular calcium in hypoglycemic injury to the rat optic nerve, a central white matter tract (Brown et al) 1999;46:489A
Hypotonia; *see* Muscle hypotonia
Hypoxia; *see* Anoxia

Ictal semiology
does ictal semiology predict outcome of neonates with seizures? (Brunquell et al) 1999;46:531A
IgE
heightened IgE response to mite antigens in inflammatory neuropathies (Horiuchi et al) 1999;46:472A
IgM
anti–myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy (Meucci et al) 1999;46:119
cytomegalovirus is not associated with IgM anti–myelin-associated glycoprotein/sulphate-3-glucuronyl paraglboside antibody–associated neuropathy (Lunn et al) 1999;46:267
serum IgM autoantibodies in patients with paraneoplastic and idiopathic opsoclonus myoclonus syndrome recognize neurofilament and histone in neural preparations (Connolly et al) 1999;46:536A

Immunoglobulins, intravenous
aseptic symptomatic pachymeningitis and intravenous immunoglobulin therapy (Mohamed) 1999;46:545A
Immunotherapy
novel strategy for specific immunotherapy of autoimmune disease by genetically engineered antigen-presenting cells (Wu et al) 1999;46:444A
Inclusion body myositis; *see* Myositis
Infant, low birth weight
seizures in very-low-birthweight infants (Wise et al) 1999;46:525A
Infant, newborn
alterations of calbindin-D_{28k} localization in cerebellar Purkinje cells in the hypoxic guinea pig fetus at term (Spandou et al) 1999;46:522A
does ictal semiology predict outcome of neonates with seizures? (Brunquell et al) 1999;46:531A
early identification of neonates at risk for development of neonatal seizures: a cohort study of near-term infants (Prasad et al) 1999;46:534A
effect of hypoxia on the expression of inducible nitric oxide synthase in the hippocampus of term fetal guinea pigs (Spandou et al) 1999;46:520A
epileptogenic action of caffeine during anoxia in the neonatal rat hippocampus (Dzhala et al) 1999;46:95
hippocampal long-term potentiation is preserved following neonatal hypoxia-ischemia (Yamada et al) 1999;46:538A
magnetic resonance line scan diffusion imaging of term neonates with perinatal brain ischemia (Rivkin et al) 1999;46:520A
neuromotor syndrome of periventricular leukomalacia in children born at term (Miller et al) 1999;46:545A
proton magnetic resonance spectroscopy in neonates with acute brain injury: comparison of short and long echo time acquisitions (Shu et al) 1999;46:527A
reduced K^+ current due to a novel mutation in KCNQ2 causes neonatal convulsions (Lerche et al) 1999;46:305
Infant, premature
echogenicity on cranial sonograms in preterm infants: risk profiles and death (Kuban et al) 1999;46:527A
periventricular white matter injury in the premature infant is followed by reduced cerebral cortical gray matter volume at term (Inder et al) 1999;46:755
Infantile spasms; *see* Spasms, infantile
Infection
herpes simplex virus 1–induced multifocal central nervous system demyelination in mice: mechanisms mediating the development of demyelination during the acute stage of infection (Kastrukoff et al) 1999;46:487A
outcome, preceding infections, and immune factors in Guillain-Barré syndrome (Hadden et al) 1999;46:484A
Infertility, male
dominantly inherited spinocerebellar ataxia with male sterility and mental deficiency: a novel spinocerebellar ataxia phenotype (Gomez et al) 1999;46:481A
Inflammation
mitogen-activated protein kinases in inflammatory myopathies and Duchenne muscular dystrophy: differential expression of ERK and its target transcription factor in inclusion body myositis (Nakano et al) 1999;46:484A
peroxynitrite in neuroinflammation (Scott et al) 1999;46:473A
Insulin-like growth factor I
insulin-like growth factor-I induces Schwann cell motility via phosphatidylinositol-3 kinase and small GTPases (Cheng et al) 1999;46:486A
insulin-like growth factor-I inhibits high glucose-induced neuronal oxidative stress and loss of mitochondrial membrane integrity in models of diabetes (Russell et al) 1999;46:460A
insulin-like growth factor-I prevents caspase-mediated apoptosis in Schwann cells following serum withdrawal (Delaney et al) 1999;46:485A
Intensive care units
should mild or moderate strokes be admitted to an intensive care unit? (Briggs et al) 1999;46:509A
Interferon beta
combination therapy with serotonin reuptake inhibitors and interferon β-1a (Avonex) in the treatment of multiple sclerosis: a pilot study (Potter and Hart) 1999;46:495A
effect of interferon β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial (Miller et al) 1999;46:850
magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis (Li et al) 1999;46:197
migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon β-1b therapy (Uhm et al) 1999;46:319
reduction of transendothelial migration of mononuclear cells in interferon-β1b–treated multiple sclerosis patients (Corsini et al) 1999;46:435 (Letter)
use of genotype–phenotype correlation to dissect liability to develop multiple sclerosis and predict response to interferon-β depending on HLA type: preliminary report (Beall et al) 1999;46:498A
why are eligible patients with multiple sclerosis not using interferon-β or glatiramer acetate? (Vollmer and Hadjimichael) 1999;46:458A
Interferons
neurtralizing antibodies to endogenous interferons in multiple sclerosis and myasthenia gravis (Bagnato et al) 1999;46:473A
Interleukin-1
population-based association study of two polymorphisms in the interleukin-1b and interleukin-1 receptor antagonist genes with susceptibility to and severity of multiple sclerosis (Kantarci et al) 1999;46:456A
Interleukin-6
interleukin-6 'knockout' mice are not protected against focal central nervous system ischemia (Clark et al) 1999;46:448A
Interleukin-10
relationship between serum levels of interleukin-10 and MRI activity in patients with relapsing–remitting multiple sclerosis (Waubant et al) 1999;46:490A
Intracerebral hemorrhage; *see* Cerebral hemorrhage
Ion channels
experimental axonal ion channel encephalitis (Burghes and Rammohan) 1999;46:456A
Iron
increased iron in the dentate nucleus of patients with Friedreich's ataxia (Waldvogel et al) 1999;46:123
Ischemia
apoptosis in perinatal hypoxic–ischemic brain damage: a histopathological study in pontosubicular neuron necrosis (Itoh and Becker) 1999;46:466A
early prediction of poor outcome in anoxic-ischemic coma (Schreiner and Pohlmann-Eden) 1999;46:468A

improvement in ischemic limb neuropathy after vascular endothelial growth factor gene therapy (Simovic et al) 1999;46:463A
interleukin-6 'knockout' mice are not protected against focal central nervous system ischemia (Clark et al) 1999;46:448A
Ischemia, cerebral; *see* Cerebral ischemia

Japan
application of conjoint analysis to the development of a novel, weighted stroke scale: Japan stroke scale (Gotoh et al) 1999;46:505A
founder effect, ancestral haplotype, and predisposing chromosome of spinocerebellar ataxia type 6 in the Japanese population (Yabe et al) 1999;46:480A
lack of association between bleomycin hydrolase gene polymorphism and Alzheimer's disease in Japanese people (Namba et al) 1999;46:136 (Letter)
occurrence of atopic myelitis in Japan: clinical, immunological, and pathological studies (Kira et al) 1999;46:469A

Kainic acid
differential expression of multiple semaphorin genes in rats after kainic acid–induced status epilepticus (Barnes et al) 1999;46:537A
Ketone bodies
ketone bodies do not directly alter excitatory or inhibitory hippocampal synaptic transmission (Thio et al) 1999;46:537A
Ketones
ketogenic diet: long-term efficacy and patient tolerance in children with intractable pediatric epilepsy (Thompson et al) 1999;46:532A

Lactams
effects of anticonvulsant lactams on in vitro seizures in the hippocampal slice preparation (Hill et al) 1999;46:539A
Lactates
dichloroacetate treatment after ischemic stroke produces declines in cerebral lactate (Graham et al) 1999;46:494A
Lamotrigine
brain GABA levels are below normal in epilepsy patients treated with valproate and lamotrigine (Petroff et al) 1999;46:455A
choreoathetosis caused by combined lamotrigine and phenytoin: a pharmacodynamic interaction? (Megdad et al) 1999;46:476A
Language
cerebral localization of reading in normal children: a functional magnetic resonance imaging language study (Gaillard et al) 1999;46:528A
language area localization with three-dimensional functional magnetic resonance imaging matches intrasulcal electrostimulation in Broca's area (Rutten et al) 1999;46:405
language recovery after left hemispherectomy in children with late-onset seizures (Boatman et al) 1999;46:579
Left ventricular assist devices; *see* Heart-assist devices
Leg
assessment of functional status, low back disability, and use of diagnostic imaging in patients with low back pain and radiating leg pain (Ren et al) 1999;46:507A

Leigh disease
loss-of-function mutations of SURF-1 are specifically associated with Leigh syndrome with cytochrome *c* oxidase deficiency (Tiranti et al) 1999;46:161
solving the COX puzzle (De Vivo) 1999;46:142 (Editorial)
Leptomeninges; *see* Arachnoid
Leukemia
paraneoplastic cerebellar degeneration in a child with leukemia (Deputy) 1999;46:550A
quality of life assessment in children with cancer at risk for brain impairment: development of a new pediatric brain-specific instrument, PBS version 1.0 (Tao and Parsons) 1999;46:502A
Leukocytes, mononuclear
effect of treatment of patients with glatiramer acetate (copolymer-1) on the proliferative response of peripheral blood mononuclear cells to glatiramer acetate in vitro (Ragheb et al) 1999;46:457A
reduction of transendothelial migration of mononuclear cells in interferon-β1b–treated multiple sclerosis patients (Corsini et al) 1999;46:435 (Letter)
Leukodystrophy
genetic localization and physical mapping of a locus for a leukodystrophy mimicking chronic progressive multiple sclerosis (Fu and Ptábrecek) 1999;46:475A
Leukoencephalopathy
cortical–subcortical magnetic resonance imaging/computed tomography lesions in reversible posterior leukoencephalopathy syndrome: encephalopathy or seizures? (Strasser et al) 1999;46:472A
developmental disorders in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (Desmond et al) 1999;46:481A
leukoencephalopathy associated with a disturbance in the metabolism of polyols (van der Knaap et al) 1999;46:925
new reversible leukoencephalopathy with bilateral anterior temporal lobe cysts (Suwan et al) 1999;46:543A
Leukoencephalopathy, progressive multifocal
correlation of human herpesvirus 6 p41 and p101 expression and oligodendroglial cell death in progressive multifocal leukoencephalopathy (Goodman et al) 1999;46:488A
Leukomalacia, periventricular
neuromotor syndrome of periventricular leukomalacia in children born at term (Miller et al) 1999;46:545A
protective effects of a glutamate receptor antagonist in a rodent model of periventricular leukomalacia (Follett et al) 1999;46:521A
Levodopa
catechol-O-methyltransferase reduced levodopa toxicity in PC12 cells: implications for treatment of Parkinson's disease (Offen et al) 1999;46:459A
internal global pallidus discharge is nearly suppressed during levodopa-induced dyskinesias (Papa et al) 1999;46:732
levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (Muriel et al) 1999;46:103
motor benefit from L-dopa in spastic cerebral palsy (Brunstrom et al) 1999;46:544A
positron emission tomography measurements of striatal dopamine transporter in untreated Parkinson's disease patients: differential regulation with levodopa versus pramipexole (Guttman et al) 1999;46:937A (Works in progress)

Lewy bodies
anti-acetylcholinesterase therapy in dementia with Lewy bodies (Querfurth et al) 1999;46:494A
Limb girdle muscular dystrophy; *see* Muscular dystrophy
Linkage (genetic)
genetic linkage of Welander distal myopathy to chromosome 2p13 (Åhlberg et al) 1999;46:399
linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis (Oturai et al) 1999;46:612
pooled association/linkage disequilibrium genome scanning for complex disorders: modeling, power calculation, variability, and examples (Uhl et al) 1999;46:936A (Works in progress)
Listeria
treatment of gliomas with a recombinant *Listeria* vaccine in rats (Bronstein et al) 1999;46:464A
Low back pain; *see* Backache
Lung transplantation
neurological complications of pediatric lung transplantation (Wong et al) 1999;46:540A
Lupus erythematosus, systemic
neurological complications of systemic lupus erythematosus in children (Quintero-Del-Rio and Miller) 1999;46:540A
Lyme disease
disseminated Lyme disease in children (Belman et al) 1999;46:458A
symptomatic early Lyme disease in adults (Coyle et al) 1999;46:488A
Lymphocytes
lymphocyte migration and multiple sclerosis: relation with disease course and therapy (Prat et al) 1999;46:253
migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon β-1b therapy (Uhm et al) 1999;46:319
Lymphoma
Charcot-Marie-Tooth disease presenting as bilateral vocal cord paralysis and ascending weakness in a teen with lymphoma (Harsanyi and Keating) 1999;46:550A
parenchymal brain lymphoma as the presenting feature of subclinical systemic lymphoma (Peterson et al) 1999;46:463A
posttransplant primary central nervous system lymphoma (Phan et al) 1999;46:463A
Lysophospholipids
lysophosphatidic acid–induced calcium signal and cation current in cultured rat microglial cells (Musante et al) 1999;46:472A

Magnetic resonance imaging
axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability (van Waesberghe et al) 1999;46:747
cerebral localization of reading in normal children: a functional magnetic resonance imaging language study (Gaillard et al) 1999;46:528A
common topological abnormalities in brains with holoprosencephaly: a magnetic resonance imaging–based analysis (Begleiter et al) 1999;46:545A
comparison of baseline magnetic resonance imaging burden of disease and proton density and T2-weighted lesion activity between patients with relapsing-remitting and secondary progressive multiple sclerosis at the time of entry into therapeutic trials (Zhao et al) 1999;46:472A
computed tomography and magnetic resonance imaging in mild to moderate head injury: early and late imaging related to outcome (van der Naalt et al) 1999;46:70
cortical–subcortical magnetic resonance imaging/computed tomography lesions in reversible posterior leukoencephalopathy syndrome: encephalopathy or seizures? (Strasser et al) 1999;46:472A
diagnosis of subtle focal dysplastic lesions: curvilinear reformatting from three-dimensional magnetic resonance imaging (Bastos et al) 1999;46:88
effect of interferon β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial (Miller et al) 1999;46:850
failure to demonstrate spreading depression by serial assessment of the apparent diffusion coefficient in acute human stroke (Back et al) 1999;46:478A
functional magnetic resonance imaging evaluation of cerebrovascular reactivity in Moyamoya (Logan et al) 1999;46:551A
functional magnetic resonance imaging in spontaneous attacks of SUNCT: short-lasting neuralgiform headache with conjunctival injection and tearing (May et al) 1999;46:791
imaging stroke in progress: magnetic resonance advances but computed tomography is poised for counterattack (Koroshetz and Gonzales) 1999;46:556 (Editorial)
language area localization with three-dimensional functional magnetic resonance imaging matches intrasulcal electrostimulation in Broca's area (Rutten et al) 1999;46:405
longitudinal functional magnetic resonance imaging study in hemiparetic stroke (Miyai et al) 1999;46:467A
longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: evolution of lesion volume and correlation with clinical outcome (Beaulieu et al) 1999;46:568
magnetic resonance imaging and clinical correlations in a cross-sectional analysis of patients in the open-label extension of the US pivotal trial of glatiramer acetate (copaxone) in relapsing multiple sclerosis (Wolinsky and Narayana) 1999;46:471A
magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis (Li et al) 1999;46:197
magnetic resonance imaging T2 shortening in multiple sclerosis brains (black T2 lesions): a new surrogate marker of disease (Bakshi et al) 1999;46:469A
magnetic resonance line scan diffusion imaging of term neonates with perinatal brain ischemia (Rivkin et al) 1999;46:520A
neuroradiological findings in Möbius syndrome (Vasconcelos et al) 1999;46:548A
optimal stimulus presentation rate to activate the somatosensory cortex: a functional magnetic resonance imaging study (Takanashi et al) 1999;46:490A
outcome prediction after acute traumatic brain injury in children using magnetic resonance imaging and proton magnetic resonance spectroscopy (Ashwal et al) 1999;46:520A
predictive value of diffusion-weighted imaging in acute ischemic stroke (Baird et al) 1999;46:478A

preliminary observations on the ability of diffusion weighted imaging and perfusion weighted imaging to predict intracranial hemorrhage in patients treated with recombinant tissue plasminogen activator (Tong et al) 1999;46:448A
recovery from optic neuritis is associated with a reorganization of the cerebral response to visual stimulation: a functional magnetic resonance imaging study (Werring et al) 1999;46:468A
relationship between serum levels of interleukin-10 and MRI activity in patients with relapsing–remitting multiple sclerosis (Waubant et al) 1999;46:490A
reversal of acute apparent diffusion coefficient abnormalities and delayed neuronal death following transient focal cerebral ischemia in rats (Li et al) 1999;46:333
serial magnetic resonance imaging in patients with Balò's concentric sclerosis: natural history of lesion development (Chen et al) 1999;46:651
treatment of acute stroke more than 3 hours after onset of symptoms: success with the use of structural and functional imaging (Kamran et al) 1999;46:495A

Magnetic stimulation
transcranial cortical magnetic stimulation in children: a noninvasive method for localization of functional motor cortex in epilepsy surgery candidates (Koo et al) 1999;46:523A

Magnetoencephalography
magnetoencephalographic localization in pediatric epilepsy surgery: comparison with invasive intracranial electroencephalography (Minassian et al) 1999;46:627

Magnetophosphenes; *see* Phosphenes

Major histocompatibility complex
influence of human major histocompatibility complex genes on the development of human immunodeficiency virus–associated dementia (McArthur et al) 1999;46:490A

Male sterility; *see* Infertility, male

Manganese
increased tissue copper and manganese content in the lentiform nucleus in primary adult-onset dystonia (Becker et al) 1999;46:260

Marinesco-Sjögren syndrome; *see* Spinocerebellar degeneration

Measurement scales
application of conjoint analysis to the development of a novel, weighted stroke scale: Japan stroke scale (Gotoh et al) 1999;46:505A
correlation of clinical spasticity scale with intraoperative electrophysiological monitoring (Nizam et al) 1999;46:536A
does the National Institutes of Health Stroke Scale favor left hemisphere strokes? (Woo et al) 1999;46:450A
improving measurement scales: is adding items the answer? (Freeman et al) 1999;46:507A
prospective, controlled study of stroke outcome as predicted by the Functional Independence Measurement Scale acquired during acute rehabilitation (Verro and Abbur) 1999;46:506A
role of item analysis in scale development and evaluation: reducing the Functional Independence Measure (Hobart et al) 1999;46:468A

Mechanical ventilation; *see* Respiration, artificial

Medicare
correlates of dementia and health care cost among Medicare elderly (Husaini et al) 1999;46:508A

Medulloblastoma
growth hormone in children with medulloblastoma: use and effect on tumor control (Packer et al) 1999;46:526A
neurocognitive deficits in medulloblastoma survivors and white matter loss (Mulhern et al) 1999;46:834
neurocognitive status in children with medulloblastoma following reduced-dose craniospinal radiotherapy and chemotherapy (Packer et al) 1999;46:526A

MELAS syndrome
mitochondrial DNA G13513A transition in ND5 is associated with a LHON/MELAS overlap syndrome and may be a frequent cause of MELAS (Pulkes et al) 1999;46:916

Memory
bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients (Ardouin et al) 1999;46:217

Meningioma
hydroxyurea chemotherapy for unresectable or residual meningioma (Newton et al) 1999;46:493A

Meningitis
tuberculous meningitis in a large urban center: prognosis and outcome (Shah and Niesen) 1999;46:542A

Mental retardation
dominantly inherited spinocerebellar ataxia with male sterility and mental deficiency: a novel spinocerebellar ataxia phenotype (Gomez et al) 1999;46:481A

Metalloproteinases
cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia (Conant et al) 1999;46:391

Methamphetamine
enhancement of human immunodeficiency virus protein–induced neurotoxicity with methamphetamine and cocaine (Nath et al) 1999;46:488A

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure (Langston et al) 1999;46:598

***N*-Methylaspartate**
hippocampal *N*-methyl-D-aspartate receptor subunit mRNA levels in temporal lobe epilepsy patients (Mathern et al) 1999;46:343

Methylphenidate
cerebral palsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? (Shalev et al) 1999;46:539A
comparing adderall and methylphenidate in attention deficit hyperactivity disorder (Pliszka et al) 1999;46:528A

Microglia; *see* Neuroglia

Microlissencephaly
diffuse pachygyria with cerebellar hypoplasia: a milder form of microlissencephaly or a new genetic syndrome? (Kato et al) 1999;46:660

Midazolam
prospective randomized study comparing intranasal midazolam with intravenous diazepam for the treatment of febrile seizures in children (Lahat et al) 1999;46:522A

Migraine
acute upside-down reversal of vision as migraine aura (Nisipeanu et al) 1999;46:475A
Comparison of magnetophosphenes and visually triggered migraine (Aurora et al) 1999;46:476A

factors precipitating migraine headaches in children (Riback) 1999;46:540A
four revertants of *Unc2*, an uncoordinated mutant calcium channel phenotype in *C. elegans*, implicate genes potentially important in migraine and neurodegeneration (Estevez et al) 1999;46:489A
migraine without aura: a population-based twin study (Gervil et al) 1999;46:606
role of topiramate for refractory migraine prophylaxis: a retrospective pilot study (Storey et al) 1999;46:495A
simulation of a randomized trial of treatment for migraine headache (de Lissovoy et al) 1999;46:509A
zolmitriptan is well tolerated in adolescents (Wasiewski and Winner) 1999;46:541A

Mirror agnosia; *see* Agnosia

Mirror ataxia; *see* Ataxia

Mites
heightened IgE response to mite antigens in inflammatory neuropathies (Horiuchi et al) 1999;46:472A

Mitochondria
increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease (Shimura-Miura et al) 1999;46:920
mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death (Borthwick et al) 1999;46:787

Mitochondria, muscle
quantitative near-infrared spectroscopy discriminates between mitochondrial myopathies and normal muscle (van Beekvelt et al) 1999;46:667

Mitochondrial DNA; *see* DNA, mitochondrial

Mitogens
involvement of p38 MAP kinase pathway in TNF-α production in human astrocytes and microglia (Lee et al) 1999;46:473A
mitogen-activated protein kinases in inflammatory myopathies and Duchenne muscular dystrophy: differential expression of ERK and its target transcription factor in inclusion body myositis (Nakano et al) 1999;46:484A

Möbius syndrome
neuroradiological findings in Möbius syndrome (Vasconcelos et al) 1999;46:548A

Modafinil
efficacy or safety profile of Provigil (modafinil) tablets in patients with and without cataplexy: results from two US multicenter, double-blind, randomized, placebo-controlled trials (Hirshkowitz et al) 1999;46:494A

Monoclonal antibodies; *see* Antibodies, monoclonal

Mononuclear cells; *see* Leukocytes, mononuclear

Mood
association of magnetic resonance spectroscopic abnormalities with quality of life and mood in patients with temporal lobe epilepsy (Maton et al) 1999;46:508A

Motor cortex
transcranial cortical magnetic stimulation in children: a noninvasive method for localization of functional motor cortex in epilepsy surgery candidates (Koo et al) 1999;46:523A

Motor neuron disease
T-588, a novel neuroprotective agent, delays progression of neuromuscular dysfunction in wobbler mouse motoneuron disease (Ikeda et al) 1999;46:492A

Motor neurons
electrophysiological evaluation of upper motor neuron involvement in amyotrophic lateral sclerosis (Kovach et al) 1999;46:461A
paired helical filaments in sporadic inclusion body myositis muscle contain RNA and survival motor neuron protein (Broccolini et al) 1999;46:482A
point mutation in exon 1 of the telomeric survival motor neuron gene in a child with progressive spinal muscular atrophy (Scavina et al) 1999;46:547A

Motor tic disorder; *see* Tic

Moyamoya disease
functional magnetic resonance imaging evaluation of cerebrovascular reactivity in Moyamoya (Logan et al) 1999;46:551A
Moyamoya in three generations of a Scottish family: association with a mitochondrial DNA polymorphism typical of Asian populations (Muir et al) 1999;46:481A

MPP^+; *see* Neurotoxins

mRNA; *see* RNA, messenger

Multiple sclerosis, analysis
amyloid-β peptide levels in serum and cerebrospinal fluid of multiple sclerosis patients (Coyle and Mehta) 1999;46:489A
migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon β-1b therapy (Uhm et al) 1999;46:319
neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy (van Walderveen et al) 1999;46:79
p-cresol sulfate is a prominent component of urinary myelin basic protein-like material in multiple sclerosis (Whitaker et al) 1999;46:457A
relationship between serum levels of interleukin-10 and MRI activity in patients with relapsing–remitting multiple sclerosis (Waubant et al) 1999;46:490A
urinary p-cresol sulfate in multiple sclerosis (Whitaker et al) 1999;46:935A (Works in progress)

Multiple sclerosis, diagnosis
new diagnostic criteria for primary progressive multiple sclerosis (Thompson et al) 1999;46:471A

Multiple sclerosis, drug therapy
effect of sildenafil citrate (Viagra) on quality of life in men with erectile dysfunction and multiple sclerosis (Miller et al) 1999;46:496A
guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from Phase III clinical trials (Goodkin et al) 1999;46:132 (Special report)
magnetic resonance imaging and clinical correlations in a cross-sectional analysis of patients in the open-label extension of the US pivotal trial of glatiramer acetate (copaxone) in relapsing multiple sclerosis (Wolinsky and Narayana) 1999;46:471A
phase 1 study of micellar paclitaxel in the treatment of secondary progressive multiple sclerosis (O'Connor et al) 1999;46:470A
prospective, controlled, open-label trial comparing the effect of Avonex, Betaseron, and glatiramer acetate on the relapse rate in patients with relapsing-remitting multiple sclerosis (Khan et al) 1999;46:938A (Works in progress)
Viagra (sildenafil citrate) for the treatment of erectile dysfunction in men with multiple sclerosis (Fowler et al) 1999;46:497A

Multiple sclerosis, etiology
Chlamydia: a role for multiple sclerosis or more confusion? (Gilden) 1999;46:4 (Editorial)
Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis (Sriram et al) 1999;46:6

demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation (Raine et al) 1999;46:144
path to damage in multiple sclerosis (McFarland) 1999; 46:141 (Editorial)
structural plasticity of a protein antigen implicated in the immunopathogenesis of multiple sclerosis (Genain et al) 1999;46:936A (Works in progress)

Multiple sclerosis, genetics
analysis of gene expression in multiple sclerosis lesions using cDNA microarrays (Whitney et al) 1999;46:425
genetic localization and physical mapping of a locus for a leukodystrophy mimicking chronic progressive multiple sclerosis (Fu and Ptábrecek) 1999;46:475A
linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis (Oturai et al) 1999;46: 612
mitochondrial DNA variants in multiple sclerosis (Kalman and Alder) 1999;46:469A
population-based association study of two polymorphisms in the interleukin-1b and interleukin-1 receptor antagonist genes with susceptibility to and severity of multiple sclerosis (Kantarci et al) 1999;46:456A
population-based study of multiple sclerosis in Italian twins (Ristori and Italian Study Group for Multiple Sclerosis in Twins) 1999;46:474A
tumor necrosis factor 2 allele does not contribute to increased tumor necrosis factor-α production in Sardinian multiple sclerosis (Sotgiu et al) 1999;46:799 (Letter)
use of genotype–phenotype correlation to dissect liability to develop multiple sclerosis and predict response to interferon-β depending on HLA type: preliminary report (Beall et al) 1999;46:498A

Multiple sclerosis, immunology
neurtralizing antibodies to endogenous interferons in multiple sclerosis and myasthenia gravis (Bagnato et al) 1999;46:473A

Multiple sclerosis, pathology
axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability (van Waesberghe et al) 1999;46:747
comparison of baseline magnetic resonance imaging burden of disease and proton density and T2-weighted lesion activity between patients with relapsing-remitting and secondary progressive multiple sclerosis at the time of entry into therapeutic trials (Zhao et al) 1999;46: 472A
elevated production of tumor necrosis factor-α by γ/δ T-cell lines generated from cerebrospinal fluid of multiple sclerosis patients (Matusevicius and Freedman) 1999;46:470A
lymphocyte migration and multiple sclerosis: relation with disease course and therapy (Prat et al) 1999;46:253
magnetic resonance imaging T2 shortening in multiple sclerosis brains (black T2 lesions): a new surrogate marker of disease (Bakshi et al) 1999;46:469A
oxidative damage to mitochondrial DNA in active lesions of multiple sclerosis (Kalman and Lu) 1999;46:456A

Multiple sclerosis, physiopathology
assessment of disease severity in early multiple sclerosis (Scott et al) 1999;46:473A
clinical profile of relapsing multiple sclerosis in African Americans: impact of immunomodulating therapy on disease course (Khan et al) 1999;46:471A
cognitive performance and magnetic resonance spectroscopy: correlates in multiple sclerosis (Pan et al) 1999; 46:475A
disability trends and outcome measures in treatment trials of relapsing-remitting multiple sclerosis (Blumhardt and Liu) 1999;46:502A
meaning of quality of life in multiple sclerosis (O'Connor et al) 1999;46:502A

Multiple sclerosis, therapy
combination therapy with serotonin reuptake inhibitors and interferon β-1a (Avonex) in the treatment of multiple sclerosis: a pilot study (Potter and Hart) 1999;46: 495A
drop in relapse rate and a shift of helper T cells in multiple sclerosis by a combination therapy of three different phosphodiesterase inhibitors (Suzumura et al) 1999; 46:474A
effect of interferon β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial (Miller et al) 1999;46: 850
magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis (Li et al) 1999;46:197
monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis (Coles et al) 1999;46:296
reduction of transendothelial migration of mononuclear cells in interferon-β1b–treated multiple sclerosis patients (Corsini et al) 1999;46:435 (Letter)
ultilization patterns among Veterans Administration patients with multiple sclerosis (Vollmer et al) 1999;46: 474A
why are eligible patients with multiple sclerosis not using interferon-β or glatiramer acetate? (Vollmer and Hadjimichael) 1999;46:458A

Murine 7E3 F(ab')$_2$
initial experience with murine 7E3 F(ab')$_2$ (GP IIb/IIIa antagonist) in focal cerebral ischemia model (Yang et al) 1999;46:491A

Muscimol
tremor arrest with thalamic microinjections of muscimol in patients with essential tremor (Pahapill et al) 1999; 46:249

Muscle cramp
muscle phosphoglycerate mutase deficiency with tubular aggregates: effect of dantrolene (Vissing et al) 1999;46: 274

Muscle hypotonia
hereditary neuropathy with liability to pressure palsy presenting as developmental delay and hypotonia (Kadakia et al) 1999;46:549A

Muscle spasticity
correlation of clinical spasticity scale with intraoperative electrophysiological monitoring (Nizam et al) 1999;46: 536A

Muscular atrophy, spinal
point mutation in exon 1 of the telomeric survival motor neuron gene in a child with progressive spinal muscular atrophy (Scavina et al) 1999;46:547A

Muscular dystrophy
autosomal dominant form of limb girdle muscular dystrophy with cardiac conduction defects (Galanopoulou et al) 1999;46:461A

copper/zinc superoxide dismutase: more is not necessarily better! (Rando and Epstein) 1999;46:135 (Letter)
does increased superoxide dismutase activity really cause muscular dystrophy? (Almer et al) 1999;46:135 (Letter)
on dystrophin abundance and C-terminal missense mutations in dystrophinopathies (Oexle and Heyer) (Letter); (Goldberg and Hoffman) (Reply) 1999;46:137
homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease (Blumen et al) 1999; 46:115
investigation of markers of cardiac muscle damage in Duchenne/Becker muscular dystrophy (Miller et al) 1999;46:462A
limb girdle myopathy and respiratory insufficiency is associated with the A3302G mutation in the $tRNA^{Leu(UUR)}$ gene (Sue et al) 1999;46:462A
mitogen-activated protein kinases in inflammatory myopathies and Duchenne muscular dystrophy: differential expression of ERK and its target transcription factor in inclusion body myositis (Nakano et al) 1999;46:484A

Mutation
de novo splice donor site mutation causes in-frame deletion of 14 amino acids in the proteolipid protein in Pelizaeus-Merzbacher disease (Aoyagi et al) 1999; 46:112
on dystrophin abundance and C-terminal missense mutations in dystrophinopathies (Oexle and Heyer) (Letter); (Goldberg and Hoffman) (Reply) 1999;46:137
familial Alzheimer's disease: site of mutation influences clinical phenotype (Lippa et al) 1999;46:453A
familial Creutzfeldt-Jakob disease with a novel 120-bp insertion in the prion protein gene (Skworc et al) 1999; 46:693
frequency of *tau* mutations in three series of non-Alzheimer's degenerative dementia (Houlden et al) 1999;46:243
FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation (Sperfeld et al) 1999;46:708
germline mutations of *p53* but not *p16/CDKN2* or *PTEN/MMAC1* tumor suppressor genes predispose to gliomas (Zhou et al) 1999;46:913
hyperekplexia phenotype due to compound heterozygosity for GLRA1 gene mutations (Vergouwe et al) 1999;46: 634
limb girdle myopathy and respiratory insufficiency is associated with the A3302G mutation in the $tRNA^{Leu(UUR)}$ gene (Sue et al) 1999;46:462A
loss-of-function mutations of SURF-1 are specifically associated with Leigh syndrome with cytochrome *c* oxidase deficiency (Tiranti et al) 1999;46:161
mitochondrial DNA G13513A transition in ND5 is associated with a LHON/MELAS overlap syndrome and may be a frequent cause of MELAS (Pulkes et al) 1999; 46:916
mutations in noncoding regions of the proteolipid protein gene in patients with Pelizaeus Merzbacher disease (PMD) and PMD-like disorders (Hobson et al) 1999; 46:530A
myelin deficiencies in both the central and the peripheral nervous systems associated with a *SOX10* mutation (Inoue et al) 1999;46:313
novel mutations in the CLCN1 gene cause a myotonic myopathy with a distinct phenotype (Nagamitsu et al) 1999;46:462A
pediatric dystonia due to mtDNA mutation at np 14459: report of the fourth family (Gropman et al) 1999;46: 548A
phenotypic variation in hereditary frontotemporal dementia with tau mutations (van Swieten et al) 1999;46:617
point mutation in exon 1 of the telomeric survival motor neuron gene in a child with progressive spinal muscular atrophy (Scavina et al) 1999;46:547A
reduced K^+ current due to a novel mutation in KCNQ2 causes neonatal convulsions (Lerche et al) 1999;46:305
role of factor XIII Val 34 Leu mutation in ischemic cerebrovascular disease (Iniesta et al) 1999;46:449A
Roussy-Lévy family: from the original description to the gene (Planté-Bordeneuve et al) 1999;46:770

Myasthenia gravis
acute bulbar weakness: thyrotoxicosis or myasthenia gravis? (Lleó et al) 1999;46:434 (Letter)
antibodies to acetylcholine receptors, potassium channels, and titin in a patient with thymoma, myasthenia gravis, and limbic encephalitis (Buckley et al) 1999;46:482A
3,4-diaminopyridine: therapeutic considerations for chronic use in children with congenital myasthenia (Bowe et al) 1999;46:534A
neurofilament is an autoantigenic determinant in myasthenia gravis (Schultz et al) 1999;46:167
neurtralizing antibodies to endogenous interferons in multiple sclerosis and myasthenia gravis (Bagnato et al) 1999;46:473A
novel functional ϵ-subunit polypeptide generated by a single nucleotide deletion in acetylcholine receptor deficiency congenital myasthenic syndrome (Croxen et al) 1999;46:639
prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis (Aissaoui et al) 1999;46:559
targeting T cells in myasthenia gravis (Drachman) 1999; 46:553 (Editorial)

Myelin
anti–myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy (Meucci et al) 1999;46:119
cytomegalovirus is not associated with IgM anti–myelin-associated glycoprotein/sulphate-3-glucuronyl paraglo-boside antibody–associated neuropathy (Lunn et al) 1999;46:267
intraventricular transplantation of oligodendrocyte progenitors into a fetal myelin mutant results in widespread formation of myelin (Learish et al) 1999;46:716
myelin deficiencies in both the central and the peripheral nervous systems associated with a *SOX10* mutation (Inoue et al) 1999;46:313
transplantation of human oligodendrocytes and Schwann cells into the brain of myelin mutant Shaker rats (Nakagawa et al) 1999;46:457A

Myelin basic proteins; *see* Encephalitogenic basic proteins

Myelin sheath
biochemical alterations in the central nervous system of aging mice lacking the gene for myelin-associated glycoprotein (Weiss and Quarles) 1999;46:486A
extracellular matrix provides mechanical stability for myelination in the peripheral nervous system (Windebank and Podratz) 1999;46:483A

Myelitis
occurrence of atopic myelitis in Japan: clinical, immunological, and pathological studies (Kira et al) 1999;46:469A
Myocardial diseases
autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q (Melberg et al) 1999;46:684
myofibrillar myopathy (Engel) 1999;46:681 (Editorial)
Myoclonus
localization of a gene for myoclonus-dystonia to chromosome 7q21-q31 (Nygaard et al) 1999;46:794
serum IgM autoantibodies in patients with paraneoplastic and idiopathic opsoclonus myoclonus syndrome recognize neurofilament and histone in neural preparations (Connolly et al) 1999;46:536A
Myofibrils
autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q (Melberg et al) 1999;46:684
myofibrillar myopathy (Engel) 1999;46:681 (Editorial)
Myositis
β-amyloid expression is associated with apoptosis in myotubes and triad protein abnormalities in inclusion body myositis (Querfurth et al) 1999;46:459A
mitogen-activated protein kinases in inflammatory myopathies and Duchenne muscular dystrophy: differential expression of ERK and its target transcription factor in inclusion body myositis (Nakano et al) 1999;46:484A
paired helical filaments in sporadic inclusion body myositis muscle contain RNA and survival motor neuron protein (Broccolini et al) 1999;46:482A
prion gene and apolipoprotein E in sporadic inclusion body myositis (Lampe et al) 1999;46:485A
Myotonia congenita
novel mutations in the CLCN1 gene cause a myotonic myopathy with a distinct phenotype (Nagamitsu et al) 1999;46:462A

Narcolepsy
critical role of orexin neurons in narcolepsy (Scammell et al) 1999;46:935A (Works in progress)
National Institutes of Health
does the National Institutes of Health Stroke Scale favor left hemisphere strokes? (Woo et al) 1999;46:450A
Near-infrared spectroscopy; *see* Spectroscopy, near-infrared
Necrosis
apoptosis in perinatal hypoxic–ischemic brain damage: a histopathological study in pontosubicular neuron necrosis (Itoh and Becker) 1999;46:466A
Neocortex; *see* Cerebral cortex
Neonate; *see* Infant, newborn
Neoplasms, embryonal and mixed
clinical and neuroradiological findings in infants with intracranial supratentorial nonpineoblastic primitive neuroectodermal tumors (Dai et al) 1999;46:526A
preradiotherapy chemotherapy and hyperfractionated craniospinal radiotherapy for high-risk primitive neuroectodermal tumors: a preliminary report of CCG protocol 9931 (Allen et al) 1999;46:526A
primary peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the leptomeninges (Antunes et al) 1999;46:550A
Neopterin
quinolinic acid and neopterin in children with autism: an analysis of cerebrospinal fluid (Comi et al) 1999;46:528A
Nerve degeneration
four revertants of *Unc2*, an uncoordinated mutant calcium channel phenotype in *C. elegans*, implicate genes potentially important in migraine and neurodegeneration (Estevez et al) 1999;46:489A
newly synthesized thiol-containing substances crossing the blood-brain barrier protect oxidative stress–induced neurodegeneration (Melamed et al) 1999;46:495A
soluble pool of amyloid β protein as a determinant of severity of neurodegeneration in Alzheimer's disease (McLean et al) 1999;46:860
Nerve growth factors
dependence of the mechanism of nerve growth factor–mediated protection of neural crest cells from apoptosis on the p75/TrkA ratio (Schor and Saragovi) 1999;46:537A
reduced nerve growth factor expression in patients with Rett syndrome (Lipani et al) 1999;46:937A (Works in progress)
Neural crest
dependence of the mechanism of nerve growth factor–mediated protection of neural crest cells from apoptosis on the p75/TrkA ratio (Schor and Saragovi) 1999;46:537A
Neuritis
opening of the blood-nerve barrier in experimental autoimmune neuritis (Hadden et al) 1999;46:484A
Neurofibromatosis 1
developmental regulation of a neuron-specific neurofibromatosis 1 isoform (Gutmann et al) 1999;46:777
evaluation of brain metabolism in neurofibromatosis type 1 by magnetic resonance spectroscopy (Kaufmann et al) 1999;46:528A
molecular pathogenesis of astrocytoma development in neurofibromatosis 1 (Gutmann et al) 1999;46:446A
Neurofilament proteins
neurofilament is an autoantigenic determinant in myasthenia gravis (Schultz et al) 1999;46:167
Neuroglia
adrenoleukodystrophy protein deficiency does not enhance the activation of microglia (Yamada and Shinnoh) 1999;46:466A
clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease (Kordower et al) 1999;46:419
effects of carbamazepine on inflammatory mediators produced by stimulated glial cells (Matoth et al) 1999;46:534A
expression and down-regulation of CXCR4 and CCR5 chemokine receptors in cultured murine microglia (Tamaru et al) 1999;46:447A
human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex (Rostasy et al) 1999;46:207
intraventricular transplantation of oligodendrocyte progenitors into a fetal myelin mutant results in widespread formation of myelin (Learish et al) 1999;46:716
involvement of p38 MAP kinase pathway in TNF-α production in human astrocytes and microglia (Lee et al) 1999;46:473A
lysophosphatidic acid–induced calcium signal and cation current in cultured rat microglial cells (Musante et al) 1999;46:472A

models of neuronal death in Alzheimer's disease: synergistic effects of β-amyloid and microglia on cell cycle–mediated death of cultured neurons (Geldmacher et al) 1999;46:937A (Works in progress)
regulation of tumor necrosis factor-α production in human microglia in culture (Kim et al) 1999;46:474A

Neuroleptic drugs; *see* Tranquilizing agents, major

Neuromuscular diseases
simple in vivo ^{31}P magnetic resonance spectroscopy protocol to study active muscle noninvasively in pediatric patients with neuromuscular disease (Arias-Mendoza et al) 1999;46:534A

Neuronal intranuclear inclusion disease
ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease (Lieberman et al) 1999;46:271

Neuronal plasticity
brain plasticity during acquisition of a script verification task (Flitman et al) 1999;46:447A

Neurons
adult-derived neural precursors transplanted into multiple regions in the adult brain (Herrera et al) 1999;46:867
amyloid-β protein 42 forms a 24-kd complex in normal cells and is deposited in apoptotic neurons (Ohyagi et al) 1999;46:453A
critical role of orexin neurons in narcolepsy (Scammell et al) 1999;46:935A (Works in progress)
developmental regulation of a neuron-specific neurofibromatosis 1 isoform (Gutmann et al) 1999;46:777
huntingtin aggregates may not predict neuronal death in Huntington's disease (Kuemmerle et al) 1999;46:842
increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease (Shimura-Miura et al) 1999;46:920
levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (Muriel et al) 1999;46:103
mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death (Borthwick et al) 1999;46:787
models of neuronal death in Alzheimer's disease: synergistic effects of β-amyloid and microglia on cell cycle–mediated death of cultured neurons (Geldmacher et al) 1999;46:937A (Works in progress)
neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus (Vitek et al) 1999; 46:22
neuronal asymmetries in primary visual cortex of dyslexic and nondyslexic brains (Jenner et al) 1999;46:189
neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy (van Walderveen et al) 1999;46:79
olfactory bulb dysplasia: a novel subtype of neuronal migration disorder (Yamanouchi et al) 1999;46:783
participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease (Duan et al) 1999;46:587
reversal of acute apparent diffusion coefficient abnormalities and delayed neuronal death following transient focal cerebral ischemia in rats (Li et al) 1999;46:333

Neuropathies, hereditary motor and sensory
hereditary auditory, vestibular, motor, and sensory neuropathy in a Slovenian Roma (Gypsy) kindred (Butinar et al) 1999;46:36

Neuropathies, hereditary sensory and autonomic
hereditary spastic paraplegia with sensory neuropathy: case report and review of the literature (Marks et al) 1999; 46:549A

Neuropathies, hypertrophic
pattern of onion-bulb distribution predicts acquired versus inherited hypertrophic neuropathy (Dyck and Engelstad) 1999;46:482A

Neurosarcoidosis; *see* Sarcoidosis

Neurotoxins
MPP^+ induces focal accumulations of α-synuclein in nigral neurons in vitro (McKee et al) 1999;46:460A
α-synuclein upregulation following MPP^+ administration in cerebellar granule cells in culture (Taniwaki et al) 1999;46:459A

Neurotrophic factors
clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease (Kordower et al) 1999;46:419

Neurotrophin-3
synthesis and release of brain-derived neurotrophic factor and neurotrophin-3 by human amniotic epithelial cells (Sakuragawa et al) 1999;46:538A

Nicotine
nicotine reduces axonal length and Schwann cell numbers in cultures of sympathetic ganglia (Johnson and Thompson) 1999;46:537A

Nipah virus
neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus (Lee et al) 1999;46:428

Nitric oxide
age-dependent nitric oxide damage of skeletal muscle (Kaminski and Richmonds) 1999;46:485A
association between Alzheimer's disease and the *NOS3* gene (Dahiyat et al) 1999;46:664
effect of hypoxia on the expression of inducible nitric oxide synthase in the hippocampus of term fetal guinea pigs (Spandou et al) 1999;46:520A
human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex (Rostasy et al) 1999;46:207

Nitrotyrosine
remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis (Tohgi et al) 1999;46:129A

Nuclear magnetic resonance
association of magnetic resonance spectroscopic abnormalities with quality of life and mood in patients with temporal lobe epilepsy (Maton et al) 1999;46:508A
C13 spectroscopy in vanishing white matter syndrome (Kovacs et al) 1999;46:544A
cognitive performance and magnetic resonance spectroscopy: correlates in multiple sclerosis (Pan et al) 1999; 46:475A
evaluation of brain metabolism in neurofibromatosis type 1 by magnetic resonance spectroscopy (Kaufmann et al) 1999;46:528A
neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy (van Walderveen et al) 1999;46:79
outcome prediction after acute traumatic brain injury in children using magnetic resonance imaging and proton magnetic resonance spectroscopy (Ashwal et al) 1999; 46:520A
phosphorus and proton magnetic resonance spectroscopy in episodic ataxia type 2 (Sappey-Marinier et al) 1999; 46:256

possible creatine synthesis deficit demonstrated by in vivo ^{31}P magnetic resonance spectroscopy (Arias-Mendoza et al) 1999;46:549A
proton magnetic resonance spectroscopy in neonates with acute brain injury: comparison of short and long echo time acquisitions (Shu et al) 1999;46:527A
proton magnetic resonance spectroscopy in patients with amyotrophic lateral sclerosis (Abe et al) 1999;46:467A
simple in vivo ^{31}P magnetic resonance spectroscopy protocol to study active muscle noninvasively in pediatric patients with neuromuscular disease (Arias-Mendoza et al) 1999;46:534A

Nucleotides
novel functional ϵ-subunit polypeptide generated by a single nucleotide deletion in acetylcholine receptor deficiency congenital myasthenic syndrome (Croxen et al) 1999;46:639

O^6-benzylguanine
phase I trial of O^6-benzylguanine plus bis(2-chloroethyl)-nitrosourea for patients undergoing surgery for malignant glioma (Cokgor et al) 1999;46:491A

Occipital lobe
nontumoural occipitotemporal epilepsy: localizing findings and surgical outcome (Aykut-Bingol and Spencer) 1999;46:894

Ocular motility disorders
ocular motor abnormalities in ataxia telangiectasia (Lewis et al) 1999;46:287

Oculopharyngeal muscular dystrophy; *see* Muscular dystrophy

Olfactory bulb
acute bulbar weakness: thyrotoxicosis or myasthenia gravis? (Lleó et al) 1999;46:434 (Letter)
olfactory bulb dysplasia: a novel subtype of neuronal migration disorder (Yamanouchi et al) 1999;46:783

Oligodendroglia
correlation of human herpesvirus 6 p41 and p101 expression and oligodendroglial cell death in progressive multifocal leukoencephalopathy (Goodman et al) 1999;46:488A
cyclic adenosine monophosphate– or cyclic guanosine monophosphate–elevating agents prevent oxygen-glucose deprivation–induced oligodendroglial injury (Yoshioka et al) 1999;46:485A
intraventricular transplantation of oligodendrocyte progenitors into a fetal myelin mutant results in widespread formation of myelin (Learish et al) 1999;46:716
transplantation of human oligodendrocytes and Schwann cells into the brain of myelin mutant Shaker rats (Nakagawa et al) 1999;46:457A

Ondansetron
ondansetron versus placebo for disabling cerebellar tremor: final report of a randomized clinical trial (Rice et al) 1999;46:493A

1p36 deletion syndrome; *see* Chromosome deletion

Ophthalmoplegia
quantitative near-infrared spectroscopy discriminates between mitochondrial myopathies and normal muscle (van Beekvelt et al) 1999;46:667

Opsoclonus myoclonus syndrome; *see* Myoclonus

Optic atrophy, hereditary
mitochondrial DNA G13513A transition in ND5 is associated with a LHON/MELAS overlap syndrome and may be a frequent cause of MELAS (Pulkes et al) 1999;46:916

Optic nerves
role of extracellular calcium in hypoglycemic injury to the rat optic nerve, a central white matter tract (Brown et al) 1999;46:489A
septo-optic dysplasia plus: a spectrum of malformations of cortical development (Miller et al) 1999;46:548A

Optic neuritis
recovery from optic neuritis is associated with a reorganization of the cerebral response to visual stimulation: a functional magnetic resonance imaging study (Werring et al) 1999;46:468A

Orexin
critical role of orexin neurons in narcolepsy (Scammell et al) 1999;46:935A (Works in progress)

Oropharynx
oropharyngeal angioedema: a clinically important complication of intravenous recombinant tissue plasminogen activator (Felberg et al) 1999;46:448A

Outcomes assessment
administrative data, comorbidity, and survival after ischemic stroke (Tirschwell et al) 1999;46:501A
disability trends and outcome measures in treatment trials of relapsing-remitting multiple sclerosis (Blumhardt and Liu) 1999;46:502A
do highly specialized services improve outcomes at academic medical centers? cerebral aneurysm treatment (Johnston) 1999;46:501A
improving outcomes comparison and benchmark selection with clinical risk adjustment models: a case study of stroke mortality among New Jersey hospitals (Hohmann) 1999;46:504A
role of item analysis in scale development and evaluation: reducing the Functional Independence Measure (Hobart et al) 1999;46:468A

Oxidation-reduction
regulation of redox factor expression by β-amyloid (Xun et al) 1999;46:487A

Pachygyria
diffuse pachygyria with cerebellar hypoplasia: a milder form of microlissencephaly or a new genetic syndrome? (Kato et al) 1999;46:660

Pachymeningitis
aseptic symptomatic pachymeningitis and intravenous immunoglobulin therapy (Mohamed) 1999;46:545A

Paclitaxel
inhibition of experimental allergic encephalomyelitis in Lewis rats by paclitaxel (Cao et al) 1999;46:470A
paclitaxel attenuates demyelination in a transgenic spontaneously demyelinating model (Moscarello et al) 1999;46:469A
phase 1 study of micellar paclitaxel in the treatment of secondary progressive multiple sclerosis (O'Connor et al) 1999;46:470A

Pain
assessment of functional status, low back disability, and use of diagnostic imaging in patients with low back pain and radiating leg pain (Ren et al) 1999;46:507A
placebo response in chronic malignant and nonmalignant pain (Presley et al) 1999;46:505A

Palliative treatment
ALS Patient Care Database: insights into end-of-life palliative care in amyotrophic lateral sclerosis (Clawson et al) 1999;46:506A

Pallido-ponto-nigral degeneration
longitudinal clinical observations and neuropsychological features of the pallido-ponto-nigral degeneration family (McRae et al) 1999;46:454A
Pallidotomy; *see* Globus pallidus
Pallister-Hall syndrome
gelastic seizure as a manifestation of Pallister-Hall syndrome (Liow et al) 1999;46:456A
Paralysis
hereditary neuropathy with liability to pressure palsy presenting as developmental delay and hypotonia (Kadakia et al) 1999;46:549A
Paramyxoviridae
neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus (Lee et al) 1999;46:428
Paraneoplastic syndromes
clinical, radiological, and electroencephalographic correlates of paraneoplastic limbic encephalitis (Lawn et al) 1999;46:464A
detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders (Saiz et al) 1999;46:774
paraneoplastic cerebellar degeneration in a child with leukemia (Deputy) 1999;46:550A
serum IgM autoantibodies in patients with paraneoplastic and idiopathic opsoclonus myoclonus syndrome recognize neurofilament and histone in neural preparations (Connolly et al) 1999;46:536A
Paraparesis, tropical spastic
cognitive impairment: a feature common to families with autosomal dominant hereditary spastic paraparesis linked to chromosome 2 (McMonagle et al) 1999;46:481A
Paraproteinemias
anti–myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy (Meucci et al) 1999;46:119
Parietal lobe
mirror agnosia and mirror ataxia constitute different parietal lobe disorders (Binkofski et al) 1999;46:51
Parkinson's disease, analysis
increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease (Shimura-Miura et al) 1999;46:920
positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy (Shinotoh et al) 1999;46:62
Parkinson's disease, drug therapy
catechol-O-methyltransferase reduced levodopa toxicity in PC12 cells: implications for treatment of Parkinson's disease (Offen et al) 1999;46:459A
clozapine replacement by quetiapine for dopamimetic psychosis in Parkinson's disease (Fernandez et al) 1999;46:491A
comparison of the efficacy and tolerability of cabergoline, pergolide, pramipexole, ropinirole, and tolcapone in Parkinson's disease (Inzelberg et al) 1999;46:492A
levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (Muriel et al) 1999;46:103
prediction of the effectiveness of tolcapone, a catechol-*O*-methyltransferase inhibitor, in patients with Parkinson's disease by COMT genotype (Chong et al) 1999;46:477A
quality of life in a double-blind surgical placebo trial for the treatment of Parkinson's disease (McRae et al) 1999;46:498A
use of dopamine agonists in very elderly patients with Parkinson's disease (Shulman et al) 1999;46:497A
vasoactive intestinal peptide protects from dopamine toxicity: relevance for Parkinson's disease (Melamed et al) 1999;46:458A
Parkinson's disease, etiology
can neuroleptic drugs cause Parkinson's disease? (Mazurek et al) 1999;46:478A
evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure (Langston et al) 1999;46:598
Parkinson's disease, genetics
acetylator genotype for *N*-acetyltransferase 2 and Parkinson's disease (Dupret et al) 1999;46:433 (Letter)
differential expression of the parkin gene in various human tissues (Sunada et al) 1999;46:459A
FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation (Sperfeld et al) 1999;46:708
rapid-onset dystonia–parkinsonism: linkage to chromosome 19q13 (Kramer et al) 1999;46:176
reduced expressoin of the G209A α-synuclein allele in familial parkinsonism (Markopoulou et al) 1999;46:374
Parkinson's disease, pathology
lesion of the subthalamic nucleus in Parkinson's disease: long-term follow-up (González et al) 1999;46:492A
participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease (Duan et al) 1999;46:587
positron emission tomography measurements of striatal dopamine transporter in untreated Parkinson's disease patients: differential regulation with levodopa versus pramipexole (Guttman et al) 1999;46:937A (Works in progress)
presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study (Ouchi et al) 1999;46:723
problems of cell death in Parkinson's disease and related disorders (Jellinger and Stadelmann) 1999;46:476A
regulation of dopaminergic activity in early Parkinson's disease (Tedroff et al) 1999;46:359
Parkinson's disease, physiopathology
assessment of quality of life in Parkinson's disease patients of different ethnic groups (Young and Locke) 1999;46:507A
function of the cerebellum in parkinsonian rest tremor and Holmes' tremor (Deuschl et al) 1999;46:126
longitudinal clinical observations and neuropsychological features of the pallido-ponto-nigral degeneration family (McRae et al) 1999;46:454A
Parkinson's disease, therapy
bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients (Ardouin et al) 1999;46:217
clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease (Kordower et al) 1999;46:419
factors influencing resource use in patients with Parkinson's disease (Siderowf et al) 1999;46:508A

Parvalbumins
paralbumin overexpression alters calcium homeostasis and prolongs survival in a transgenic model of familial amyotrophic lateral sclerosis (Appel et al) 1999; 46:463A
Patient readmission
early readmission rates in patients with ischemic stroke: the UAB experience (Tulyapronchote et al) 1999;46: 510A
Pelizaeus Merzbacher disease; *see* Cerebral sclerosis, diffuse
Penile erection
effect of sildenafil citrate (Viagra) on quality of life in men with erectile dysfunction and multiple sclerosis (Miller et al) 1999;46:496A
randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury (Giuliano et al) 1999; 46:15
Viagra (sildenafil citrate) for the treatment of erectile dysfunction in men with multiple sclerosis (Fowler et al) 1999;46:497A
Peptides
novel functional ϵ-subunit polypeptide generated by a single nucleotide deletion in acetylcholine receptor deficiency congenital myasthenic syndrome (Croxen et al) 1999;46:639
Perfusion weighted imaging; *see* Magnetic resonance imaging
Pergolide
comparison of the efficacy and tolerability of cabergoline, pergolide, pramipexole, ropinirole, and tolcapone in Parkinson's disease (Inzelberg et al) 1999;46:492A
Perineal nerve
cortical evoked responses from the perineal nerve (Uchio et al) 1999;46:490A
Peripheral nerve diseases
effect of age on presentation of peripheral neuropathy (Gellido et al) 1999;46:451A
peripheral neuropathy and restless legs syndrome (Smith et al) 1999;46:484A
Peripheral nerves
extracellular matrix provides mechanical stability for myelination in the peripheral nervous system (Windebank and Podratz) 1999;46:483A
Peripheral nervous system
myelin deficiencies in both the central and the peripheral nervous systems associated with a *SOX10* mutation (Inoue et al) 1999;46:313
Perisylvian syndrome
hypokinetic dysarthria as seen in congenital bilateral perisylvian syndrome (Fishman) 1999;46:544A
Periventricular leukomalacia; *see* Leukomalacia, periventricular
Peroxynitrite
peroxynitrite in neuroinflammation (Scott et al) 1999;46: 473A
Phenotype
classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects (Parchi et al) 1999;46:224
familial Alzheimer's disease: site of mutation influences clinical phenotype (Lippa et al) 1999;46:453A
FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation (Sperfeld et al) 1999;46:708
hyperekplexia phenotype due to compound heterozygosity for GLRA1 gene mutations (Vergouwe et al) 1999;46: 634
phenotypic variation in hereditary frontotemporal dementia with tau mutations (van Swieten et al) 1999;46:617
use of genotype–phenotype correlation to dissect liability to develop multiple sclerosis and predict response to interferon-β depending on HLA type: preliminary report (Beall et al) 1999;46:498A
Phenytoin
choreoathetosis caused by combined lamotrigine and phenytoin: a pharmacodynamic interaction? (Megdad et al) 1999;46:476A
Phosphatidylinositols
insulin-like growth factor-I induces Schwann cell motility via phosphatidylinositol-3 kinase and small GTPases (Cheng et al) 1999;46:486A
Phosphenes
Comparison of magnetophosphenes and visually triggered migraine (Aurora et al) 1999;46:476A
Phosphodiesterase inhibitors
drop in relapse rate and a shift of helper T cells in multiple sclerosis by a combination therapy of three different phosphodiesterase inhibitors (Suzumura et al) 1999; 46:474A
Phosphoglycerate dehydrogenase
amino acid loading studies and L-serine supplementation in 3-phosphoglycerate dehydrogenase deficiency (Swoboda et al) 1999;46:547A
Phosphoglycerate mutase
muscle phosphoglycerate mutase deficiency with tubular aggregates: effect of dantrolene (Vissing et al) 1999;46: 274
Phosphorus
phosphorus and proton magnetic resonance spectroscopy in episodic ataxia type 2 (Sappey-Marinier et al) 1999; 46:256
Photic stimulation
recovery from optic neuritis is associated with a reorganization of the cerebral response to visual stimulation: a functional magnetic resonance imaging study (Werring et al) 1999;46:468A
Physician referral; *see* Referral and consultation
Pigment epithelium-derived factor
elevated pigment epithelium-derived factor levels in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (Bilak et al) 1999;46:462A
Pituitary neoplasms
false pituitary tumor in spontaneous cerebrospinal fluid leak (Mokri and Atkinson) 1999;46:475A
Placebo effect
placebo response in chronic malignant and nonmalignant pain (Presley et al) 1999;46:505A
Plasma exchange
randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease (Weinshenker et al) 1999;46:878
Platelet activating factor
platelet-activating factor rescues migration defects in Pafah1b1 (LIS1)-deficient cerebellar granule cells (Bix et al) 1999;46:522A
Platelet membrane glycoproteins
initial experience with murine 7E3 $F(ab')_2$ (GP IIb/IIIa antagonist) in focal cerebral ischemia model (Yang et al) 1999;46:491A
Pleomorphic xanthoastrocytoma; *see* Xanthoastrocytoma
Polyglutamic acid
role for heat shock protein chaperones in polyglutamine disease: the misfolded protein stress response and suppression of polyglutamine aggregation and neural tox-

icity by an Hsp40 molecular chaperone (Paulson et al) 1999;46:935A (Works in progress)
Polyglutamines
fine mapping of the spinocerebellar ataxia type 10 region and search for a polyglutamine expansion (Matsuura et al) 1999;46:480A
Polymicrogyria
case report of Prader-Willi syndrome with polymicrogyria (Yoshii et al) 1999;46:548A
Polyols
leukoencephalopathy associated with a disturbance in the metabolism of polyols (van der Knaap et al) 1999;46:925
Polyradiculoneuritis
epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: a reappraisal (Paradiso et al) 1999;46:701
heightened IgE response to mite antigens in inflammatory neuropathies (Horiuchi et al) 1999;46:472A
long-term outcome in patients requiring mechanical ventilation for Guillain-Barré syndrome (Fletcher et al) 1999;46:467A
outcome, preceding infections, and immune factors in Guillain-Barré syndrome (Hadden et al) 1999;46:484A
Positron emission tomography; *see* Tomography, emission-computed
Potassium
reduced K^+ current due to a novel mutation in KCNQ2 causes neonatal convulsions (Lerche et al) 1999;46:305
Potassium channels
antibodies to acetylcholine receptors, potassium channels, and titin in a patient with thymoma, myasthenia gravis, and limbic encephalitis (Buckley et al) 1999;46:482A
antibodies to acetylcholine receptors and voltage-gated potassium channels in apparently healthy elderly subjects (Vincent et al) 1999;46:483A
Prader-Willi syndrome
case report of Prader-Willi syndrome with polymicrogyria (Yoshii et al) 1999;46:548A
PRAJA1 protein
PRAJA1, a novel RING finger protein involved in apoptosis, and a marker of hepatic stem cells, is expressed in specific embryonic neuroblasts (Mishra et al) 1999;46:487A
Pramipexole
comparison of the efficacy and tolerability of cabergoline, pergolide, pramipexole, ropinirole, and tolcapone in Parkinson's disease (Inzelberg et al) 1999;46:492A
positron emission tomography measurements of striatal dopamine transporter in untreated Parkinson's disease patients: differential regulation with levodopa versus pramipexole (Guttman et al) 1999;46:937A (Works in progress)
Precursor cells; *see* Stem cells
Pregnancy
antiepileptic drug regimens and major congenital abnormalities in the offspring (Samrén et al) 1999;46:739
Premature infant; *see* Infant, premature
Preproenkephalin
antinociceptive effect of gene transfer with a herpes simplex virus vector coding for human preproenkephalin (Goss et al) 1999;46:935A (Works in progress)
Primitive neuroectodermal tumors; *see* Neoplasms, embryonal and mixed
Prions
classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects (Parchi et al) 1999;46:224
familial Creutzfeldt-Jakob disease with a novel 120-bp insertion in the prion protein gene (Skworc et al) 1999;46:693
prion gene and apolipoprotein E in sporadic inclusion body myositis (Lampe et al) 1999;46:485A
Progressive multifocal leukoencephalopathy; *see* Leukoencephalopathy, progressive multifocal
Propentofylline
propentofylline for the treatment of vascular dementia: a 48-week study assessing safety, efficacy, and impact on disease progression (Schweiger and European/Canadian Propentofylline Study Group) 1999;46:493A
72-week study assessing propentofylline's safety, efficacy, and impact on disease progression in patients with Alzheimer's disease (Rother and European/Canadian Propentofylline Study Group) 1999;46:493A
Prostate
participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease (Duan et al) 1999;46:587
Protein kinases
role of cyclin-dependent kinase 5 in developing and aging nervous system: spatial and temporal expression and phenotype studies by generating new transgenic mice (Tanaka et al) 1999;46:536A
Proteins
detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders (Saiz et al) 1999;46:774
structural plasticity of a protein antigen implicated in the immunopathogenesis of multiple sclerosis (Genain et al) 1999;46:936A (Works in progress)
Proteolipids
continuous secretion of proteolipid protein epitope suppresses relapsing experimental autoimmune encephalitis in SJL/J mice (Weiner et al) 1999;46:938A (Works in progress)
de novo splice donor site mutation causes in-frame deletion of 14 amino acids in the proteolipid protein in Pelizaeus-Merzbacher disease (Aoyagi et al) 1999;46:112
mutations in noncoding regions of the proteolipid protein gene in patients with Pelizaeus Merzbacher disease (PMD) and PMD-like disorders (Hobson et al) 1999;46:530A
Proton magnetic resonance spectroscopy; *see* Nuclear magnetic resonance
Protoporphyrins
neuroprotection in intracerebral hemorrhage with tin-protoporphyrin (Koeppen and Dickson) 1999;46:938A (Works in progress)
Provigil; *see* Modafinil
Pseudotumor cerebri
infantile pseudotumor cerebri (Legarda et al) 1999;46:543A
Psychotic disorders
forced normalization in an adolescent (Caruso et al) 1999;46:545A
Pupil
relative afferent pupillary defect with normal vision: a localizing sign of midbrain or brachium injury (Jacobson) 1999;46:489A
Purkinje cells
alterations of calbindin-D_{28k} localization in cerebellar Purkinje cells in the hypoxic guinea pig fetus at term (Spandou et al) 1999;46:522A

Purkinje cell antibody type 2: a new marker of neurological autoimmunity related to small cell lung cancer (Vernino and Lennon) 1999;46:465A

Quadriplegia
progressive spastic tetraplegia: a central motor pathway degeneration with autosomal recessive inheritance (Bertini et al) 1999;46:530A

Quality of life
assessment of quality of life in Parkinson's disease patients of different ethnic groups (Young and Locke) 1999;46:507A
association of magnetic resonance spectroscopic abnormalities with quality of life and mood in patients with temporal lobe epilepsy (Maton et al) 1999;46:508A
effect of sildenafil citrate (Viagra) on quality of life in men with erectile dysfunction and multiple sclerosis (Miller et al) 1999;46:496A
health utilities in Alzheimer's disease: exploring health states 'worse than dead' (Araki and Neumann) 1999;46:502A
meaning of quality of life in multiple sclerosis (O'Connor et al) 1999;46:502A
prospective evaluation of health-related quality of life and cost in acute stroke (Kim et al) 1999;46:508A
quality of life assessment in children with cancer at risk for brain impairment: development of a new pediatric brain-specific instrument, PBS version 1.0 (Tao and Parsons) 1999;46:502A
quality of life in a double-blind surgical placebo trial for the treatment of Parkinson's disease (McRae et al) 1999;46:498A
vagus nerve stimulation in children: quality of life and side effects (Wheless et al) 1999;46:523A

Quetiapine
clozapine replacement by quetiapine for dopamimetic psychosis in Parkinson's disease (Fernandez et al) 1999;46:491A

Quinolinic acids
quinolinic acid and neopterin in children with autism: an analysis of cerebrospinal fluid (Comi et al) 1999;46:528A

Radiotherapy
neurocognitive status in children with medulloblastoma following reduced-dose craniospinal radiotherapy and chemotherapy (Packer et al) 1999;46:526A
preradiotherapy chemotherapy and hyperfractionated craniospinal radiotherapy for high-risk primitive neuroectodermal tumors: a preliminary report of CCG protocol 9931 (Allen et al) 1999;46:526A

Rasmussen's syndrome
predilection of frontotemporal cortex involvement in early Rasmussen's syndrome: a positron emission tomographic study (Kaddurah et al) 1999;46:532A

Reading
cerebral localization of reading in normal children: a functional magnetic resonance imaging language study (Gaillard et al) 1999;46:528A

Readmission; *see* Patient readmission

Recombinant tissue plasminogen activator; *see* Alteplase

Redox; *see* Oxidation-reduction

Referral and consultation
direction of referral bias in subarachnoid hemorrhage (Johnston and Brown) 1999;46:505A
physician referral choices in the management of patients with neurological conditions (Swarztrauber et al) 1999;46:501A

Reflex
toward molecular characterization of a reflex epilepsy in the Frings audiogenic seizure-susceptible mouse (Ptáček and White) 1999;46:455A

Reperfusion injury
caspase expression following ischemia-reperfusion injury in rat retina (Singh et al) 1999;46:479A

Respiration
sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis (Fitting et al) 1999;46:887

Respiration, artificial
long-term outcome in patients requiring mechanical ventilation for Guillain-Barré syndrome (Fletcher et al) 1999;46:467A
outcomes of prolonged mechanical ventilation in the elderly (Diaz) 1999;46:508A

Respiratory insufficiency
limb girdle myopathy and respiratory insufficiency is associated with the A3302G mutation in the $tRNA^{Leu(UUR)}$ gene (Sue et al) 1999;46:462A
mortality and morbidity rates in pediatric patients with acute respiratory failure: comparison between patients with and without preexisting neurological conditions (Coffman et al) 1999;46:542A

Restless legs
amelioration of sensory limb discomfort of restless legs syndrome by pallidotomy (Rye and DeLong) 1999;46:800 (Letter)
peripheral neuropathy and restless legs syndrome (Smith et al) 1999;46:484A

Retina
caspase expression following ischemia-reperfusion injury in rat retina (Singh et al) 1999;46:479A

Rett syndrome
reduced nerve growth factor expression in patients with Rett syndrome (Lipani et al) 1999;46:937A (Works in progress)

Ribitol
leukoencephalopathy associated with a disturbance in the metabolism of polyols (van der Knaap et al) 1999;46:925

Risk factors
cardiovascular disease risk factor status of patients referred to a private practice stroke secondary prevention program (Lafranchise et al) 1999;46:504A
early identification of neonates at risk for development of neonatal seizures: a cohort study of near-term infants (Prasad et al) 1999;46:534A
echogenicity on cranial sonograms in preterm infants: risk profiles and death (Kuban et al) 1999;46:527A
risk of inpatient, outpatient, and ambulatory care associated with dementia (Albert et al) 1999;46:504A

Rivastigmine
behavioral effects of rivastigmine: interim results from the Neuropsychiatric Inventory-Nursing Home version in nursing home patients with Alzheimer's disease (Edwards et al) 1999;46:453A
effect of rivastigmine on activities of daily living in Alzheimer's disease patients (Grossberg and Messina) 1999;46:497A

RNA
paired helical filaments in sporadic inclusion body myositis muscle contain RNA and survival motor neuron

protein (Broccolini et al) 1999;46:482A
reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis (Takuma et al) 1999;46:806

RNA, messenger
distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain (Augood et al) 1999;46:761
hippocampal *N*-methyl-D-aspartate receptor subunit mRNA levels in temporal lobe epilepsy patients (Mathern et al) 1999;46:343
overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease (Chambers et al) 1999;46:325
sequence-specific cleavage of huntingtin mRNA by catalytic DNA (Yen et al) 1999;46:366

RNA, transfer, Leu
limb girdle myopathy and respiratory insufficiency is associated with the A3302G mutation in the $tRNA^{Leu(UUR)}$ gene (Sue et al) 1999;46:462A

Ropinirole
comparison of the efficacy and tolerability of cabergoline, pergolide, pramipexole, ropinirole, and tolcapone in Parkinson's disease (Inzelberg et al) 1999;46:492A

Roussy-Levy syndrome; *see* Charcot-Marie-Tooth disease

Sarcoidosis
neurosarcoidosis without systematic sarcoid (Aksamit and Norona) 1999;46:471A

Sarcolemma
identification of aquaporin 4 molecule in the replica of normal rat sarcolemma: fracture-label immunoelectron microscopic study (Shibuya et al) 1999;46:460A

Sarcoma, Ewing's
primary peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the leptomeninges (Antunes et al) 1999;46:550A

Sardinia
tumor necrosis factor 2 allele does not contribute to increased tumor necrosis factor-α production in Sardinian multiple sclerosis (Sotgiu et al) 1999;46:799 (Letter)

Scalp
progressive central and peripheral nervous system involvement in Adams-Oliver syndrome (Asleson et al) 1999;46:467A

Scandinavia
linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis (Oturai et al) 1999;46:612

Schwann cells
insulin-like growth factor-I induces Schwann cell motility via phosphatidylinositol-3 kinase and small GTPases (Cheng et al) 1999;46:486A
insulin-like growth factor-I prevents caspase-mediated apoptosis in Schwann cells following serum withdrawal (Delaney et al) 1999;46:485A
nicotine reduces axonal length and Schwann cell numbers in cultures of sympathetic ganglia (Johnson and Thompson) 1999;46:537A
transplantation of human oligodendrocytes and Schwann cells into the brain of myelin mutant Shaker rats (Nakagawa et al) 1999;46:457A

Scotland
Moyamoya in three generations of a Scottish family: association with a mitochondrial DNA polymorphism typical of Asian populations (Muir et al) 1999;46:481A

Script verification task; *see* Task performance and analysis

Secretin
secretin used in the treatment of autism: a double-blind clinical trial in children (Chez et al) 1999;46:523A

Seizures, analysis
epileptiform discharges in the human dysplastic neocortex: in vitro physiology and pharmacology (Avoli et al) 1999;46:816
toward molecular characterization of a reflex epilepsy in the Frings audiogenic seizure-susceptible mouse (Ptáček and White) 1999;46:455A

Seizures, diagnosis
autosomal dominant cerebellar ataxia with generalized convulsive seizures: a distinct syndrome (Achari) 1999;46:476A
cortical–subcortical magnetic resonance imaging/computed tomography lesions in reversible posterior leukoencephalopathy syndrome: encephalopathy or seizures? (Strasser et al) 1999;46:472A
gelastic seizure as a manifestation of Pallister-Hall syndrome (Liow et al) 1999;46:456A

Seizures, drug therapy
effect of topiramate on height and weight in children with partial-onset seizures (Glauser et al) 1999;46:533A
effects of anticonvulsant lactams on in vitro seizures in the hippocampal slice preparation (Hill et al) 1999;46:539A
liposteroid (dexamethasone palmitate) therapy for refractory seizures in children (Yoshikawa et al) 1999;46:546A
vigabatrin in the treatment of refractory seizures in children with brain malformations (Holder et al) 1999;46:547A

Seizures, epidemiology
seizures in very-low-birthweight infants (Wise et al) 1999;46:525A

Seizures, etiology
clinical characterization of the neurogenetic disorder and 1p36 deletion syndrome (Chedrawi et al) 1999;46:529A

Seizures, genetics
FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation (Sperfeld et al) 1999;46:708

Seizures, pathology
association between hippocampal volume and epilepsy duration (Theodore and Gaillard) 1999;46:800 (Letter)

Seizures, physiopathology
declining incidence and changing profile of seizures after cardiac surgery (Menache et al) 1999;46:546A
does ictal semiology predict outcome of neonates with seizures? (Brunquell et al) 1999;46:531A
language recovery after left hemispherectomy in children with late-onset seizures (Boatman et al) 1999;46:579

Seizures, prevention and control
early identification of neonates at risk for development of neonatal seizures: a cohort study of near-term infants (Prasad et al) 1999;46:534A
seizure control and mortality in epilepsy (Sperling et al) 1999;46:45

Semaphorins
differential expression of multiple semaphorin genes in rats after kainic acid–induced status epilepticus (Barnes et al) 1999;46:537A

Septo-optic dysplasia
septo-optic dysplasia plus: a spectrum of malformations of cortical development (Miller et al) 1999;46:548A
Septum pellucidum
septo-optic dysplasia plus: a spectrum of malformations of cortical development (Miller et al) 1999;46:548A
Serine
amino acid loading studies and L-serine supplementation in 3-phosphoglycerate dehydrogenase deficiency (Swoboda et al) 1999;46:547A
serine/threonine phosphorylation of *N*-ethylmaleimide–sensitive factor is associated with Ca^{2+}-dependent K^{+}-stimulated release of L-glutamate in neocortical synaptosomes (Slevin et al) 1999;46:487A
Serotonin
combination therapy with serotonin reuptake inhibitors and interferon β-1a (Avonex) in the treatment of multiple sclerosis: a pilot study (Potter and Hart) 1999;46:495A
Severe combined immunodeficiency
prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis (Aissaoui et al) 1999;46:559
Sialorrhea
prevalence and treatment outcome of sialorrhea in amyotrophic lateral sclerosis patients as assessed by the ALS Patient Care Database (Sufit et al) 1999;46:506A
Sildenafil
effect of sildenafil citrate (Viagra) on quality of life in men with erectile dysfunction and multiple sclerosis (Miller et al) 1999;46:496A
randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury (Giuliano et al) 1999;46:15
Viagra (sildenafil citrate) for the treatment of erectile dysfunction in men with multiple sclerosis (Fowler et al) 1999;46:497A
Skin
quantitative epidermal nerve analysis in skin blister and skin biopsies (Kennedy et al) 1999;46:461A
Skull
progressive central and peripheral nervous system involvement in Adams-Oliver syndrome (Asleson et al) 1999;46:467A
Sleep disorders
critical role of orexin neurons in narcolepsy (Scammell et al) 1999;46:935A (Works in progress)
pediatric posttraumatic hypersomnolence: an underidentified condition? (Milrod and Yalamanchi) 1999;46:546A
sleep disorders in children with blindness (Leger et al) 1999;46:648
sleep disturbances in children with attention deficit hyperactivity disorder (Pearl et al) 1999;46:524A
Slovenia
hereditary auditory, vestibular, motor, and sensory neuropathy in a Slovenian Roma (Gypsy) kindred (Butinar et al) 1999;46:36
Small cell lung cancer; *see* Carcinoma, oat cell
Sniff nasal pressure
sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis (Fitting et al) 1999;46:887
Somatosensory cortex
optimal stimulus presentation rate to activate the somatosensory cortex: a functional magnetic resonance imaging study (Takanashi et al) 1999;46:490A
Somatosensory evoked potentials; *see* Evoked potentials, somatosensory
Spasm
motor benefit from L-dopa in spastic cerebral palsy (Brunstrom et al) 1999;46:544A
progressive spastic tetraplegia: a central motor pathway degeneration with autosomal recessive inheritance (Bertini et al) 1999;46:530A
Spasms, infantile
efficacy and tolerability of tiagabine in infantile spasms (Mandelbaum et al) 1999;46:531A
Spastic paraplegia, hereditary
hereditary spastic paraplegia with sensory neuropathy: case report and review of the literature (Marks et al) 1999;46:549A
Specialties, medical
do highly specialized services improve outcomes at academic medical centers? cerebral aneurysm treatment (Johnston) 1999;46:501A
physician referral choices in the management of patients with neurological conditions (Swarztrauber et al) 1999;46:501A
Spectrin
elf3, a novel β-spectrin gene in brain development (Mishra et al) 1999;46:486A
Spectroscopy, near-infrared
quantitative near-infrared spectroscopy discriminates between mitochondrial myopathies and normal muscle (van Beekvelt et al) 1999;46:667
Speech
animal model of speech motor control and stuttering (Rosenfield et al) 1999;46:447A
Spinal cord injuries
randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury (Giuliano et al) 1999;46:15
Spinal muscular atrophy; *see* Muscular atrophy, spinal
Spinocerebellar degeneration; *see also* Cerebellar ataxia
dominantly inherited spinocerebellar ataxia with male sterility and mental deficiency: a novel spinocerebellar ataxia phenotype (Gomez et al) 1999;46:481A
fine mapping of the spinocerebellar ataxia type 10 region and search for a polyglutamine expansion (Matsuura et al) 1999;46:480A
founder effect, ancestral haplotype, and predisposing chromosome of spinocerebellar ataxia type 6 in the Japanese population (Yabe et al) 1999;46:480A
vitamin E deficiency as a result of chylomicron retention disease in autosomal recessive Marinesco-Sjögren syndrome (Aguglia et al) 1999;46:465A
Startle reaction
hyperekplexia phenotype due to compound heterozygosity for GLRA1 gene mutations (Vergouwe et al) 1999;46:634
neurological complications of hyperekplexia in infancy (Chaves-Carballo et al) 1999;46:466A
Status epilepticus
differential expression of multiple semaphorin genes in rats after kainic acid–induced status epilepticus (Barnes et al) 1999;46:537A
status epilepticus among hospitalized children in the United States, 1988–1995 (Trevathan and Rurangirwa) 1999;46:531A
Stem cells
adult-derived neural precursors transplanted into multiple regions in the adult brain (Herrera et al) 1999;46:867

intraventricular transplantation of oligodendrocyte progenitors into a fetal myelin mutant results in widespread formation of myelin (Learish et al) 1999;46:716
PRAJA1, a novel RING finger protein involved in apoptosis, and a marker of hepatic stem cells, is expressed in specific embryonic neuroblasts (Mishra et al) 1999;46:487A

Stents
neurological protocols and outcomes following carotid stenting (Bonomo et al) 1999;46:496A

Sterility, male; *see* Infertility, male

Stroke; *see* Cerebrovascular disorders

Stuttering
animal model of speech motor control and stuttering (Rosenfield et al) 1999;46:447A

Subarachnoid hemorrhage
cerebral edema after subarachnoid hemorrhage: frequency, causes, and impact on outcome (Mayer et al) 1999;46:450A
direction of referral bias in subarachnoid hemorrhage (Johnston and Brown) 1999;46:505A

Substantia nigra
evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure (Langston et al) 1999;46:598
increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease (Shimura-Miura et al) 1999;46:920
MPP^+ induces focal accumulations of α-synuclein in nigral neurons in vitro (McKee et al) 1999;46:460A
presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study (Ouchi et al) 1999;46:723

Succinic acids
succinic acid–responsive complex I deficiency (Tein et al) 1999;46:549A

Sulfhydryl compounds
newly synthesized thiol-containing substances crossing the blood-brain barrier protect oxidative stress–induced neurodegeneration (Melamed et al) 1999;46:495A

SUNCT
functional magnetic resonance imaging in spontaneous attacks of SUNCT: short-lasting neuralgiform headache with conjunctival injection and tearing (May et al) 1999;46:791

Superoxide dismutase
copper/zinc superoxide dismutase: more is not necessarily better! (Rando and Epstein) 1999;46:135 (Letter)
does increased superoxide dismutase activity really cause muscular dystrophy? (Almer et al) 1999;46:135 (Letter)

Supranuclear palsy, progressive
overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease (Chambers et al) 1999;46:325
positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy (Shinotoh et al) 1999;46:62

Supratentorial neoplasms
clinical and neuroradiological findings in infants with intracranial supratentorial nonpineoblastic primitive neuroectodermal tumors (Dai et al) 1999;46:526A

Suramin
electrophysiological and morphological characteristics of suramin-induced neuropathy in rats (Russell et al) 1999;46:483A

Swallowing; *see* Deglutition

Sydenham chorea
Sydenham chorea: the Utah experience (Thompson et al) 1999;46:523A

Sympathetic nervous system
Alzheimer's disease and sympathetic ingrowth (Harrell et al) 1999;46:451A

Synapses
decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease (Tiraboschi et al) 1999;46:454A
ketone bodies do not directly alter excitatory or inhibitory hippocampal synaptic transmission (Thio et al) 1999;46:537A

Synaptosomes
serine/threonine phosphorylation of *N*-ethylmaleimide–sensitive factor is associated with Ca^{2+}-dependent K^+-stimulated release of L-glutamate in neocortical synaptosomes (Slevin et al) 1999;46:487A

Synuclein
MPP^+ induces focal accumulations of α-synuclein in nigral neurons in vitro (McKee et al) 1999;46:460A
reduced expressoin of the G209A α-synuclein allele in familial parkinsonism (Markopoulou et al) 1999;46:374
α-synuclein upregulation following MPP^+ administration in cerebellar granule cells in culture (Taniwaki et al) 1999;46:459A

Systemic lupus erythematosus; *see* Lupus erythematosus, systemic

T-588
T-588, a novel neuroprotective agent, delays progression of neuromuscular dysfunction in wobbler mouse motoneuron disease (Ikeda et al) 1999;46:492A

Tamoxifen
cognitive function in breast cancer patients treated with tamoxifen (Paganini-Hill and Clark) 1999;46:455A

Task performance and analysis
brain plasticity during acquisition of a script verification task (Flitman et al) 1999;46:447A
functional anatomy of error correction during pointing without vision of the hand (Grafton et al) 1999;46:447A

tau proteins
frequency of *tau* mutations in three series of non-Alzheimer's degenerative dementia (Houlden et al) 1999;46:243
overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease (Chambers et al) 1999;46:325
phenotypic variation in hereditary frontotemporal dementia with tau mutations (van Swieten et al) 1999;46:617

Temozolomide
temozolomide: an oral cytotoxic agent with promising activity against recurrent malignant glioma (Mason) 1999;46:464A

Temporal lobe
FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation (Sperfeld et al) 1999;46:708
new reversible leukoencephalopathy with bilateral anterior temporal lobe cysts (Suwan et al) 1999;46:543A

nontumoural occipitotemporal epilepsy: localizing findings and surgical outcome (Aykut-Bingol and Spencer) 1999;46:894
phenotypic variation in hereditary frontotemporal dementia with tau mutations (van Swieten et al) 1999;46:617
Temporal lobe epilepsy; *see* Epilepsy, temporal lobe
Teratogens
antiepileptic drug regimens and major congenital abnormalities in the offspring (Samrén et al) 1999;46:739
Tetraplegia; *see* Quadriplegia
Tetrodotoxin
tetrodotoxin prevents posttraumatic epileptogenesis in rats (Graber and Prince) 1999;46:234
Thalamic nucleus
lesion of the subthalamic nucleus in Parkinson's disease: long-term follow-up (González et al) 1999;46:492A
Thalamus
tremor arrest with thalamic microinjections of muscimol in patients with essential tremor (Pahapill et al) 1999;46:249
Thiols; *see* Sulfhydryl compounds
Threonine
serine/threonine phosphorylation of *N*-ethylmaleimide–sensitive factor is associated with Ca^{2+}-dependent K^{+}-stimulated release of L-glutamate in neocortical synaptosomes (Slevin et al) 1999;46:487A
Thrombophlebitis
cerebral venous thrombosis in pediatric patients: a review of 22 cases (Wasay et al) 1999;46:541A
Thymoma
antibodies to acetylcholine receptors, potassium channels, and titin in a patient with thymoma, myasthenia gravis, and limbic encephalitis (Buckley et al) 1999;46:482A
Thyroiditis, autoimmune
acquired cerebellar degeneration with Hashimoto's thyroiditis: possible autoimmune mechanisms (Selim and Drachman) 1999;46:458A
Thyrotoxicosis
acute bulbar weakness: thyrotoxicosis or myasthenia gravis? (Lleó et al) 1999;46:434 (Letter)
Tiagabine
efficacy and tolerability of tiagabine in infantile spasms (Mandelbaum et al) 1999;46:531A
Tic
home alone: methods to maximize tic expression for objective videotape assessments in Gilles de la Tourette syndrome (Goetz et al) 1999;46:477A
retrospective study of efficacy of tizanidine in children and young adults presenting with Tourette's syndrome, motor tic disorders, attention deficit disorder, or attention deficit hyperactivity disorder (Foradada) 1999;46:529A
Tin
neuroprotection in intracerebral hemorrhage with tin-protoporphyrin (Koeppen and Dickson) 1999;46:938A (Works in progress)
Titin
antibodies to acetylcholine receptors, potassium channels, and titin in a patient with thymoma, myasthenia gravis, and limbic encephalitis (Buckley et al) 1999;46:482A
Tizanidine
retrospective study of efficacy of tizanidine in children and young adults presenting with Tourette's syndrome, motor tic disorders, attention deficit disorder, or attention deficit hyperactivity disorder (Foradada) 1999;46:529A
T-lymphocytes
path to damage in multiple sclerosis (McFarland) 1999;46:141 (Editorial)
prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis (Aissaoui et al) 1999;46:559
targeting T cells in myasthenia gravis (Drachman) 1999;46:553 (Editorial)
V-chain T-cell receptor transcripts are clonally expanded in the cerebrospinal fluid of a patient with demyelinating diseases following hepatitis A infection (Oleszak et al) 1999;46:542A
Tolcapone
comparison of the efficacy and tolerability of cabergoline, pergolide, pramipexole, ropinirole, and tolcapone in Parkinson's disease (Inzelberg et al) 1999;46:492A
prediction of the effectiveness of tolcapone, a catechol-*O*-methyltransferase inhibitor, in patients with Parkinson's disease by COMT genotype (Chong et al) 1999;46:477A
Tomography, emission-computed
children with epilepsy and aggression: a distinct pattern of positron emission tomography glucose metabolism (Chugani et al) 1999;46:533A
evolution of functional reorganization in hemiplegic stroke: a serial positron emission tomographic activation study (Nelles et al) 1999;46:901
positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy (Shinotoh et al) 1999;46:62
positron emission tomography measurements of striatal dopamine transporter in untreated Parkinson's disease patients: differential regulation with levodopa versus pramipexole (Guttman et al) 1999;46:937A (Works in progress)
positron emission tomography studies of auditory pathways in patients with auditory neuropathy (Lockwood et al) 1999;46:460A
predilection of frontotemporal cortex involvement in early Rasmussen's syndrome: a positron emission tomographic study (Kaddurah et al) 1999;46:532A
presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study (Ouchi et al) 1999;46:723
role of FDG positron emission tomography imaging in the clinical management of pediatric brain tumor patients (Molloy et al) 1999;46:522A
use of positron emission tomography in predicting malignant change of pleomorphic xanthoastrocytomas (Kaplan et al) 1999;46:550A
Tomography, x-ray computed
computed tomography and magnetic resonance imaging in mild to moderate head injury: early and late imaging related to outcome (van der Naalt et al) 1999;46:70
cortical–subcortical magnetic resonance imaging/computed tomography lesions in reversible posterior leukoencephalopathy syndrome: encephalopathy or seizures? (Strasser et al) 1999;46:472A
imaging stroke in progress: magnetic resonance advances but computed tomography is poised for counterattack (Koroshetz and Gonzales) 1999;46:556 (Editorial)
neuroradiological findings in Möbius syndrome (Vasconcelos et al) 1999;46:548A
treatment of acute stroke more than 3 hours after onset of symptoms: success with the use of structural and functional imaging (Kamran et al) 1999;46:495A

use and validity of a quantitative computed tomographic score in early cerebral ischemia (Barber et al) 1999;46:450A

Topiramate
effect of topiramate on height and weight in children with partial-onset seizures (Glauser et al) 1999;46:533A
efficacy of topiramate in infants and children with symptomatic generalized epilepsies (Hosain et al) 1999;46:532A
role of topiramate for refractory migraine prophylaxis: a retrospective pilot study (Storey et al) 1999;46:495A
weight loss due to topiramate (Lin et al) 1999;46:531A

Torsin
distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain (Augood et al) 1999;46:761

Tourette syndrome
home alone: methods to maximize tic expression for objective videotape assessments in Gilles de la Tourette syndrome (Goetz et al) 1999;46:477A
retrospective study of efficacy of tizanidine in children and young adults presenting with Tourette's syndrome, motor tic disorders, attention deficit disorder, or attention deficit hyperactivity disorder (Foradada) 1999;46:529A

Tranquilizing agents, major
can neuroleptic drugs cause Parkinson's disease? (Mazurek et al) 1999;46:478A

Transcranial Doppler ultrasonography; *see* Ultrasonography

Transfection
antinociceptive effect of gene transfer with a herpes simplex virus vector coding for human preproenkephalin (Goss et al) 1999;46:935A (Works in progress)
calbindin 827K overexpression using gene transfer therapy improves striatal neuron survival following transient focal cerebral ischemia (Yenari et al) 1999;46:479A

Transient cerebral ischemia; *see* Cerebral ischemia, transient

Transplantation
adult-derived neural precursors transplanted into multiple regions in the adult brain (Herrera et al) 1999;46:867
intraventricular transplantation of oligodendrocyte progenitors into a fetal myelin mutant results in widespread formation of myelin (Learish et al) 1999;46:716
posttransplant primary central nervous system lymphoma (Phan et al) 1999;46:463A

Tremor
distinct form of dominantly inherited late onset pure cerebellar ataxia associated with maternal anticipation and intermittent axial tremor (Yamashita et al) 1999;46:480A
function of the cerebellum in parkinsonian rest tremor and Holmes' tremor (Deuschl et al) 1999;46:126
ondansetron versus placebo for disabling cerebellar tremor: final report of a randomized clinical trial (Rice et al) 1999;46:493A
tremor arrest with thalamic microinjections of muscimol in patients with essential tremor (Pahapill et al) 1999;46:249

Tuberculosis, meningeal
tuberculous meningitis in a large urban center: prognosis and outcome (Shah and Niesen) 1999;46:542A

Tumor necrosis factor
elevated production of tumor necrosis factor-α by γ/δ T-cell lines generated from cerebrospinal fluid of multiple sclerosis patients (Matusevicius and Freedman) 1999;46:470A
involvement of p38 MAP kinase pathway in TNF-α production in human astrocytes and microglia (Lee et al) 1999;46:473A
regulation of tumor necrosis factor-α production in human microglia in culture (Kim et al) 1999;46:474A
tumor necrosis factor 2 allele does not contribute to increased tumor necrosis factor-α production in Sardinian multiple sclerosis (Sotgiu et al) 1999;46:799 (Letter)

Tumor suppressor genes; *see* Genes, suppressor, tumor

Twins
migraine without aura: a population-based twin study (Gervil et al) 1999;46:606
population-based study of multiple sclerosis in Italian twins (Ristori and Italian Study Group for Multiple Sclerosis in Twins) 1999;46:474A

Ultrasonography
echogenicity on cranial sonograms in preterm infants: risk profiles and death (Kuban et al) 1999;46:527A
transcranial Doppler ultrasonography in childhood ischemic stroke (Thorarensen et al) 1999;46:521A

United States Department of Veterans Affairs
ultilization patterns among Veterans Administration patients with multiple sclerosis (Vollmer et al) 1999;46:474A

University-based practices; *see* Hospitals, university

Upper limb; *see* Arm

Vagus nerve
observations on intermittent stimulation of the left vagal nerve in children with pharmacoresistant epilepsy (Murphy et al) 1999;46:525A
vagus nerve stimulation does not induce significant changes in striatal fluoro-dopa uptake (Henry et al) 1999;46:477A
vagus nerve stimulation in children: quality of life and side effects (Wheless et al) 1999;46:523A

Valproic acid
brain GABA levels are below normal in epilepsy patients treated with valproate and lamotrigine (Petroff et al) 1999;46:455A

Vanishing white matter syndrome
C13 spectroscopy in vanishing white matter syndrome (Kovacs et al) 1999;46:544A

Varicella

Vascular dementia; *see* Dementia, vascular

Vascular endothelial growth factor; *see* Endothelial growth factors

Vasoactive intestinal peptide
vasoactive intestinal peptide protects from dopamine toxicity: relevance for Parkinson's disease (Melamed et al) 1999;46:458A

Vestibular nerve
distribution of herpes simplex virus type 1 in human geniculate and vestibular ganglia: implications for vestibular neuritis (Arbusow et al) 1999;46:416
hereditary auditory, vestibular, motor, and sensory neuropathy in a Slovenian Roma (Gypsy) kindred (Butinar et al) 1999;46:36

Veterans Administration; *see* United States Department of Veterans Affairs

Viagra; *see* Sildenafil

Videotape recording
home alone: methods to maximize tic expression for objective videotape assessments in Gilles de la Tourette syndrome (Goetz et al) 1999;46:477A

Vigabatrin
ophthalmological abnormalities in children with epilepsy treated with vigabatrin (Gross-Tsur et al) 1999;46:524A
vigabatrin in the treatment of refractory seizures in children with brain malformations (Holder et al) 1999;46:547A
Vincristine
calpain inhibition is protective in experimental vincristine neuropathy (Glass et al) 1999;46:937A (Works in progress)
Vision
Comparison of magnetophosphenes and visually triggered migraine (Aurora et al) 1999;46:476A
functional anatomy of error correction during pointing without vision of the hand (Grafton et al) 1999;46:447A
Vision disorders
acute upside-down reversal of vision as migraine aura (Nisipeanu et al) 1999;46:475A
ophthalmological abnormalities in children with epilepsy treated with vigabatrin (Gross-Tsur et al) 1999;46:524A
Visual cortex
neuronal asymmetries in primary visual cortex of dyslexic and nondyslexic brains (Jenner et al) 1999;46:189
Visual stimulation; *see* Photic stimulation
Vitamin E
vitamin E deficiency as a result of chylomicron retention disease in autosomal recessive Marinesco-Sjögren syndrome (Aguglia et al) 1999;46:465A
Vocal cord paralysis
Charcot-Marie-Tooth disease presenting as bilateral vocal cord paralysis and ascending weakness in a teen with lymphoma (Harsanyi and Keating) 1999;46:550A

Weight loss
weight loss due to topiramate (Lin et al) 1999;46:531A
Welander distal myopathy
genetic linkage of Welander distal myopathy to chromosome 2p13 (Åhlberg et al) 1999;46:399
White matter
follow-up study of blood pressure and cerebral white matter lesions (de Leeuw et al) 1999;46:827
neurocognitive deficits in medulloblastoma survivors and white matter loss (Mulhern et al) 1999;46:834
periventricular white matter injury in the premature infant is followed by reduced cerebral cortical gray matter volume at term (Inder et al) 1999;46:755
Wine
will a glass of wine or Irish coffee lessen the severity of ischemic stroke? a lesson from rats (Grotta et al) 1999;46:496A
Wounds and injuries
pediatric posttraumatic hypersomnolence: an underidentified condition? (Milrod and Yalamanchi) 1999;46:546A
tetrodotoxin prevents posttraumatic epileptogenesis in rats (Graber and Prince) 1999;46:234

X chromosome
role of very-long-chain acyl–coenzyme A synthetase in X-linked adrenoleukodystrophy (Steinberg et al) 1999;46:409
Xanthoastrocytoma
use of positron emission tomography in predicting malignant change of pleomorphic xanthoastrocytomas (Kaplan et al) 1999;46:550A

Zinc
copper/zinc superoxide dismutase: more is not necessarily better! (Rando and Epstein) 1999;46:135 (Letter)
Zolmitriptan
zolmitriptan is well tolerated in adolescents (Wasiewski and Winner) 1999;46:541A